[{"id": 194001, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Netilmicin", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194229/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Chlorhexidine, Povidone-iodine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194002, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Novobiocin", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194230/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194003, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Oxytetracycline", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194231/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Ganciclovir, Acyclovir, Famciclovir, Chlorhexidine, Povidone-iodine, Mupirocin, Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194004, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Plicamycin", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194232/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194005, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Pfizer-BioNTech Covid-19 Vaccine", "severity": "Moderate", "effect": "INTERVAL: The safety, immunogenicity, and efficacy of SARS-CoV-2 (COVID-19) vaccines when administered concurrently with other vaccines have not been assessed.", "source": "DDInter", "management_text": "Given the lack of data, the U.S. Centers for Disease Control and Prevention (CDC) advises that COVID-19 vaccines should routinely be administered alone, with a minimum interval of 14 days before or after administration of any other vaccine. However, COVID-19 and other vaccines may be administered within a shorter period in situations where the benefits of vaccination are deemed to outweigh the potential unknown risks of vaccine coadministration (e.g., tetanus toxoid-containing vaccination as part of wound management; rabies vaccination for post-exposure prophylaxis; measles or hepatitis A vaccination during an outbreak) or to avoid barriers or delays to COVID-19 vaccination (e.g., in long-term care facility residents or healthcare personnel who received influenza or other vaccinations prior to/upon admission or onboarding). If COVID-19 vaccines are administered within 14 days of another vaccine, no extra doses are needed for either vaccine. COVID-19 vaccines should not be mixed with any other vaccine in the same syringe or vial. If administration of COVID-19 vaccines must occur concurrently with another vaccine, it is advisable to use different injection sites.", "mechanism_text": "Others", "recommendation": "Given the lack of data, the U.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194233/", "reference_text": "[1] US Food and Drug Administration \"Emergency Use Authorization. Emergency Use Authorization (EUA) information, and list of all current EUAs. Available from: URL: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.\" ([2020 Apr 06]):[2] Centers for Disease Control and Prevention (CDC) \"Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. Available from: URL: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html.\" ([2021, Jan 6]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194006, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Sparfloxacin", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194234/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194007, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Sulfadoxine", "severity": "Minor", "effect": "According to the prescribing information for live, attenuated oral typhoid vaccine, chemoprophylactic doses of the antimalarials chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Previously, there had been concerns that these agents may interfere with the immunogenicity of the vaccine based on in vitro data demonstrating antibacterial activity against the vaccine strain of Salmonella typhi (Ty21a), which could prevent a sufficient degree of multiplication to occur in order to induce a protective immune response. This led to recommendations to complete the vaccination at least 3 days before the first dose of antimalarial or delaying vaccination until at least 3 days after completion of antimalarial prophylaxis.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194235/", "reference_text": "[1] Kollaritsch H, Que JU, Kunz C, Wiedermann G, Herzog C, Cryz SJ Jr \"Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine.\" J Infect Dis 175 (1997): 871-5[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Vivotif Berna (typhoid vaccine, live)\" Crucell Vaccine Inc, Coral Gables, FL.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Lariam (mefloquine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Atovaquone, Halofantrine, Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194008, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Sulfamethizole", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194236/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Sorbitol, Sodium citrate, Magnesium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194009, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Sulfamethoxazole", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194237/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Pyridoxine, Pretomanid, Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194010, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Sulfisoxazole", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194238/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Trichlormethiazide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194011, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Tositumomab", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194239/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Iodide I-131", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194012, "ingredient1": "Typhoid vaccine (live)", "ingredient2": "Troleandomycin", "severity": "Major", "effect": "INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.", "source": "DDInter", "management_text": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.", "mechanism_text": "Others", "recommendation": "Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194240/", "reference_text": "[1] UK government \"Typhoid. Available from: URL: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/148512/Green-Book-Chapter-33-dh_125348.pdf.\" ([cited 2014]):[2] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] CDC. Centers for Disease Control and Prevention \"Typhoid & Paratyphoid Fever. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.\" ([2013]):", "alternatives_a": "Dirithromycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194013, "ingredient1": "Uracil mustard", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194241/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194014, "ingredient1": "Vinblastine", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194242/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194015, "ingredient1": "Vincristine (liposome)", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194243/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194016, "ingredient1": "Iodipamide", "ingredient2": "Urea", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194244/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Tromethamine", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 194017, "ingredient1": "Iodixanol", "ingredient2": "Urea", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194245/", "reference_text": "[1] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006): 1799-806[5] \"Product Information. Lasix (furosemide).\" sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992): 413-5[8] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006): 420[15] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tromethamine", "updated_at": 1767369485}, {"id": 194018, "ingredient1": "Urea", "ingredient2": "Phenolphthalein", "severity": "Moderate", "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194246/", "reference_text": "[1] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993): 138-45[2] Blumenthal M, Goldberg A, Brinckmann J, eds. \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications (2000):[3] Atsmon J, Dolev E \"Drug-induced hypomagnesaemia : scope and management.\" Drug Saf 28 (2005): 763-88[4] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998): 517-8[5] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984): 455-61", "alternatives_a": "Tromethamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 194019, "ingredient1": "Ephedrine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Minor", "effect": "Acidic urine increases the elimination of ephedrine and pseudoephedrine and decreases the elimination half-life. The clinical significance is unknown. The therapeutic effects of these agents may be decreased.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194247/", "reference_text": "[1] Wilkinson GR, Beckett AH \"Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output.\" J Pharmacol Exp Ther 162 (1968): 139-47[2] Kuntzman RG, Tsai I, Brand L, Mark LC \"The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma.\" Clin Pharmacol Ther 12 (1971): 62-7[3] Brater DC, Kaojarern S, Benet LZ, et al \"Renal excretion of pseudoephedrine.\" Clin Pharmacol Ther 28 (1980): 690-4", "alternatives_a": "Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 194020, "ingredient1": "Ephedrine (nasal)", "ingredient2": "Sodium phosphate, monobasic", "severity": "Minor", "effect": "Acidic urine increases the elimination of ephedrine and pseudoephedrine and decreases the elimination half-life. The clinical significance is unknown. The therapeutic effects of these agents may be decreased.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194248/", "reference_text": "[1] Wilkinson GR, Beckett AH \"Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output.\" J Pharmacol Exp Ther 162 (1968): 139-47[2] Kuntzman RG, Tsai I, Brand L, Mark LC \"The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma.\" Clin Pharmacol Ther 12 (1971): 62-7[3] Brater DC, Kaojarern S, Benet LZ, et al \"Renal excretion of pseudoephedrine.\" Clin Pharmacol Ther 28 (1980): 690-4", "alternatives_a": "Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 194021, "ingredient1": "Flecainide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Minor", "effect": "Agents that acidify the urine enhance the renal elimination of flecainide. The result may be decreased plasma flecainide levels and decreased effectiveness. The antiarrhythmic effectiveness of flecainide should be monitored, and plasma flecainide levels should be checked as appropriate. Also, the risk of flecainide toxicity is increased when an agent that acidifies the urine is discontinued.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194249/", "reference_text": "[1] Hertrampf R, Gundert-Remy U, Beckmann J, et al \"Elimination of flecainide as a function of urinary flow rate and pH.\" Eur J Clin Pharmacol 41 (1991): 61-3", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 194022, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Methadone", "severity": "Minor", "effect": "Urinary acidifiers may increase the renal excretion of methadone. Decreased methadone levels may result. This interaction can be used to clinical advantage in cases of methadone overdose.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194250/", "reference_text": "[1] Nilsson M-I, Widerlov E, Meresaar U, Anggard E \"Effect of urinary pH on the disposition of methadone in man.\" Eur J Clin Pharmacol 22 (1982): 337-42[2] Benmebarek M, Devaud C, Gex-Fabry M, et al. \"Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone.\" Clin Pharmacol Ther 76 (2004): 55-63[3] Oda Y, Kharasch ED \"Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation.\" J Pharmacol Exp Ther 298 (2001): 1021-32[4] Foster DJ, Somogyi AA, Bochner F \"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.\" Br J Clin Pharmacol 47 (1999): 403-12[5] Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF \"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes.\" Chem Res Toxicol 9 (1996): 365-73", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 194023, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Mexiletine", "severity": "Minor", "effect": "Agents that acidify the urine enhance the plasma clearance of mexiletine. The result may be decreased plasma mexiletine levels and decreased effectiveness. The clinical significance is unknown. It is recommended that such drugs or diet be discontinued or that mexiletine dosage increased as needed and tolerated.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194251/", "reference_text": "[1] Mitchell BG, Clements JA, Pottage A, Prescott LF \"Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.\" Br J Clin Pharmacol 16 (1983): 281-4", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 194024, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Pseudoephedrine", "severity": "Minor", "effect": "Acidic urine increases the elimination of ephedrine and pseudoephedrine and decreases the elimination half-life. The clinical significance is unknown. The therapeutic effects of these agents may be decreased.", "source": "DDInter", "management_text": "-", "mechanism_text": "Excretion", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194252/", "reference_text": "[1] Wilkinson GR, Beckett AH \"Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output.\" J Pharmacol Exp Ther 162 (1968): 139-47[2] Kuntzman RG, Tsai I, Brand L, Mark LC \"The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma.\" Clin Pharmacol Ther 12 (1971): 62-7[3] Brater DC, Kaojarern S, Benet LZ, et al \"Renal excretion of pseudoephedrine.\" Clin Pharmacol Ther 28 (1980): 690-4", "alternatives_a": "Phenylephrine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 194025, "ingredient1": "Valerian", "ingredient2": "Azatadine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194253/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone, Dichloralphenazone", "updated_at": 1767369485}, {"id": 194026, "ingredient1": "Clofedanol", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194254/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Benzonatate", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 194027, "ingredient1": "Chloral hydrate", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194255/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone, Valerian", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "updated_at": 1767369485}, {"id": 194028, "ingredient1": "Chlormezanone", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194256/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Methylphenobarbital, Zolpidem, Ethchlorvynol, Zopiclone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194029, "ingredient1": "Chlorphenesin", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194257/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More", "alternatives_b": "Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone, Dichloralphenazone", "updated_at": 1767369485}, {"id": 194030, "ingredient1": "Cyclizine", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194258/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Butabarbital, Chloral hydrate, Nitrazepam, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Methylphenobarbital, Zopiclone, Dichloralphenazone", "updated_at": 1767369485}, {"id": 194031, "ingredient1": "Dezocine", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194259/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "updated_at": 1767369485}, {"id": 194032, "ingredient1": "Ethchlorvynol", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194260/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone, Valerian", "alternatives_b": "Butabarbital, Nitrazepam, Thiopental, Paraldehyde, Butalbital, Propiomazine, Meprobamate, Dexmedetomidine, Methylphenobarbital, Zolpidem, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 194033, "ingredient1": "Halazepam", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194261/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194034, "ingredient1": "Diamorphine", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194262/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "updated_at": 1767369485}, {"id": 194035, "ingredient1": "Valerian", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194263/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "updated_at": 1767369485}, {"id": 194036, "ingredient1": "Valerian", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194264/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Chloral hydrate, Nitrazepam, Quazepam, Paraldehyde, Propiomazine, Estazolam, Ethchlorvynol, Zolpidem, Zopiclone, Zaleplon, Dichloralphenazone", "updated_at": 1767369485}, {"id": 194037, "ingredient1": "Valerian", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194265/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Temazepam, Chloral hydrate, Triazolam, Flurazepam, Quazepam, Paraldehyde, Nitrazepam, Propiomazine, Meprobamate, Eszopiclone, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 194038, "ingredient1": "Valerian", "ingredient2": "Morphine (liposomal)", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194266/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Loperamide, Eluxadoline, Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Methohexital, Ethchlorvynol, Zopiclone, Melatonin", "updated_at": 1767369485}, {"id": 194039, "ingredient1": "Valerian", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194267/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone, Valerian", "alternatives_b": "Chloral hydrate, Nitrazepam, Thiopental, Paraldehyde, Propiomazine, Ethchlorvynol, Zolpidem, Zopiclone, Pentobarbital, Zaleplon", "updated_at": 1767369485}, {"id": 194040, "ingredient1": "Valerian", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194268/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ethchlorvynol, Methylphenobarbital, Zopiclone", "updated_at": 1767369485}, {"id": 194041, "ingredient1": "Valerian", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194269/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone", "updated_at": 1767369485}, {"id": 194042, "ingredient1": "Valerian", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194270/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Butabarbital, Chloral hydrate, Nitrazepam, Quazepam, Paraldehyde, Propiomazine, Butalbital, Dexmedetomidine, Estazolam, Methylphenobarbital, Zolpidem, More", "updated_at": 1767369485}, {"id": 194043, "ingredient1": "Valerian", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194271/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ethchlorvynol, Methylphenobarbital, Zopiclone", "updated_at": 1767369485}, {"id": 194044, "ingredient1": "Valerian", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194272/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone", "updated_at": 1767369485}, {"id": 194045, "ingredient1": "Valerian", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194273/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nitrazepam, Zopiclone, Valerian", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone", "updated_at": 1767369485}, {"id": 194046, "ingredient1": "Valerian", "ingredient2": "Thiethylperazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194274/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Paraldehyde, Quazepam, Estazolam, Ethchlorvynol, Zolpidem, Zopiclone, Zaleplon, Dichloralphenazone", "updated_at": 1767369485}, {"id": 194047, "ingredient1": "Valerian", "ingredient2": "Thiopental", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194275/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Nitrazepam, Zopiclone, Valerian", "alternatives_b": "Temazepam, Butabarbital, Nitrazepam, Flurazepam, Paraldehyde, Thiopental, Meprobamate, Ethchlorvynol, Zolpidem, Zopiclone, Amobarbital, Zaleplon", "updated_at": 1767369485}, {"id": 194048, "ingredient1": "Valerian", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194276/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "Chloral hydrate, Nitrazepam, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone, Dichloralphenazone", "updated_at": 1767369485}, {"id": 194049, "ingredient1": "Alimemazine", "ingredient2": "Valerian", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194277/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone", "updated_at": 1767369485}, {"id": 194050, "ingredient1": "Valerian", "ingredient2": "Trimethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194278/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Lacosamide", "alternatives_b": "Ethchlorvynol, Methylphenobarbital, Zopiclone, Nitrazepam", "updated_at": 1767369485}, {"id": 194051, "ingredient1": "Valerian", "ingredient2": "Tripelennamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194279/", "reference_text": "[1] \"Product Information. Belsomra (suvorexant).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981): 381-3[3] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980): 317-9[4] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988): 412-9[5] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[6] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000): 328-35[7] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[8] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977): 345-9[9] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982): 791-7[10] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company, Whippany, NJ.[11] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[12] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990): 477-82[13] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[14] Cerner Multum, Inc. \"Australian Product Information.\" O 0[15] \"Product Information. Iopidine (apraclonidine).\" Alcon Laboratories Inc, Fort Worth, TX.[16] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[17] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977): 22[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994): 447-61[20] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989): 282-5[21] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[22] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988): 63-6[23] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories, Wayne, NJ.[24] \"Product Information. Trileptal (oxcarbazepine)\" Novartis Pharmaceuticals, East Hanover, NJ.[25] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical, Raritan, NJ.[26] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984): 451-5[27] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970): 336-8[28] \"Product Information. Precedex (dexmedetomidine)\" Abbott Pharmaceutical, Abbott Park, IL.[29] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[30] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[31] Sotaniemi EA, Anttila M, Rautio A, et al \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981): 705-10[32] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals, Costa Mesa, CA.[33] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[34] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989): 95-8[35] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.[36] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983): 111-7[37] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[38] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[39] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[40] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[41] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[42] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[43] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[44] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Desloratadine, Azelastine, Terfenadine, Astemizole, Lidocaine, Tetracaine", "alternatives_b": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone", "updated_at": 1767369485}, {"id": 194052, "ingredient1": "Vecuronium", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194280/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, Darunavir, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 194053, "ingredient1": "Vecuronium", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194281/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, Darunavir, More", "alternatives_b": "Botulinum toxin type A, Pipecuronium, Tubocurarine", "updated_at": 1767369485}, {"id": 194054, "ingredient1": "Vecuronium", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Some calcium channel blockers may enhance the neuromuscular blocking properties of nondepolarizing muscle relaxants. The mechanism is not known, but may involve blockage of calcium channels on skeletal muscle. Data are available for verapamil, diltiazem, nicardipine, atracurium, vecuronium, and pancuronium.", "source": "DDInter", "management_text": "Patients should be closely monitored for prolonged neuromuscular blockade. Reduced doses of muscle relaxants may be necessary. Profound neuromuscular blockade may be reversed by neostigmine or edrophonium.", "mechanism_text": "Synergism", "recommendation": "Patients should be closely monitored for prolonged neuromuscular blockade.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194282/", "reference_text": "[1] Carlos R, Erill S \"Therapeutic Rounds.\" Clin Ther 9 (1986): 22-3[2] Saitoh Y, Makita K, Tanaka H \"Diltiazem and vecuronium: neuromuscular and cardiovascular effects.\" Can J Anaesth 44 (1997): 99[3] Sekerci S, Tulunay M \"Interactions of calcium channel blockers with non-depolarising muscle relaxants in vitro.\" Anaesthesia 51 (1996): 140-4[4] Wali FA \"Interaction of verapamil with d-tubocurarine and cholinergic agonists at the avian neuromuscular junction.\" Acta Anaesthesiol Scand 31 (1987): 15-20[5] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[6] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[7] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[8] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[9] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[10] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[11] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[12] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[13] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[14] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[17] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[18] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[19] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[20] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[21] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[23] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[24] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[28] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[29] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[30] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[31] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[32] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[33] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[34] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[35] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[36] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Botulinum toxin type A, Pipecuronium, Tubocurarine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194055, "ingredient1": "Carteolol", "ingredient2": "Vecuronium", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194283/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Latanoprost, Apraclonidine, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, More", "alternatives_b": "Botulinum toxin type A, Pipecuronium, Tubocurarine", "updated_at": 1767369485}, {"id": 194056, "ingredient1": "Digitoxin", "ingredient2": "Vecuronium", "severity": "Moderate", "effect": "Limited data indicate that the risk of new cardiac arrhythmias is greater when digoxin is given with some depolarizing and nondepolarizing muscle relaxants than when the muscle relaxants are given alone.", "source": "DDInter", "management_text": "Continuous cardiac monitoring is recommended during coadministration.", "mechanism_text": "Others", "recommendation": "Continuous cardiac monitoring is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194284/", "reference_text": "[1] \"Product Information. Lanoxin (digoxin).\" Glaxo Wellcome, Research Triangle Park, NC.", "alternatives_a": "Botulinum toxin type A, Pipecuronium, Tubocurarine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194057, "ingredient1": "Halazepam", "ingredient2": "Vecuronium", "severity": "Moderate", "effect": "Benzodiazepines may have variable effects on nondepolarizing muscle relaxants. Potentiation, attenuation, and no effect have all been reported.", "source": "DDInter", "management_text": "Patients should be monitored closely for respiratory difficulty when these agents are used together.", "mechanism_text": "Others", "recommendation": "Patients should be monitored closely for respiratory difficulty when these agents are used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194285/", "reference_text": "[1] Feldman SA, Crawley BE \"Diazepam and muscle relaxants.\" Br Med J 1 (1970): 691[2] Driessen JJ, Crul JF, Vree TB, van Egmond J, Booij LH \"Benzodiazepines and neuromuscular blocking drugs in patients.\" Acta Anaesthesiol Scand 30 (1986): 642-6[3] Driessen JJ, Vree TB, van Egmond J, Booij LH, Crul JF \"In vitro interaction of diazepam and oxazepam with pancuronium and suxamethonium.\" Br J Anaesth 56 (1984): 1131-8[4] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984): 244-7[5] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965): 223-7[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Meprobamate, Buspirone", "alternatives_b": "Botulinum toxin type A, Pipecuronium, Tubocurarine", "updated_at": 1767369485}, {"id": 194058, "ingredient1": "Vecuronium", "ingredient2": "Levobetaxolol (ophthalmic)", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194286/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Botulinum toxin type A, Pipecuronium, Tubocurarine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194059, "ingredient1": "Vecuronium", "ingredient2": "Methoxyflurane", "severity": "Moderate", "effect": "Inhalation anesthetics may potentiate the effects of nondepolarizing muscle relaxants. Long-acting muscle relaxants such as pancuronium and d-tubocurarine are more affected than other agents.", "source": "DDInter", "management_text": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures. In general, inhalation anesthetics should be administered only by health care providers specially trained in the use of these agents and in the care of anesthetized patients.", "mechanism_text": "Synergism", "recommendation": "The muscle relaxant dosage may need to be reduced when inhalation anesthetics are used, especially during longer procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194287/", "reference_text": "[1] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[2] Duncalf D, Nagashima H, Hollinger I, Badola RP, Kaplan R, Foldes FF \"Relaxation with ORG-NC45 during enflurane anesthesia.\" Anesthesiology 55 (1981): a203[3] Withington DE, Donati F, Bevan DR, Varin F \"Potentiation of atracurium neuromuscular blockade by enflurane: time-course of effect.\" Anesth Analg 72 (1991): 469-73[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Swen J, Rashkovsky OM, Ket JM, Koot HW, Hermans J, Agoston S \"Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.\" Anesth Analg 69 (1989): 752-5[6] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical, Abbott Park, IL.[7] Miller RD, Eger EI, Way WL, Stevens WC, Dolan WM \"Comparative neuromuscular effects of forane and halothane alone and in combination with d-tubocurarine in man.\" Anesthesiology 35 (1971): 38-42[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Ramsey FM, White PA, Stullken EH, Allen LL, Roy RC \"Enflurane potentiation of neuromuscular blockade by atracurium.\" Anesthesiology 57 (1982): a255", "alternatives_a": "Salicylic acid, Choline salicylate, Ziconotide, Diflunisal, Salsalate", "alternatives_b": "Botulinum toxin type A, Pipecuronium, Tubocurarine", "updated_at": 1767369485}, {"id": 194060, "ingredient1": "Vecuronium", "ingredient2": "Metocurine", "severity": "Moderate", "effect": "When combined with vecuronium, other nondepolarizing neuromuscular blocking agents may have additive effects or modifying influences.", "source": "DDInter", "management_text": "There are insufficient data to support the concomitant use of vecuronium and other neuromuscular blockers.", "mechanism_text": "Synergism", "recommendation": "There are insufficient data to support the concomitant use of vecuronium and other neuromuscular blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194288/", "reference_text": "[1] Pandit SK, Ferres CJ, Gibson FM, Mirakhur RK \"Time course of action of combinations of vecuronium and pancuronium.\" Anaesthesia 41 (1986): 151-4[2] \"Product Information. Norcuron (vecuronium).\" Organon, West Orange, NJ.[3] Rashkovsky OM, Agoston S, Ket JM \"Interaction between pancuronium bromide and vecuronium bromide.\" Br J Anaesth 57 (1985): 1063-6", "alternatives_a": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194061, "ingredient1": "Vecuronium", "ingredient2": "Netilmicin", "severity": "Major", "effect": "Aminoglycosides possess neuromuscular blocking activity, which may be additive with that of depolarizing and nondepolarizing muscle relaxants, potentially resulting in severe and/or prolonged respiratory depression during concomitant use. Aminoglycosides inhibit the release of acetylcholine at neuromuscular junctions by interfering with calcium influx. They also appear to decrease the sensitivity of postsynaptic membrane to acetylcholine. The interaction has been observed with various routes of aminoglycoside administration including oral, intramuscular, intravenous, intraperitoneal, esophageal, intraluminal, intradural, and beneath skin flaps. Respiratory paralysis and fatalities have been reported. Patients at increased risk include those with renal impairment and/or hypocalcemia.", "source": "DDInter", "management_text": "The use of aminoglycosides should generally be avoided during and immediately after surgery in which neuromuscular blockers have been employed. If these agents are used concurrently, vital signs should be closely monitored and drug dosages adjusted accordingly. In addition, ventilatory support should be readily available in case of respiratory arrest. Treatment with anticholinesterases and calcium may not always be effective in reversing the neuromuscular blockade caused by these agents.", "mechanism_text": "Synergism", "recommendation": "The use of aminoglycosides should generally be avoided during and immediately after surgery in which neuromuscular blockers have been employed.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194289/", "reference_text": "[1] Jedeikin R, Dolgunski E, Kaplan R, Hoffman S \"Prolongation of neuromuscular blocking effect of vecuronium by antibiotics.\" Anaesthesia 42 (1987): 858-60[2] Kronenfeld MA, Thomas SJ, Turndorf H \"Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation.\" Anesthesiology 65 (1986): 93-4[3] Geha DG, Blitt CD, Moon BJ \"Prolonged neuromuscular blockade with pancuronium in the presence of acute renal failure: a case report.\" Anesth Analg 55 (1976): 343-5[4] Giala MM, Paradelis AG \"Two cases of prolonged respiratory depression due to interaction of pancuronium with colistin and streptomycin.\" J Antimicrob Chemother 5 (1979): 234-5[5] Regan AG, Perumbetti PP \"Pancuronium and gentamicin interaction in patients with renal failure.\" Anesth Analg 59 (1980): 393[6] Pittinger CB, Eryasa Y, Adamson R \"Antibiotic-induced paralysis.\" Anesth Analg 49 (1970): 487-501[7] Levanen J, Nordman R \"Complete respiratory paralysis caused by a large dose of streptomycin and its treatment with calcium chloride.\" Ann Clin Res 7 (1975): 47-9[8] \"Product Information. Humatin (paromomycin).\" Parke-Davis, Morris Plains, NJ.[9] Warner WA, Sanders E \"Neuromuscular blockade associated with gentamicin therapy.\" JAMA 215 (1971): 1153-4[10] Vanacker BF, Van de Walle J \"The neuromuscular blocking action of vecuronium in normal patients and in patients with no renal function and interaction vecuronium- tobramycin in renal transplant patients.\" Acta Anaesthesiol Belg 37 (1986): 95-9[11] Dupuis JY, Martin R, Tetrault JP \"Atracurium and vecuronium interaction with gentamicin and tobramycin.\" Can J Anaesth 36 (1989): 407-11[12] Chapple DJ, Clark JL, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl (1983): s17-22[13] \"Product Information. Arikayce (amikacin liposome).\" Insmed Incorporated, Bridgewater, NJ.[14] Burkett L, Bikhazi GB, Thomas KC Jr, Rosenthal DA, Wirta MG, Foldes FF \"Mutual potentiation of the neuromuscular effects of antibiotics and relaxants.\" Anesth Analg 58 (1979): 107-15[15] Lippmann M, Yang E, Au E, Lee C \"Neuromuscular blocking effects of tobramycin, gentamicin, and cefazolin.\" Anesth Analg 61 (1982): 767-70[16] Hasfurther DL, Bailey PL \"Failure of neuromuscular blockade reversal after rocuronium in a patient who received oral neomycin.\" Can J Anaesth 43 (1996): 617-20[17] Giala M, Sareyiannis C, Cortsaris N, Paradelis A, Lappas DG \"Possible interaction of pancuronium and tubocurarine with oral neomycin.\" Anaesthesia 37 (1982): 776", "alternatives_a": "Gatifloxacin, Ganciclovir, Rifamycin, Norfloxacin, Lomefloxacin, Famciclovir, Trifluridine, Sulfamethizole, Moxifloxacin, Ampicillin, Benzylpenicillin, More", "alternatives_b": "Pipecuronium, Tubocurarine", "updated_at": 1767369485}, {"id": 194062, "ingredient1": "Vecuronium", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Methylxanthines may antagonize the effects of neuromuscular blockers. The mechanism is unknown. In patients stabilized on aminophylline, resistance to pancuronium has been reported.", "source": "DDInter", "management_text": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "mechanism_text": "Antagonism", "recommendation": "The patient should be monitored for adequate neuromuscular blockade and the dosage adjusted, if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194290/", "reference_text": "[1] Doll DC, Rosenberg H \"Antagonism of neuromuscular blockage by theophylline.\" Anesth Analg 58 (1979): 139-40[2] Azar I, Kumar D, Betcher AM \"Resistance to pancuronium in an asthmatic patient treated with aminophylline and steroids.\" Can Anaesth Soc J 29 (1982): 280-2[3] Daller JA, Erstad B, Rosado L, Otto C, Putnam CW \"Aminophylline antagonizes the neuromuscular blockade of pancuronium but not vecuronium.\" Crit Care Med 19 (1991): 983-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 194063, "ingredient1": "Vecuronium", "ingredient2": "Oxytetracycline", "severity": "Moderate", "effect": "Some drugs may enhance the effects of neuromuscular blocking agents.", "source": "DDInter", "management_text": "Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.", "mechanism_text": "Synergism", "recommendation": "Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194291/", "reference_text": "[1] \"Product Information. Anectine (succinylcholine).\" Glaxo Wellcome, Research Triangle Park, NC.[2] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Tigecycline, Sarecycline, Omadacycline, Eravacycline, Gatifloxacin, Ganciclovir, Rifamycin, Norfloxacin, Lomefloxacin, Famciclovir, Trifluridine, More", "alternatives_b": "Pipecuronium, Botulinum toxin type A, Doxacurium, Tubocurarine", "updated_at": 1767369485}, {"id": 194064, "ingredient1": "Vecuronium", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194292/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Botulinum toxin type A", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194065, "ingredient1": "Vecuronium", "ingredient2": "Pipecuronium", "severity": "Moderate", "effect": "When combined with vecuronium, other nondepolarizing neuromuscular blocking agents may have additive effects or modifying influences.", "source": "DDInter", "management_text": "There are insufficient data to support the concomitant use of vecuronium and other neuromuscular blockers.", "mechanism_text": "Synergism", "recommendation": "There are insufficient data to support the concomitant use of vecuronium and other neuromuscular blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194293/", "reference_text": "[1] Pandit SK, Ferres CJ, Gibson FM, Mirakhur RK \"Time course of action of combinations of vecuronium and pancuronium.\" Anaesthesia 41 (1986): 151-4[2] \"Product Information. Norcuron (vecuronium).\" Organon, West Orange, NJ.[3] Rashkovsky OM, Agoston S, Ket JM \"Interaction between pancuronium bromide and vecuronium bromide.\" Br J Anaesth 57 (1985): 1063-6", "alternatives_a": "Vecuronium", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 194066, "ingredient1": "Vecuronium", "ingredient2": "Ranitidine (bismuth citrate)", "severity": "Minor", "effect": "Ranitidine may or may not decrease the effectiveness of neuromuscular blocking agents. Until more information is available, the clinician should be aware of the possibility of an interaction.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194294/", "reference_text": "[1] Woodworth GE, Sears DH, Grove TM, et al \"The effect of cimetidine and ranitidine on the duration of action of succinylcholine.\" Anesth Analg 68 (1989): 295-7[2] Katende RS, Dimich I \"Resistance to nondepolarizing muscle relaxants in a patient treated with ranitidine.\" Mt Sinai J Med 54 (1987): 330-1[3] McCarthy G, Mirakhur RK, Elliott P, Wright J \"Effect of H2-receptor antagonist pretreatment on vecuronium- and atracurium-induced neuromuscular block.\" Br J Anaesth 66 (1991): 713-5", "alternatives_a": "Botulinum toxin type A, Pipecuronium, Tubocurarine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194067, "ingredient1": "Vecuronium", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194295/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, Darunavir, More", "alternatives_b": "Botulinum toxin type A, Pipecuronium, Tubocurarine", "updated_at": 1767369485}, {"id": 194068, "ingredient1": "Vecuronium", "ingredient2": "Trimethaphan", "severity": "Moderate", "effect": "Some drugs may enhance the effects of neuromuscular blocking agents.", "source": "DDInter", "management_text": "Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.", "mechanism_text": "Synergism", "recommendation": "Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194296/", "reference_text": "[1] \"Product Information. Anectine (succinylcholine).\" Glaxo Wellcome, Research Triangle Park, NC.[2] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Mecamylamine", "alternatives_b": "Pipecuronium, Botulinum toxin type A, Doxacurium, Tubocurarine", "updated_at": 1767369485}, {"id": 194069, "ingredient1": "Vecuronium", "ingredient2": "Tubocurarine", "severity": "Moderate", "effect": "When combined with vecuronium, other nondepolarizing neuromuscular blocking agents may have additive effects or modifying influences.", "source": "DDInter", "management_text": "There are insufficient data to support the concomitant use of vecuronium and other neuromuscular blockers.", "mechanism_text": "Synergism", "recommendation": "There are insufficient data to support the concomitant use of vecuronium and other neuromuscular blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194297/", "reference_text": "[1] Pandit SK, Ferres CJ, Gibson FM, Mirakhur RK \"Time course of action of combinations of vecuronium and pancuronium.\" Anaesthesia 41 (1986): 151-4[2] \"Product Information. Norcuron (vecuronium).\" Organon, West Orange, NJ.[3] Rashkovsky OM, Agoston S, Ket JM \"Interaction between pancuronium bromide and vecuronium bromide.\" Br J Anaesth 57 (1985): 1063-6", "alternatives_a": "Vecuronium", "alternatives_b": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "updated_at": 1767369485}, {"id": 194070, "ingredient1": "Aminoglutethimide", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein may significantly decrease the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St. John's wort should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194298/", "reference_text": "[1] \"Product Information. Marqibo (vinCRIStine liposome).\" Talon Therapeutics Inc, South San Francisco,, CA.", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Topotecan, Teniposide, Etoposide", "updated_at": 1767369485}, {"id": 194071, "ingredient1": "Vinblastine", "ingredient2": "Aurothioglucose", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194299/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Topotecan, Irinotecan", "alternatives_b": "Penicillamine", "updated_at": 1767369485}, {"id": 194072, "ingredient1": "Vinblastine", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194300/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194073, "ingredient1": "Vinblastine", "ingredient2": "Berotralstat", "severity": "Moderate", "effect": "Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.", "source": "DDInter", "management_text": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194301/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.", "alternatives_a": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194074, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194302/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194075, "ingredient1": "Boceprevir", "ingredient2": "Vinblastine", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194303/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 194076, "ingredient1": "Candida albicans", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194304/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194077, "ingredient1": "Cerivastatin", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194305/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More", "alternatives_b": "Topotecan, Irinotecan", "updated_at": 1767369485}, {"id": 194078, "ingredient1": "Vinblastine", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194306/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194079, "ingredient1": "Cinoxacin", "ingredient2": "Vinblastine", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194307/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194080, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194308/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194081, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Vinblastine", "severity": "Minor", "effect": "An in vitro test has shown doxorubicin to have inhibitory effects on the biotransformation of vinblastine. Both drugs are believed to be metabolized by the liver cytochrome P-450. The clinical significance of this interaction has not been established. If doxorubicin and vinblastine are used concomitantly, caution and close observation are advised.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194309/", "reference_text": "[1] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6", "alternatives_a": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "alternatives_b": "Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 194082, "ingredient1": "Efalizumab", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194310/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194083, "ingredient1": "Enoxacin", "ingredient2": "Vinblastine", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194311/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194084, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Coadministration with glycerol phenylbutyrate may decrease the systemic exposure to and therapeutic efficacy of drugs that are substrates of CYP450 3A4. Glycerol phenylbutyrate, its active moiety phenylbutyrate, and active metabolite phenylacetic acid are considered weak CYP450 3A4 inducers in vivo.", "source": "DDInter", "management_text": "Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.g., oral midazolam) or CYP450 3A4 substrates with a narrow therapeutic index (e.g., alfentanil, oral contraceptives, quinidine, and cyclosporine) should be done with caution and monitoring for reduced efficacy. Dosage adjustment as well as clinical and laboratory monitoring may be appropriate whenever glycerol phenylbutyrate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194312/", "reference_text": "[1] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc, South San Francisco, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Trabectedin, Cabazitaxel, Paclitaxel, Topotecan, Teniposide, Irinotecan, Etoposide, Docetaxel", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 194085, "ingredient1": "Grepafloxacin", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.", "source": "DDInter", "management_text": "Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194313/", "reference_text": "[1] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194086, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194314/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Irinotecan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194087, "ingredient1": "Interferon alfa-n1", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194315/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon beta-1a, Interferon beta-1a, Histamine, Pegademase, Glatiramer", "alternatives_b": "Irinotecan", "updated_at": 1767369485}, {"id": 194088, "ingredient1": "Vinblastine", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194316/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 194089, "ingredient1": "Vinblastine", "ingredient2": "Lomefloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194317/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "updated_at": 1767369485}, {"id": 194090, "ingredient1": "Vinblastine", "ingredient2": "Lyme disease vaccine (recombinant OspA)", "severity": "Moderate", "effect": "The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194318/", "reference_text": "[1] \"Product Information. Lymerix (Lyme disease vaccine).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194091, "ingredient1": "Vinblastine", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194319/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Trabectedin, Cabazitaxel, Vincristine, Paclitaxel, Teniposide, Irinotecan", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 194092, "ingredient1": "Vinblastine", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194320/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194093, "ingredient1": "Vinblastine", "ingredient2": "Nalidixic acid", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194321/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194094, "ingredient1": "Vinblastine", "ingredient2": "Naxitamab", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194322/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Irinotecan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194095, "ingredient1": "Vinblastine", "ingredient2": "Radium Ra 223 dichloride", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194323/", "reference_text": "[1] \"Product Information. Xofigo (radium Ra 223 dichloride).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194096, "ingredient1": "Vinblastine", "ingredient2": "Rubella virus vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194324/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194097, "ingredient1": "Vinblastine", "ingredient2": "Pfizer-BioNTech Covid-19 Vaccine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194325/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194098, "ingredient1": "Vinblastine", "ingredient2": "Sodium phosphate, monobasic (p32)", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194326/", "reference_text": "[1] AnazaoHealth Corporation \"P32 Sodium Phosphate. Available from: URL: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=735f92e3-cc92-4d9b-afe8-f935a685ee78\" ([2012 Jun]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194099, "ingredient1": "Vinblastine", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194327/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Topotecan", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 194100, "ingredient1": "Vinblastine", "ingredient2": "Sparfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194328/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194101, "ingredient1": "Vinblastine", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194329/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 194102, "ingredient1": "Vinblastine", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with troglitazone may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by troglitazone.", "source": "DDInter", "management_text": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever troglitazone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194330/", "reference_text": "[1] \"Product Information. Rezulin (troglitazone).\" Parke-Davis, Morris Plains, NJ.[2] Fraser CG, Fierro L \"Comment: troglitazone.\" Ann Pharmacother 32 (1998): 1111-2[3] Park MH, Pelegrin D, Haug MT, Young JB \"Troglitazone, a new antidiabetic agent, decreases cyclosporine level.\" J Heart Lung Transplant 17 (1998): 1139-40[4] Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P, Bonomini L, Mulgaonkar SP \"Potential interaction of troglitazone and cyclosporine.\" Transplantation 65 (1998): 1399-400[5] Frantz RP, Nguyen TT \"Rezulin (troglitazone) greatly increases cyclosporine metabolism.\" J Heart Lung Transplant 17 (1998): 1037-8[6] Burgess SJ, Singer GG, Brennan DC \"Effect of troglitazone on cyclosporine whole blood levels.\" Transplantation 66 (1998): 272[7] Terra SG, Washam JB, May DB \"Comment: troglitazone drug interactions.\" Ann Pharmacother 32 (1998): 1111[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "Topotecan, Teniposide, Etoposide, Vinorelbine", "updated_at": 1767369485}, {"id": 194103, "ingredient1": "Vinblastine", "ingredient2": "Troleandomycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194331/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 194104, "ingredient1": "Vinblastine", "ingredient2": "Typhoid vaccine (inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194332/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194105, "ingredient1": "Vitamin E", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.", "source": "DDInter", "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.", "mechanism_text": "Others", "recommendation": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194333/", "reference_text": "[1] Conklin KA \"Cancer chemotherapy and antioxidants.\" J Nutr 134 (2004): 3201S-4S[2] Labriola D, Livingston R \"Possible interactions between dietary antioxidants and chemotherapy.\" Oncology (Williston Park) 13 (1999): 1003-8; discussion 1008, 1011-2[3] D'Andrea GM \"Use of antioxidants during chemotherapy and radiotherapy should be avoided.\" CA Cancer J Clin 55 (2005): 319-21[4] Pace A, Savarese A, Picardo M, et al \"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.\" J Clin Oncol 21 (2003): 927-31[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Prasad KN \"Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.\" J Nutr 134 (2004): 3182S-3S[7] Whittaker JA, Al-Ismail SA \"Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.\" Br Med J (Clin Res Ed) 288 (1984): 283-4[8] Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C \"Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials.\" Int J Cancer 123 (2008): 1227-39[9] Lonn E, Bosch J, Yusuf S, et al. \"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.\" JAMA 293 (2005): 1338-47", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194106, "ingredient1": "Vincristine (liposome)", "ingredient2": "Aurothioglucose", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194334/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Topotecan, Irinotecan", "alternatives_b": "Penicillamine", "updated_at": 1767369485}, {"id": 194107, "ingredient1": "Vincristine (liposome)", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194335/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194108, "ingredient1": "Vincristine (liposome)", "ingredient2": "Berotralstat", "severity": "Moderate", "effect": "Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.", "source": "DDInter", "management_text": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194336/", "reference_text": "[1] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc, Durham, NC.", "alternatives_a": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194109, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194337/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194110, "ingredient1": "Boceprevir", "ingredient2": "Vincristine (liposome)", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194338/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 194111, "ingredient1": "Candida albicans", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194339/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194112, "ingredient1": "Cerivastatin", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194340/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, Niacin, More", "alternatives_b": "Topotecan, Irinotecan", "updated_at": 1767369485}, {"id": 194113, "ingredient1": "Vincristine (liposome)", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194341/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194114, "ingredient1": "Cinoxacin", "ingredient2": "Vincristine (liposome)", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194342/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194115, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194343/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194116, "ingredient1": "Efalizumab", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194344/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194117, "ingredient1": "Enoxacin", "ingredient2": "Vincristine (liposome)", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194345/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194118, "ingredient1": "Grepafloxacin", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.", "source": "DDInter", "management_text": "Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194346/", "reference_text": "[1] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194119, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194347/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Irinotecan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194120, "ingredient1": "Interferon alfa-n1", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194348/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Aldesleukin, Pegademase, Glatiramer", "alternatives_b": "Irinotecan", "updated_at": 1767369485}, {"id": 194121, "ingredient1": "Vincristine (liposome)", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194349/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Tamsulosin, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 194122, "ingredient1": "Vincristine (liposome)", "ingredient2": "Lomefloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194350/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "updated_at": 1767369485}, {"id": 194123, "ingredient1": "Vincristine (liposome)", "ingredient2": "Lyme disease vaccine (recombinant OspA)", "severity": "Moderate", "effect": "The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194351/", "reference_text": "[1] \"Product Information. Lymerix (Lyme disease vaccine).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194124, "ingredient1": "Vincristine (liposome)", "ingredient2": "Nalidixic acid", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194352/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194125, "ingredient1": "Vincristine (liposome)", "ingredient2": "Naxitamab", "severity": "Moderate", "effect": "The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.", "source": "DDInter", "management_text": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194353/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6", "alternatives_a": "Irinotecan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194126, "ingredient1": "Vincristine (liposome)", "ingredient2": "Radium Ra 223 dichloride", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194354/", "reference_text": "[1] \"Product Information. Xofigo (radium Ra 223 dichloride).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194127, "ingredient1": "Vincristine (liposome)", "ingredient2": "Rubella virus vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194355/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194128, "ingredient1": "Vincristine (liposome)", "ingredient2": "Pfizer-BioNTech Covid-19 Vaccine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194356/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194129, "ingredient1": "Vincristine (liposome)", "ingredient2": "Sodium phosphate, monobasic (p32)", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194357/", "reference_text": "[1] AnazaoHealth Corporation \"P32 Sodium Phosphate. Available from: URL: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=735f92e3-cc92-4d9b-afe8-f935a685ee78\" ([2012 Jun]):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194130, "ingredient1": "Vincristine (liposome)", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194358/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Topotecan", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 194131, "ingredient1": "Vincristine (liposome)", "ingredient2": "Sparfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194359/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Trabectedin, Cabazitaxel", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194132, "ingredient1": "Vincristine (liposome)", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194360/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 194133, "ingredient1": "Vincristine (liposome)", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with troglitazone may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by troglitazone.", "source": "DDInter", "management_text": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever troglitazone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194361/", "reference_text": "[1] \"Product Information. Rezulin (troglitazone).\" Parke-Davis, Morris Plains, NJ.[2] Fraser CG, Fierro L \"Comment: troglitazone.\" Ann Pharmacother 32 (1998): 1111-2[3] Park MH, Pelegrin D, Haug MT, Young JB \"Troglitazone, a new antidiabetic agent, decreases cyclosporine level.\" J Heart Lung Transplant 17 (1998): 1139-40[4] Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P, Bonomini L, Mulgaonkar SP \"Potential interaction of troglitazone and cyclosporine.\" Transplantation 65 (1998): 1399-400[5] Frantz RP, Nguyen TT \"Rezulin (troglitazone) greatly increases cyclosporine metabolism.\" J Heart Lung Transplant 17 (1998): 1037-8[6] Burgess SJ, Singer GG, Brennan DC \"Effect of troglitazone on cyclosporine whole blood levels.\" Transplantation 66 (1998): 272[7] Terra SG, Washam JB, May DB \"Comment: troglitazone drug interactions.\" Ann Pharmacother 32 (1998): 1111[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "Topotecan, Teniposide, Etoposide, Vinorelbine", "updated_at": 1767369485}, {"id": 194134, "ingredient1": "Vincristine (liposome)", "ingredient2": "Troleandomycin", "severity": "Major", "effect": "Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194362/", "reference_text": "[1] Bermudez M, Fuster JL, Llinares E, Galera A, Gonzalez C \"Itraconazole-related increased vincristine neurotoxicity: case report and review of literature.\" J Pediatr Hematol Oncol 27 (2005): 389-392[2] \"Product Information. Velban (vinblastine).\" Lilly, Eli and Company, Indianapolis, IN.[3] Porter CC, Carver AE, Albano EA \"Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X.\" Pediatr Blood Cancer 52 (2009): 298-300[4] Gillies J, Hung KA, Fitzsimons E, Soutar R \"Severe vincristine toxicity in combination with itraconazole.\" Clin Lab Haematol 20 (1998): 123-4[5] Eiden C, Palenzuela G, Hillaire-Buys D, et al. \"Posaconazole-increased vincristine neurotoxicity in a child: a case report.\" J Pediatr Hematol Oncol 31 (2009): 292-5[6] Bohme A, Ganser A, Hoelzer D \"Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.\" Ann Hematol 71 (1995): 311-2[7] Sathiapalan RK, El-Solh H \"Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature.\" Pediatr Hematol Oncol 18 (2001): 543-6[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] Jain S, Kapoor G \"Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.\" Pediatr Blood Cancer 54 (2010): 783[10] Antoniou T, Tseng AL \"Interactions between antiretrovirals and antineoplastic drug therapy.\" Clin Pharmacokinet 44 (2005): 111-145[11] Murphy JA, Ross LM, Gibson BE \"Vincristine toxicity in five children with acute lymphoblastic leukaemia.\" Lancet 346 (1995): 443[12] Tobe SW, Siu LL, Jamal SA, Skorecki KL, Murphy GF, Warner E \"Vinblastine and erythromycin: an unrecognized serious drug interaction.\" Cancer Chemother Pharmacol 35 (1995): 188-90[13] Zhou-Pan XR, Seree E, Zhou XJ, et al \"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.\" Cancer Res 53 (1993): 5121-6[14] van Schie RM, Bruggemann RJ, Hoogerbrugge PM, Te Loo DM \"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.\" J Antimicrob Chemother 66 (2011): 1853-6[15] Kamaluddin M, McNally P, Breatnach F, et al \"Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies.\" Acta Paediatr 90 (2001): 1204-7[16] Ariffin H, Omar KZ, Ang EL, Shekhar K \"Severe vincristine neurotoxicity with concomitant use of itraconazole.\" J Paediatr Child Health 39 (2003): 638-9[17] Mantadakis E, Amoiridis G, Kondi A, Kalmanti M \"Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.\" J Pediatr Hematol Oncol 29 (2007): 130[18] Kotb R, Vincent I, Dulioust A, et al. \"Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.\" Eur J Haematol 76 (2006): 269-71[19] Jeng MR, Feusner J \"Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.\" Pediatr Hematol Oncol 18 (2001): 137-42[20] Corona G, Vaccher E, Spina M, Toffoli G \"Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma.\" AIDS 27 (2013): 1033-5[21] Yano R, Tani D, Watanabe K, et al. \"Evaluation of potential interaction between vinorelbine and clarithromycin.\" Ann Pharmacother 43 (2009): 453-8[22] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[23] Bosque E \"Possible drug interaction between itraconazole and vinorelbine tartrate leading to death after one dose of chemotherapy.\" Ann Intern Med 134 (2001): 427[24] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[25] Moriyama B, Falade-Nwulia O, Leung J, et al. \"Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.\" Mycoses 54 (2011): e877-9[26] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R \"Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.\" Biochem Pharmacol 45 (1993): 853-61[27] Chan JD \"Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.\" Pharmacotherapy 18 (1998): 1304-7[28] Chen S, Wu D, Sun A, et al \"Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.\" Am J Hematol 82 (2007): 942[29] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995): 201[30] Kivisto KT, Kroemer HK, Eichelbaum M \"The role of human cytochrome p450 enzymes in the metabolism of anticancer agents: implications for drug interactions.\" Br J Clin Pharmacol 40 (1995): 523-30[31] Harnicar S, Adel N, Jurcic J \"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.\" J Oncol Pharm Pract 15 (2009): 175-82[32] Haddad A, Davis M, Lagman R \"The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.\" Support Care Cancer 15 (2007): 251-7[33] Fedeli L, Colozza M, Boschetti E, et al. \"Pharmacokinetics of vincristine in cancer patients treated with nifedipine.\" Cancer 64 (1989): 1805-11[34] Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y \"Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.\" Cancer Res 43 (1983): 2267-72[35] Leveque D, Santucci R, Pavillet J, Herbrecht R, Bergerat JP \"Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.\" Pharm World Sci 31 (2009): 619-21[36] Kajita J, Kuwabara T, Kobayashi H, Kobayashi S \"CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.\" Drug Metab Dispos 28 (2000): 1121-7[37] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[38] Bashir H, Motl S, Metzger ML, et al. \"Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma.\" J Pediatr Hematol Oncol 28 (2006): 33-35[39] Takahashi N, Kameoka Y, Yamanaka Y, et al. \"Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma.\" Intern Med 47 (2008): 651-3[40] \"Product Information. Sporanox (itraconazole).\" Janssen Pharmaceutica, Titusville, NJ.[41] Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S \"Vincristine-itraconazole interaction: cause for increasing concern.\" J Pediatr Hematol Oncol 24 (2002): 591", "alternatives_a": "Topotecan, Teniposide, Etoposide", "alternatives_b": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "updated_at": 1767369485}, {"id": 194135, "ingredient1": "Vincristine (liposome)", "ingredient2": "Typhoid vaccine (inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194363/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194136, "ingredient1": "Vitamin E", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.", "source": "DDInter", "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.", "mechanism_text": "Others", "recommendation": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194364/", "reference_text": "[1] Conklin KA \"Cancer chemotherapy and antioxidants.\" J Nutr 134 (2004): 3201S-4S[2] Labriola D, Livingston R \"Possible interactions between dietary antioxidants and chemotherapy.\" Oncology (Williston Park) 13 (1999): 1003-8; discussion 1008, 1011-2[3] D'Andrea GM \"Use of antioxidants during chemotherapy and radiotherapy should be avoided.\" CA Cancer J Clin 55 (2005): 319-21[4] Pace A, Savarese A, Picardo M, et al \"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.\" J Clin Oncol 21 (2003): 927-31[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Prasad KN \"Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.\" J Nutr 134 (2004): 3182S-3S[7] Whittaker JA, Al-Ismail SA \"Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.\" Br Med J (Clin Res Ed) 288 (1984): 283-4[8] Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C \"Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials.\" Int J Cancer 123 (2008): 1227-39[9] Lonn E, Bosch J, Yusuf S, et al. \"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.\" JAMA 293 (2005): 1338-47", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194137, "ingredient1": "Anisindione", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194365/", "reference_text": "[1] Helson L \"The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors.\" Thromb Res 35 (1984): 11-8[2] Kakishita E, Suehiro A, Oura Y, Nagai K \"Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood.\" Thromb Res 60 (1990): 489-99[3] Gonzalez-Correa JA, Arrebola MM, Guerrero A, et al. \"Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.\" Platelets 16(3-4) (2005): 171-9[4] Stampfer MJ, Jakubowski JA, Faigel D, Vaillancourt R, Deykin D \"Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels.\" Am J Clin Nutr 47 (1988): 700-6[5] Kim JM, White RH \"Effect of vitamin E on the anticoagulant response to warfarin.\" Am J Cardiol 77 (1996): 545-6[6] \"Vitamin K, vitamin E and the coumarin drugs.\" Nutr Rev 40 (1982): 180-2[7] Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C \"Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis.\" Pharmacotherapy 27 (2007): 1237-47[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Corrigan JJ, Ulfers LL \"Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency.\" Am J Clin Nutr 34 (1981): 1701-5[10] Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T \"Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms.\" Am J Clin Nutr 77 (2003): 700-6[11] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[12] \"Megavitamin E supplementation and vitamin K-dependent carboxylation.\" Nutr Rev 41 (1983): 268-70[13] Jandak J, Steiner M, Richardson PD \"Alpha-tocopherol, an effective inhibitor of platelet adhesion.\" Blood 73 (1989): 141-9[14] Celestini A, Pulcinelli FM, Pignatelli P, et al. \"Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets.\" Haematologica 87 (2002): 420-6[15] Freedman JE, Farhat JH, Loscalzo J, Keaney JF \"Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C--dependent mechanism.\" Circulation 94 (1996): 2434-40[16] Corrigan JJ \"The effect of vitamin E on warfarin-induced vitamin K deficiency.\" Ann N Y Acad Sci 393 (1982): 361-8[17] Schrogie JJ \"Coagulopathy and fat-soluble vitamins.\" JAMA 232 (1975): 19[18] Mardla V, Kobzar G, Samel N \"Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.\" Platelets 15 (2004): 319-24[19] Murohara T, Ikeda H, Otsuka Y, Aoki M, Takajo Y, et al \"Inhibition of platelet adherence to Mononuclear cells by alpha-tocopherol: role of P-selection.\" Circulation 110 (2004): 141-8[20] Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al \"Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status.\" Am J Clin Nutr 80 (2004): 143-8", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194138, "ingredient1": "Vitamin E", "ingredient2": "Ardeparin", "severity": "Moderate", "effect": "Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194366/", "reference_text": "[1] Helson L \"The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors.\" Thromb Res 35 (1984): 11-8[2] Kakishita E, Suehiro A, Oura Y, Nagai K \"Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood.\" Thromb Res 60 (1990): 489-99[3] Gonzalez-Correa JA, Arrebola MM, Guerrero A, et al. \"Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.\" Platelets 16(3-4) (2005): 171-9[4] Stampfer MJ, Jakubowski JA, Faigel D, Vaillancourt R, Deykin D \"Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels.\" Am J Clin Nutr 47 (1988): 700-6[5] Kim JM, White RH \"Effect of vitamin E on the anticoagulant response to warfarin.\" Am J Cardiol 77 (1996): 545-6[6] \"Vitamin K, vitamin E and the coumarin drugs.\" Nutr Rev 40 (1982): 180-2[7] Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C \"Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis.\" Pharmacotherapy 27 (2007): 1237-47[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Corrigan JJ, Ulfers LL \"Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency.\" Am J Clin Nutr 34 (1981): 1701-5[10] Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T \"Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms.\" Am J Clin Nutr 77 (2003): 700-6[11] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[12] \"Megavitamin E supplementation and vitamin K-dependent carboxylation.\" Nutr Rev 41 (1983): 268-70[13] Jandak J, Steiner M, Richardson PD \"Alpha-tocopherol, an effective inhibitor of platelet adhesion.\" Blood 73 (1989): 141-9[14] Celestini A, Pulcinelli FM, Pignatelli P, et al. \"Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets.\" Haematologica 87 (2002): 420-6[15] Freedman JE, Farhat JH, Loscalzo J, Keaney JF \"Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C--dependent mechanism.\" Circulation 94 (1996): 2434-40[16] Corrigan JJ \"The effect of vitamin E on warfarin-induced vitamin K deficiency.\" Ann N Y Acad Sci 393 (1982): 361-8[17] Schrogie JJ \"Coagulopathy and fat-soluble vitamins.\" JAMA 232 (1975): 19[18] Mardla V, Kobzar G, Samel N \"Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.\" Platelets 15 (2004): 319-24[19] Murohara T, Ikeda H, Otsuka Y, Aoki M, Takajo Y, et al \"Inhibition of platelet adherence to Mononuclear cells by alpha-tocopherol: role of P-selection.\" Circulation 110 (2004): 141-8[20] Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al \"Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status.\" Am J Clin Nutr 80 (2004): 143-8", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194139, "ingredient1": "Danaparoid", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194367/", "reference_text": "[1] Helson L \"The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors.\" Thromb Res 35 (1984): 11-8[2] Kakishita E, Suehiro A, Oura Y, Nagai K \"Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood.\" Thromb Res 60 (1990): 489-99[3] Gonzalez-Correa JA, Arrebola MM, Guerrero A, et al. \"Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.\" Platelets 16(3-4) (2005): 171-9[4] Stampfer MJ, Jakubowski JA, Faigel D, Vaillancourt R, Deykin D \"Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels.\" Am J Clin Nutr 47 (1988): 700-6[5] Kim JM, White RH \"Effect of vitamin E on the anticoagulant response to warfarin.\" Am J Cardiol 77 (1996): 545-6[6] \"Vitamin K, vitamin E and the coumarin drugs.\" Nutr Rev 40 (1982): 180-2[7] Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C \"Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis.\" Pharmacotherapy 27 (2007): 1237-47[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Corrigan JJ, Ulfers LL \"Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency.\" Am J Clin Nutr 34 (1981): 1701-5[10] Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T \"Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms.\" Am J Clin Nutr 77 (2003): 700-6[11] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[12] \"Megavitamin E supplementation and vitamin K-dependent carboxylation.\" Nutr Rev 41 (1983): 268-70[13] Jandak J, Steiner M, Richardson PD \"Alpha-tocopherol, an effective inhibitor of platelet adhesion.\" Blood 73 (1989): 141-9[14] Celestini A, Pulcinelli FM, Pignatelli P, et al. \"Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets.\" Haematologica 87 (2002): 420-6[15] Freedman JE, Farhat JH, Loscalzo J, Keaney JF \"Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C--dependent mechanism.\" Circulation 94 (1996): 2434-40[16] Corrigan JJ \"The effect of vitamin E on warfarin-induced vitamin K deficiency.\" Ann N Y Acad Sci 393 (1982): 361-8[17] Schrogie JJ \"Coagulopathy and fat-soluble vitamins.\" JAMA 232 (1975): 19[18] Mardla V, Kobzar G, Samel N \"Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.\" Platelets 15 (2004): 319-24[19] Murohara T, Ikeda H, Otsuka Y, Aoki M, Takajo Y, et al \"Inhibition of platelet adherence to Mononuclear cells by alpha-tocopherol: role of P-selection.\" Circulation 110 (2004): 141-8[20] Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al \"Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status.\" Am J Clin Nutr 80 (2004): 143-8", "alternatives_a": "Alteplase, Streptokinase, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194140, "ingredient1": "Dicoumarol", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194368/", "reference_text": "[1] Helson L \"The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors.\" Thromb Res 35 (1984): 11-8[2] Kakishita E, Suehiro A, Oura Y, Nagai K \"Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood.\" Thromb Res 60 (1990): 489-99[3] Gonzalez-Correa JA, Arrebola MM, Guerrero A, et al. \"Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.\" Platelets 16(3-4) (2005): 171-9[4] Stampfer MJ, Jakubowski JA, Faigel D, Vaillancourt R, Deykin D \"Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels.\" Am J Clin Nutr 47 (1988): 700-6[5] Kim JM, White RH \"Effect of vitamin E on the anticoagulant response to warfarin.\" Am J Cardiol 77 (1996): 545-6[6] \"Vitamin K, vitamin E and the coumarin drugs.\" Nutr Rev 40 (1982): 180-2[7] Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C \"Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis.\" Pharmacotherapy 27 (2007): 1237-47[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Corrigan JJ, Ulfers LL \"Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency.\" Am J Clin Nutr 34 (1981): 1701-5[10] Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T \"Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms.\" Am J Clin Nutr 77 (2003): 700-6[11] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[12] \"Megavitamin E supplementation and vitamin K-dependent carboxylation.\" Nutr Rev 41 (1983): 268-70[13] Jandak J, Steiner M, Richardson PD \"Alpha-tocopherol, an effective inhibitor of platelet adhesion.\" Blood 73 (1989): 141-9[14] Celestini A, Pulcinelli FM, Pignatelli P, et al. \"Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets.\" Haematologica 87 (2002): 420-6[15] Freedman JE, Farhat JH, Loscalzo J, Keaney JF \"Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C--dependent mechanism.\" Circulation 94 (1996): 2434-40[16] Corrigan JJ \"The effect of vitamin E on warfarin-induced vitamin K deficiency.\" Ann N Y Acad Sci 393 (1982): 361-8[17] Schrogie JJ \"Coagulopathy and fat-soluble vitamins.\" JAMA 232 (1975): 19[18] Mardla V, Kobzar G, Samel N \"Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.\" Platelets 15 (2004): 319-24[19] Murohara T, Ikeda H, Otsuka Y, Aoki M, Takajo Y, et al \"Inhibition of platelet adherence to Mononuclear cells by alpha-tocopherol: role of P-selection.\" Circulation 110 (2004): 141-8[20] Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al \"Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status.\" Am J Clin Nutr 80 (2004): 143-8", "alternatives_a": "Alteplase, Streptokinase, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194141, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.", "source": "DDInter", "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.", "mechanism_text": "Others", "recommendation": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194369/", "reference_text": "[1] Conklin KA \"Cancer chemotherapy and antioxidants.\" J Nutr 134 (2004): 3201S-4S[2] Labriola D, Livingston R \"Possible interactions between dietary antioxidants and chemotherapy.\" Oncology (Williston Park) 13 (1999): 1003-8; discussion 1008, 1011-2[3] D'Andrea GM \"Use of antioxidants during chemotherapy and radiotherapy should be avoided.\" CA Cancer J Clin 55 (2005): 319-21[4] Pace A, Savarese A, Picardo M, et al \"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.\" J Clin Oncol 21 (2003): 927-31[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Prasad KN \"Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.\" J Nutr 134 (2004): 3182S-3S[7] Whittaker JA, Al-Ismail SA \"Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.\" Br Med J (Clin Res Ed) 288 (1984): 283-4[8] Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C \"Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials.\" Int J Cancer 123 (2008): 1227-39[9] Lonn E, Bosch J, Yusuf S, et al. \"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.\" JAMA 293 (2005): 1338-47", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194142, "ingredient1": "Drotrecogin alfa", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194370/", "reference_text": "[1] Helson L \"The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors.\" Thromb Res 35 (1984): 11-8[2] Kakishita E, Suehiro A, Oura Y, Nagai K \"Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood.\" Thromb Res 60 (1990): 489-99[3] Gonzalez-Correa JA, Arrebola MM, Guerrero A, et al. \"Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.\" Platelets 16(3-4) (2005): 171-9[4] Stampfer MJ, Jakubowski JA, Faigel D, Vaillancourt R, Deykin D \"Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels.\" Am J Clin Nutr 47 (1988): 700-6[5] Kim JM, White RH \"Effect of vitamin E on the anticoagulant response to warfarin.\" Am J Cardiol 77 (1996): 545-6[6] \"Vitamin K, vitamin E and the coumarin drugs.\" Nutr Rev 40 (1982): 180-2[7] Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C \"Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis.\" Pharmacotherapy 27 (2007): 1237-47[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Corrigan JJ, Ulfers LL \"Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency.\" Am J Clin Nutr 34 (1981): 1701-5[10] Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T \"Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms.\" Am J Clin Nutr 77 (2003): 700-6[11] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[12] \"Megavitamin E supplementation and vitamin K-dependent carboxylation.\" Nutr Rev 41 (1983): 268-70[13] Jandak J, Steiner M, Richardson PD \"Alpha-tocopherol, an effective inhibitor of platelet adhesion.\" Blood 73 (1989): 141-9[14] Celestini A, Pulcinelli FM, Pignatelli P, et al. \"Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets.\" Haematologica 87 (2002): 420-6[15] Freedman JE, Farhat JH, Loscalzo J, Keaney JF \"Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C--dependent mechanism.\" Circulation 94 (1996): 2434-40[16] Corrigan JJ \"The effect of vitamin E on warfarin-induced vitamin K deficiency.\" Ann N Y Acad Sci 393 (1982): 361-8[17] Schrogie JJ \"Coagulopathy and fat-soluble vitamins.\" JAMA 232 (1975): 19[18] Mardla V, Kobzar G, Samel N \"Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.\" Platelets 15 (2004): 319-24[19] Murohara T, Ikeda H, Otsuka Y, Aoki M, Takajo Y, et al \"Inhibition of platelet adherence to Mononuclear cells by alpha-tocopherol: role of P-selection.\" Circulation 110 (2004): 141-8[20] Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al \"Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status.\" Am J Clin Nutr 80 (2004): 143-8", "alternatives_a": "Alteplase, Streptokinase, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194143, "ingredient1": "Efalizumab", "ingredient2": "Vitamin E", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194371/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Alemtuzumab, Siponimod, Pegcetacoplan, Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Thalidomide, Pomalidomide, Emapalumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194144, "ingredient1": "Iron protein succinylate", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia.", "source": "DDInter", "management_text": "Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194372/", "reference_text": "[1] Melhorn DK, Gross S \"Relationships between iron-dextran and vitamin E in iron deficiency anemia in children.\" J Lab Clin Med 74 (1969): 789-802[2] Graeber JE, Williams ML, Oski FA \"The use of intramuscular vitamin E in the premature infant. Optimum dose and iron interaction.\" J Pediatr 90 (1977): 282-4", "alternatives_a": "Cyanocobalamin, Folic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194145, "ingredient1": "Vitamin E", "ingredient2": "Melphalan flufenamide", "severity": "Moderate", "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.", "source": "DDInter", "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.", "mechanism_text": "Others", "recommendation": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194373/", "reference_text": "[1] Conklin KA \"Cancer chemotherapy and antioxidants.\" J Nutr 134 (2004): 3201S-4S[2] Labriola D, Livingston R \"Possible interactions between dietary antioxidants and chemotherapy.\" Oncology (Williston Park) 13 (1999): 1003-8; discussion 1008, 1011-2[3] D'Andrea GM \"Use of antioxidants during chemotherapy and radiotherapy should be avoided.\" CA Cancer J Clin 55 (2005): 319-21[4] Pace A, Savarese A, Picardo M, et al \"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.\" J Clin Oncol 21 (2003): 927-31[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Prasad KN \"Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.\" J Nutr 134 (2004): 3182S-3S[7] Whittaker JA, Al-Ismail SA \"Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.\" Br Med J (Clin Res Ed) 288 (1984): 283-4[8] Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C \"Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials.\" Int J Cancer 123 (2008): 1227-39[9] Lonn E, Bosch J, Yusuf S, et al. \"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.\" JAMA 293 (2005): 1338-47", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194146, "ingredient1": "Vitamin E", "ingredient2": "Muromonab", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194374/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Alemtuzumab, Siponimod, Pegcetacoplan, Apremilast, Pirfenidone, Belumosudil, Ozanimod, Teprotumumab, Thalidomide, Pomalidomide, Emapalumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194147, "ingredient1": "Vitamin E", "ingredient2": "Naxitamab", "severity": "Moderate", "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.", "source": "DDInter", "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.", "mechanism_text": "Others", "recommendation": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194375/", "reference_text": "[1] Conklin KA \"Cancer chemotherapy and antioxidants.\" J Nutr 134 (2004): 3201S-4S[2] Labriola D, Livingston R \"Possible interactions between dietary antioxidants and chemotherapy.\" Oncology (Williston Park) 13 (1999): 1003-8; discussion 1008, 1011-2[3] D'Andrea GM \"Use of antioxidants during chemotherapy and radiotherapy should be avoided.\" CA Cancer J Clin 55 (2005): 319-21[4] Pace A, Savarese A, Picardo M, et al \"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.\" J Clin Oncol 21 (2003): 927-31[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Prasad KN \"Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.\" J Nutr 134 (2004): 3182S-3S[7] Whittaker JA, Al-Ismail SA \"Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.\" Br Med J (Clin Res Ed) 288 (1984): 283-4[8] Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C \"Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials.\" Int J Cancer 123 (2008): 1227-39[9] Lonn E, Bosch J, Yusuf S, et al. \"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.\" JAMA 293 (2005): 1338-47", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194148, "ingredient1": "Vitamin E", "ingredient2": "Plicamycin", "severity": "Moderate", "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.", "source": "DDInter", "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.", "mechanism_text": "Others", "recommendation": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194376/", "reference_text": "[1] Conklin KA \"Cancer chemotherapy and antioxidants.\" J Nutr 134 (2004): 3201S-4S[2] Labriola D, Livingston R \"Possible interactions between dietary antioxidants and chemotherapy.\" Oncology (Williston Park) 13 (1999): 1003-8; discussion 1008, 1011-2[3] D'Andrea GM \"Use of antioxidants during chemotherapy and radiotherapy should be avoided.\" CA Cancer J Clin 55 (2005): 319-21[4] Pace A, Savarese A, Picardo M, et al \"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.\" J Clin Oncol 21 (2003): 927-31[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Prasad KN \"Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.\" J Nutr 134 (2004): 3182S-3S[7] Whittaker JA, Al-Ismail SA \"Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.\" Br Med J (Clin Res Ed) 288 (1984): 283-4[8] Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C \"Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials.\" Int J Cancer 123 (2008): 1227-39[9] Lonn E, Bosch J, Yusuf S, et al. \"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.\" JAMA 293 (2005): 1338-47", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194149, "ingredient1": "Vitamin E", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194377/", "reference_text": "[1] Helson L \"The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors.\" Thromb Res 35 (1984): 11-8[2] Kakishita E, Suehiro A, Oura Y, Nagai K \"Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood.\" Thromb Res 60 (1990): 489-99[3] Gonzalez-Correa JA, Arrebola MM, Guerrero A, et al. \"Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.\" Platelets 16(3-4) (2005): 171-9[4] Stampfer MJ, Jakubowski JA, Faigel D, Vaillancourt R, Deykin D \"Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels.\" Am J Clin Nutr 47 (1988): 700-6[5] Kim JM, White RH \"Effect of vitamin E on the anticoagulant response to warfarin.\" Am J Cardiol 77 (1996): 545-6[6] \"Vitamin K, vitamin E and the coumarin drugs.\" Nutr Rev 40 (1982): 180-2[7] Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C \"Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis.\" Pharmacotherapy 27 (2007): 1237-47[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Corrigan JJ, Ulfers LL \"Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency.\" Am J Clin Nutr 34 (1981): 1701-5[10] Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T \"Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms.\" Am J Clin Nutr 77 (2003): 700-6[11] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[12] \"Megavitamin E supplementation and vitamin K-dependent carboxylation.\" Nutr Rev 41 (1983): 268-70[13] Jandak J, Steiner M, Richardson PD \"Alpha-tocopherol, an effective inhibitor of platelet adhesion.\" Blood 73 (1989): 141-9[14] Celestini A, Pulcinelli FM, Pignatelli P, et al. \"Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets.\" Haematologica 87 (2002): 420-6[15] Freedman JE, Farhat JH, Loscalzo J, Keaney JF \"Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C--dependent mechanism.\" Circulation 94 (1996): 2434-40[16] Corrigan JJ \"The effect of vitamin E on warfarin-induced vitamin K deficiency.\" Ann N Y Acad Sci 393 (1982): 361-8[17] Schrogie JJ \"Coagulopathy and fat-soluble vitamins.\" JAMA 232 (1975): 19[18] Mardla V, Kobzar G, Samel N \"Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.\" Platelets 15 (2004): 319-24[19] Murohara T, Ikeda H, Otsuka Y, Aoki M, Takajo Y, et al \"Inhibition of platelet adherence to Mononuclear cells by alpha-tocopherol: role of P-selection.\" Circulation 110 (2004): 141-8[20] Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al \"Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status.\" Am J Clin Nutr 80 (2004): 143-8", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194150, "ingredient1": "Vitamin E", "ingredient2": "Tinzaparin", "severity": "Moderate", "effect": "Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194378/", "reference_text": "[1] Helson L \"The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors.\" Thromb Res 35 (1984): 11-8[2] Kakishita E, Suehiro A, Oura Y, Nagai K \"Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood.\" Thromb Res 60 (1990): 489-99[3] Gonzalez-Correa JA, Arrebola MM, Guerrero A, et al. \"Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.\" Platelets 16(3-4) (2005): 171-9[4] Stampfer MJ, Jakubowski JA, Faigel D, Vaillancourt R, Deykin D \"Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels.\" Am J Clin Nutr 47 (1988): 700-6[5] Kim JM, White RH \"Effect of vitamin E on the anticoagulant response to warfarin.\" Am J Cardiol 77 (1996): 545-6[6] \"Vitamin K, vitamin E and the coumarin drugs.\" Nutr Rev 40 (1982): 180-2[7] Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C \"Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis.\" Pharmacotherapy 27 (2007): 1237-47[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Corrigan JJ, Ulfers LL \"Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency.\" Am J Clin Nutr 34 (1981): 1701-5[10] Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T \"Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms.\" Am J Clin Nutr 77 (2003): 700-6[11] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[12] \"Megavitamin E supplementation and vitamin K-dependent carboxylation.\" Nutr Rev 41 (1983): 268-70[13] Jandak J, Steiner M, Richardson PD \"Alpha-tocopherol, an effective inhibitor of platelet adhesion.\" Blood 73 (1989): 141-9[14] Celestini A, Pulcinelli FM, Pignatelli P, et al. \"Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets.\" Haematologica 87 (2002): 420-6[15] Freedman JE, Farhat JH, Loscalzo J, Keaney JF \"Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C--dependent mechanism.\" Circulation 94 (1996): 2434-40[16] Corrigan JJ \"The effect of vitamin E on warfarin-induced vitamin K deficiency.\" Ann N Y Acad Sci 393 (1982): 361-8[17] Schrogie JJ \"Coagulopathy and fat-soluble vitamins.\" JAMA 232 (1975): 19[18] Mardla V, Kobzar G, Samel N \"Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.\" Platelets 15 (2004): 319-24[19] Murohara T, Ikeda H, Otsuka Y, Aoki M, Takajo Y, et al \"Inhibition of platelet adherence to Mononuclear cells by alpha-tocopherol: role of P-selection.\" Circulation 110 (2004): 141-8[20] Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al \"Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status.\" Am J Clin Nutr 80 (2004): 143-8", "alternatives_a": "Alteplase, Streptokinase, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194151, "ingredient1": "Vitamin E", "ingredient2": "Uracil mustard", "severity": "Moderate", "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.", "source": "DDInter", "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.", "mechanism_text": "Others", "recommendation": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194379/", "reference_text": "[1] Conklin KA \"Cancer chemotherapy and antioxidants.\" J Nutr 134 (2004): 3201S-4S[2] Labriola D, Livingston R \"Possible interactions between dietary antioxidants and chemotherapy.\" Oncology (Williston Park) 13 (1999): 1003-8; discussion 1008, 1011-2[3] D'Andrea GM \"Use of antioxidants during chemotherapy and radiotherapy should be avoided.\" CA Cancer J Clin 55 (2005): 319-21[4] Pace A, Savarese A, Picardo M, et al \"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.\" J Clin Oncol 21 (2003): 927-31[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Prasad KN \"Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.\" J Nutr 134 (2004): 3182S-3S[7] Whittaker JA, Al-Ismail SA \"Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.\" Br Med J (Clin Res Ed) 288 (1984): 283-4[8] Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C \"Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials.\" Int J Cancer 123 (2008): 1227-39[9] Lonn E, Bosch J, Yusuf S, et al. \"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.\" JAMA 293 (2005): 1338-47", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194152, "ingredient1": "Anisindione", "ingredient2": "Drotrecogin alfa", "severity": "Major", "effect": "Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Treatment with drotrecogin alfa alone has been associated with serious and life-threatening bleeding episodes, including gastrointestinal, intracranial and retroperitoneal hemorrhage, although most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin time (PT).", "source": "DDInter", "management_text": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day). Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs. Continued use of other agents that may have contributed to the bleeding should be carefully assessed. Once adequate hemostasis is attained, drotrecogin alfa may be resumed if necessary.", "mechanism_text": "Synergism", "recommendation": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194380/", "reference_text": "[1] \"Product Information. Xigris (drotrecogin alfa).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Warfarin, Cilostazol, Dicoumarol, Antithrombin III human, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194153, "ingredient1": "Anistreplase", "ingredient2": "Drotrecogin alfa", "severity": "Major", "effect": "Concurrent administration of thrombolytic agents and drotrecogin alfa may increase the risk of serious or life-threatening bleeding complications due to additive or synergistic effects on the clotting cascade. Drotrecogin alfa inactivates blood clotting Factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin times (PT).", "source": "DDInter", "management_text": "When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.", "mechanism_text": "Synergism", "recommendation": "When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194381/", "reference_text": "[1] \"Product Information. Xigris (drotrecogin alfa).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Acenocoumarol, Selexipag, Drotrecogin alfa", "alternatives_b": "Alteplase, Dicoumarol, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "updated_at": 1767369485}, {"id": 194154, "ingredient1": "Drotrecogin alfa", "ingredient2": "Ardeparin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194382/", "reference_text": "[1] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] \"Product Information. Lovenox (enoxaparin).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Innohep (tinzaparin)\" DuPont Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Arixtra (fondaparinux).\" Organon, West Orange, NJ.[6] \"Product Information. Orgaran (danaparoid).\" Organon, West Orange, NJ.[7] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995): 395", "alternatives_a": "Acenocoumarol, Selexipag", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194155, "ingredient1": "Drotrecogin alfa", "ingredient2": "Bromfenac", "severity": "Major", "effect": "Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT).", "source": "DDInter", "management_text": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia. Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs.", "mechanism_text": "Synergism", "recommendation": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194383/", "reference_text": "[1] \"Product Information. Xigris (drotrecogin alfa).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Abciximab, Tirofiban, Dicoumarol, Eptifibatide, Protein C, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone", "updated_at": 1767369485}, {"id": 194156, "ingredient1": "Drotrecogin alfa", "ingredient2": "Danaparoid", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194384/", "reference_text": "[1] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] \"Product Information. Lovenox (enoxaparin).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Innohep (tinzaparin)\" DuPont Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Arixtra (fondaparinux).\" Organon, West Orange, NJ.[6] \"Product Information. Orgaran (danaparoid).\" Organon, West Orange, NJ.[7] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995): 395", "alternatives_a": "Danaparoid, Acenocoumarol, Selexipag", "alternatives_b": "Acenocoumarol, Selexipag, Drotrecogin alfa", "updated_at": 1767369485}, {"id": 194157, "ingredient1": "Drotrecogin alfa", "ingredient2": "Dexfenfluramine", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194385/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Dicoumarol, Protein C, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 194158, "ingredient1": "Drotrecogin alfa", "ingredient2": "Dextran (-1)", "severity": "Major", "effect": "Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT).", "source": "DDInter", "management_text": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia. Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs.", "mechanism_text": "Synergism", "recommendation": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194386/", "reference_text": "[1] \"Product Information. Xigris (drotrecogin alfa).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Argatroban, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194159, "ingredient1": "Drotrecogin alfa", "ingredient2": "Dicoumarol", "severity": "Major", "effect": "Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Treatment with drotrecogin alfa alone has been associated with serious and life-threatening bleeding episodes, including gastrointestinal, intracranial and retroperitoneal hemorrhage, although most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin time (PT).", "source": "DDInter", "management_text": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day). Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs. Continued use of other agents that may have contributed to the bleeding should be carefully assessed. Once adequate hemostasis is attained, drotrecogin alfa may be resumed if necessary.", "mechanism_text": "Synergism", "recommendation": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194387/", "reference_text": "[1] \"Product Information. Xigris (drotrecogin alfa).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Warfarin, Cilostazol, Dicoumarol, Antithrombin III human, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "Acenocoumarol, Selexipag, Drotrecogin alfa", "updated_at": 1767369485}, {"id": 194160, "ingredient1": "Hemin", "ingredient2": "Drotrecogin alfa", "severity": "Moderate", "effect": "Theoretically, hemin may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. Hemin has exhibited mild, transient anticoagulant effects during clinical studies.", "source": "DDInter", "management_text": "The use of hemin with concurrent anticoagulant therapy should be avoided. Caution is advised if hemin is used in combination with other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "The use of hemin with concurrent anticoagulant therapy should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194388/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc, Lebanon, NJ.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 194161, "ingredient1": "Drotrecogin alfa", "ingredient2": "Phenylbutazone", "severity": "Major", "effect": "Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT).", "source": "DDInter", "management_text": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia. Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs.", "mechanism_text": "Synergism", "recommendation": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194389/", "reference_text": "[1] \"Product Information. Xigris (drotrecogin alfa).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Clopidogrel, Dicoumarol, Protein C, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "Rabeprazole, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Celecoxib, Valdecoxib, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 194162, "ingredient1": "Drotrecogin alfa", "ingredient2": "Plicamycin", "severity": "Major", "effect": "Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT).", "source": "DDInter", "management_text": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia. Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs.", "mechanism_text": "Synergism", "recommendation": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194390/", "reference_text": "[1] \"Product Information. Xigris (drotrecogin alfa).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Clopidogrel, Cilostazol, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, Argatroban, Desirudin, More", "alternatives_b": "Idarubicin, Valrubicin, Ixabepilone, Mitoxantrone, Bleomycin, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "updated_at": 1767369485}, {"id": 194163, "ingredient1": "Drotrecogin alfa", "ingredient2": "Salicylic acid (sodium)", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X, occasionally increasing the prothrombin time. While these effects are generally slight for most salicylates (except aspirin) at recommended dosages, they may be of clinical significance when combined with the inhibitory effects of anticoagulants on the clotting cascade. Moreover, salicylates are known to cause dose-related gastrointestinal bleeding, which may be complicated by anticoagulant therapy.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194391/", "reference_text": "[1] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[2] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970): 403-8[3] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971): 487-98[4] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971): 547-58[5] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[6] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967): 620-4[7] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968): 2169-80[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005): 439-44", "alternatives_a": "Cilostazol, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Streptokinase, Tinzaparin, Selexipag, Vorapaxar, Dicoumarol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194164, "ingredient1": "Drotrecogin alfa", "ingredient2": "Streptokinase", "severity": "Major", "effect": "Concurrent administration of thrombolytic agents and drotrecogin alfa may increase the risk of serious or life-threatening bleeding complications due to additive or synergistic effects on the clotting cascade. Drotrecogin alfa inactivates blood clotting Factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin times (PT).", "source": "DDInter", "management_text": "When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.", "mechanism_text": "Synergism", "recommendation": "When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194392/", "reference_text": "[1] \"Product Information. Xigris (drotrecogin alfa).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Alteplase, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "Acenocoumarol, Selexipag, Drotrecogin alfa, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 194165, "ingredient1": "Drotrecogin alfa", "ingredient2": "Sulfinpyrazone", "severity": "Major", "effect": "Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Treatment with drotrecogin alfa alone has been associated with serious and life-threatening bleeding episodes, including gastrointestinal, intracranial and retroperitoneal hemorrhage, although most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin time (PT).", "source": "DDInter", "management_text": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day). Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs. Continued use of other agents that may have contributed to the bleeding should be carefully assessed. Once adequate hemostasis is attained, drotrecogin alfa may be resumed if necessary.", "mechanism_text": "Synergism", "recommendation": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day).", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194393/", "reference_text": "[1] \"Product Information. Xigris (drotrecogin alfa).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Dipyridamole, Abciximab, Tirofiban, Caplacizumab, Clopidogrel, Cilostazol, Prasugrel, Eptifibatide, Antithrombin III human, Protein C, Acenocoumarol, More", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Rasburicase, Probenecid, Allopurinol", "updated_at": 1767369485}, {"id": 194166, "ingredient1": "Drotrecogin alfa", "ingredient2": "Tinzaparin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194394/", "reference_text": "[1] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] \"Product Information. Lovenox (enoxaparin).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Innohep (tinzaparin)\" DuPont Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Arixtra (fondaparinux).\" Organon, West Orange, NJ.[6] \"Product Information. Orgaran (danaparoid).\" Organon, West Orange, NJ.[7] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995): 395", "alternatives_a": "Tinzaparin, Acenocoumarol, Selexipag", "alternatives_b": "Acenocoumarol, Selexipag, Drotrecogin alfa", "updated_at": 1767369485}, {"id": 194167, "ingredient1": "Drotrecogin alfa", "ingredient2": "Tositumomab", "severity": "Major", "effect": "Coadministration of tositumomab and iodine I 131 tositumomab with drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Tositumomab and iodine I 131 tositumomab alone can cause severe or life-threatening thrombocytopenia.", "source": "DDInter", "management_text": "Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously. Close clinical and laboratory observation for bleeding complications is recommended during and after the therapeutic regimen.", "mechanism_text": "Synergism", "recommendation": "Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194395/", "reference_text": "[1] \"Product Information. BexxarTherapy (tositumomab).\" GlaxoSmithKline Inc, Oakville, IA.[2] \"Product Information. Bexxar I 131 Therapeutic (iodine I 131 tositumomab).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Dicoumarol, Desirudin, Protein C, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194168, "ingredient1": "Drotrecogin alfa", "ingredient2": "Urokinase", "severity": "Major", "effect": "Concurrent administration of thrombolytic agents and drotrecogin alfa may increase the risk of serious or life-threatening bleeding complications due to additive or synergistic effects on the clotting cascade. Drotrecogin alfa inactivates blood clotting Factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin times (PT).", "source": "DDInter", "management_text": "When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.", "mechanism_text": "Synergism", "recommendation": "When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194396/", "reference_text": "[1] \"Product Information. Xigris (drotrecogin alfa).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Acenocoumarol, Selexipag, Drotrecogin alfa", "alternatives_b": "Alteplase, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "updated_at": 1767369485}, {"id": 194169, "ingredient1": "Yohimbine", "ingredient2": "Morphine (liposomal)", "severity": "Minor", "effect": "double-blind, placebo-controlled study of patients with postoperative dental pain found that while yohimbine itself did not affect pain, the overall analgesic effect of morphine was significantly enhanced in the presence of yohimbine. The mechanism of interaction is unknown. Additional research involving other pain states is needed.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194397/", "reference_text": "[1] Gear RW, Gordon NC, Heller PH, Levine JD \"Enhancement of morphine analgesia by the alpha(2)-adrenergic antagonist yohimbine.\" Neuroscience 66 (1995): 5-8", "alternatives_a": "Diphenoxylate, Opium, Eluxadoline, Difenoxin, Loperamide, Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Avanafil, Papaverine, Vardenafil, More", "updated_at": 1767369485}, {"id": 194170, "ingredient1": "Yohimbine", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with troglitazone may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by troglitazone.", "source": "DDInter", "management_text": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever troglitazone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194398/", "reference_text": "[1] \"Product Information. Rezulin (troglitazone).\" Parke-Davis, Morris Plains, NJ.[2] Fraser CG, Fierro L \"Comment: troglitazone.\" Ann Pharmacother 32 (1998): 1111-2[3] Park MH, Pelegrin D, Haug MT, Young JB \"Troglitazone, a new antidiabetic agent, decreases cyclosporine level.\" J Heart Lung Transplant 17 (1998): 1139-40[4] Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P, Bonomini L, Mulgaonkar SP \"Potential interaction of troglitazone and cyclosporine.\" Transplantation 65 (1998): 1399-400[5] Frantz RP, Nguyen TT \"Rezulin (troglitazone) greatly increases cyclosporine metabolism.\" J Heart Lung Transplant 17 (1998): 1037-8[6] Burgess SJ, Singer GG, Brennan DC \"Effect of troglitazone on cyclosporine whole blood levels.\" Transplantation 66 (1998): 272[7] Terra SG, Washam JB, May DB \"Comment: troglitazone drug interactions.\" Ann Pharmacother 32 (1998): 1111[8] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[9] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[10] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[15] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[16] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Alprostadil, Acetohydroxamic acid, Flavoxate, Papaverine, Vardenafil, More", "updated_at": 1767369485}, {"id": 194171, "ingredient1": "Efalizumab", "ingredient2": "Zinc chloride", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194399/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Procaine, Fluorometholone, Nitroglycerin, Calcium chloride, Potassium chloride, More", "updated_at": 1767369485}, {"id": 194172, "ingredient1": "Zinc chloride", "ingredient2": "Melphalan", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194400/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Betamethasone, Fluorometholone, Triamcinolone, More", "updated_at": 1767369485}, {"id": 194173, "ingredient1": "Zinc chloride", "ingredient2": "Melphalan flufenamide", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194401/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "alternatives_b": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More", "updated_at": 1767369485}, {"id": 194174, "ingredient1": "Zinc chloride", "ingredient2": "Muromonab", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194402/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "updated_at": 1767369485}, {"id": 194175, "ingredient1": "Zinc chloride", "ingredient2": "Naxitamab", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194403/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194176, "ingredient1": "Zinc chloride", "ingredient2": "Oxytetracycline", "severity": "Moderate", "effect": "INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.", "mechanism_text": "Absorption", "recommendation": "Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194404/", "reference_text": "[1] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[2] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[3] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[4] Gothoni G, Neuvonen PJ, Mattila M, Hackman R \"Iron-tetracycline interaction: effect of time interval between the drugs.\" Acta Med Scand 191 (1972): 409-11[5] Penttila O, Hurme H, Neuvonen PJ \"Effect of zinc sulphate on the absorption of tetracycline and doxycycline in man.\" Eur J Clin Pharmacol 9 (1975): 131-4[6] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[7] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Doxycycline, Tigecycline, Eravacycline, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Betamethasone, Fluorometholone, Triamcinolone, More", "updated_at": 1767369485}, {"id": 194177, "ingredient1": "Cinoxacin", "ingredient2": "Zinc gluconate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194405/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Fluorometholone, Nitroglycerin, Sodium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194178, "ingredient1": "Dolutegravir", "ingredient2": "Zinc gluconate", "severity": "Major", "effect": "INTERVAL: Coadministration with medications or supplements containing polyvalent cations such as zinc may decrease the plasma concentrations of integrase strand transfer inhibitors (INSTIs). The proposed mechanism involves chelation of the INSTI by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.", "mechanism_text": "Absorption", "recommendation": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194406/", "reference_text": "[1] US National Library of Medicine \"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available from: URL: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/287/insti-drug-interactions.\" ([2019, Nov 6]):[2] \"Product Information. Tivicay (dolutegravir).\" ViiV Healthcare, Research Triangle Park, NC.[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences, Foster City, CA.[4] \"Product Information. Tivicay (dolutegravir).\" ViiV Healthcare, Research Triangle Park, NC.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "Lidocaine, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "updated_at": 1767369485}, {"id": 194179, "ingredient1": "Efalizumab", "ingredient2": "Zinc gluconate", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194407/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Procaine, Fluorometholone, Nitroglycerin, Magnesium gluconate, Magnesium sulfate, More", "updated_at": 1767369485}, {"id": 194180, "ingredient1": "Enoxacin", "ingredient2": "Zinc gluconate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194408/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Fluorometholone, Nitroglycerin, Sodium chloride, Magnesium aspartate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194181, "ingredient1": "Grepafloxacin", "ingredient2": "Zinc gluconate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194409/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Lidocaine, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Fluorometholone, Nitroglycerin, Sodium chloride, Magnesium aspartate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194182, "ingredient1": "Iron protein succinylate", "ingredient2": "Zinc gluconate", "severity": "Minor", "effect": "Iron and zinc may reduce each other's absorption when they are coadministered orally. The mechanism of interaction is unknown. In clinical studies, concurrent supplementation with iron and zinc was associated with reduced efficacy in improving the growth and iron and zinc status of malnourished infants compared to supplementation with either one alone. In any case, the clinical significance is probably minimal in healthy individuals. However, monitoring for reduced therapeutic response may be advisable in malnourished patients. Limited data suggest that the magnitude of the interaction may be lessened by separating the times of administration of each by 12 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194410/", "reference_text": "[1] Sreedhar B \"Conflicting evidence of iron and zinc interactions in humans: does iron affect zinc absorption?\" Am J Clin Nutr 78 (2003): 1226; author reply 1226-7[2] Lind T, Lonnerdal B, Stenlund H, et al. \"A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc.\" Am J Clin Nutr 77 (2003): 883-90", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Prednisolone, Betamethasone, More", "updated_at": 1767369485}, {"id": 194183, "ingredient1": "Zinc gluconate", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194411/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Fluorometholone, Nitroglycerin, Sodium chloride, Magnesium aspartate", "updated_at": 1767369485}, {"id": 194184, "ingredient1": "Zinc gluconate", "ingredient2": "Melphalan", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194412/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Betamethasone, Fluorometholone, Triamcinolone, More", "updated_at": 1767369485}, {"id": 194185, "ingredient1": "Zinc gluconate", "ingredient2": "Melphalan flufenamide", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194413/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "alternatives_b": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Ifosfamide, More", "updated_at": 1767369485}, {"id": 194186, "ingredient1": "Zinc gluconate", "ingredient2": "Muromonab", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194414/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Ravulizumab, Methotrexate, Siponimod, Apremilast, Cladribine, Belumosudil, Ozanimod, Thalidomide, Emapalumab, Fingolimod, Alemtuzumab, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "updated_at": 1767369485}, {"id": 194187, "ingredient1": "Zinc gluconate", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194415/", "reference_text": "[1] \"Product Information. NegGram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Fluorometholone, Nitroglycerin, Sodium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194188, "ingredient1": "Zinc gluconate", "ingredient2": "Naxitamab", "severity": "Minor", "effect": "Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194416/", "reference_text": "[1] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Pepping J \"Echinacea.\" Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):", "alternatives_a": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Prednisolone, Betamethasone, Fluorometholone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194189, "ingredient1": "Zinc gluconate", "ingredient2": "Oxytetracycline", "severity": "Moderate", "effect": "INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.", "mechanism_text": "Absorption", "recommendation": "Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194417/", "reference_text": "[1] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[2] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[3] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[4] Gothoni G, Neuvonen PJ, Mattila M, Hackman R \"Iron-tetracycline interaction: effect of time interval between the drugs.\" Acta Med Scand 191 (1972): 409-11[5] Penttila O, Hurme H, Neuvonen PJ \"Effect of zinc sulphate on the absorption of tetracycline and doxycycline in man.\" Eur J Clin Pharmacol 9 (1975): 131-4[6] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[7] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Doxycycline, Tigecycline, Eravacycline, Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, More", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Procaine, Betamethasone, Fluorometholone, Triamcinolone, More", "updated_at": 1767369485}, {"id": 194190, "ingredient1": "Zinc gluconate", "ingredient2": "Sparfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194418/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Fluorometholone, Nitroglycerin, Sodium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194191, "ingredient1": "Zinc gluconate", "ingredient2": "Tiludronic acid", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194419/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Lidocaine, Diltiazem, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Prednisolone, Betamethasone, More", "updated_at": 1767369485}, {"id": 194192, "ingredient1": "Goserelin", "ingredient2": "Gefitinib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194420/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Triptorelin, Ethinylestradiol", "alternatives_b": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 194193, "ingredient1": "Goserelin", "ingredient2": "Zoledronic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194421/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Triptorelin, Ethinylestradiol", "alternatives_b": "Tiludronic acid, Vosoritide, Etidronic acid, Denosumab, Ibandronate, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194194, "ingredient1": "Goserelin", "ingredient2": "Allopurinol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194422/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Triptorelin, Ethinylestradiol", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 194195, "ingredient1": "Goserelin", "ingredient2": "Montelukast", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194423/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Bicalutamide, Triptorelin, Ethinylestradiol", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More", "updated_at": 1767369485}, {"id": 194196, "ingredient1": "Goserelin", "ingredient2": "Duloxetine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194424/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Bicalutamide, Triptorelin, Ethinylestradiol", "alternatives_b": "Phenelzine, Tranylcypromine, Vilazodone, Desvenlafaxine, St. John's Wort, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, More", "updated_at": 1767369485}, {"id": 194197, "ingredient1": "Goserelin", "ingredient2": "Lenalidomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194425/", "reference_text": "-", "alternatives_a": "Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 194198, "ingredient1": "Goserelin", "ingredient2": "Simvastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194426/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Triptorelin, Ethinylestradiol", "alternatives_b": "Guar gum, Cholestyramine, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Cerivastatin, Lomitapide, Ezetimibe, Niacin, Colesevelam, More", "updated_at": 1767369485}, {"id": 194199, "ingredient1": "Goserelin", "ingredient2": "Tamsulosin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194427/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Triptorelin, Ethinylestradiol", "alternatives_b": "Silodosin, Tadalafil, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 194200, "ingredient1": "Goserelin", "ingredient2": "Misoprostol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194428/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Bicalutamide, Triptorelin, Ethinylestradiol", "alternatives_b": "Methylergometrine, Ergometrine, Dinoprostone, Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Bismuth subcitrate potassium, Rifabutin, Cimetidine, More", "updated_at": 1767369485}, {"id": 194201, "ingredient1": "Goserelin", "ingredient2": "Fulvestrant", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194429/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Bicalutamide, Triptorelin, Ethinylestradiol", "alternatives_b": "Darolutamide, Aminoglutethimide, Abarelix, Enzalutamide, Relugolix, Degarelix, Nilutamide, Apalutamide, Abiraterone", "updated_at": 1767369485}, {"id": 194202, "ingredient1": "Goserelin", "ingredient2": "Exemestane", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194430/", "reference_text": "-", "alternatives_a": "Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin", "alternatives_b": "Darolutamide, Aminoglutethimide, Abarelix, Enzalutamide, Relugolix, Degarelix, Nilutamide, Apalutamide, Abiraterone", "updated_at": 1767369485}, {"id": 194203, "ingredient1": "Goserelin", "ingredient2": "Rosuvastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194431/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Triptorelin", "alternatives_b": "Lovastatin, Ezetimibe, Perindopril, Pravastatin, Niacin, Bempedoic acid, Fenofibrate, Cholestyramine, Fenofibrate, Mipomersen, Evinacumab, More", "updated_at": 1767369485}, {"id": 194204, "ingredient1": "Goserelin", "ingredient2": "Capecitabine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194432/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Bicalutamide, Triptorelin, Ethinylestradiol", "alternatives_b": "Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, More", "updated_at": 1767369485}, {"id": 194205, "ingredient1": "Goserelin", "ingredient2": "Dutasteride", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194433/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Triptorelin, Ethinylestradiol", "alternatives_b": "Silodosin, Tadalafil", "updated_at": 1767369485}, {"id": 194206, "ingredient1": "Goserelin", "ingredient2": "Tiotropium", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194434/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Bicalutamide, Triptorelin, Ethinylestradiol", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Epinephrine, Beclomethasone dipropionate, Ciclesonide, Umeclidinium, More", "updated_at": 1767369485}, {"id": 194207, "ingredient1": "Goserelin", "ingredient2": "Fluticasone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194435/", "reference_text": "-", "alternatives_a": "Diethylstilbestrol, Histrelin, Megestrol acetate, Leuprolide, Medroxyprogesterone acetate, Bicalutamide, Triptorelin, Ethinylestradiol", "alternatives_b": "Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More", "updated_at": 1767369485}, {"id": 194208, "ingredient1": "Desmopressin", "ingredient2": "Allopurinol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194436/", "reference_text": "-", "alternatives_a": "Terlipressin, Oxytocin", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 194209, "ingredient1": "Desmopressin", "ingredient2": "Lactulose", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194437/", "reference_text": "-", "alternatives_a": "Terlipressin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 194210, "ingredient1": "Desmopressin", "ingredient2": "Simvastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194438/", "reference_text": "-", "alternatives_a": "Terlipressin, Oxytocin", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "updated_at": 1767369485}, {"id": 194211, "ingredient1": "Ezetimibe", "ingredient2": "Desmopressin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194439/", "reference_text": "-", "alternatives_a": "Terlipressin, Oxytocin", "alternatives_b": "Amlodipine, Ramipril, Atorvastatin, Lovastatin, Rosuvastatin, Lisinopril, Perindopril, Niacin, Bempedoic acid, Indapamide, Cholestyramine, More", "updated_at": 1767369485}, {"id": 194212, "ingredient1": "Desmopressin", "ingredient2": "Levetiracetam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194440/", "reference_text": "-", "alternatives_a": "Terlipressin, Oxytocin", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 194213, "ingredient1": "Folic acid", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194441/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "updated_at": 1767369485}, {"id": 194214, "ingredient1": "Cyclosporine", "ingredient2": "Lorazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194442/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194215, "ingredient1": "Cyclosporine", "ingredient2": "Bortezomib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194443/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 194216, "ingredient1": "Cyclosporine", "ingredient2": "Tramadol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194444/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Oliceridine, Oxymorphone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Dihydrocodeine, Naloxone, Codeine", "updated_at": 1767369485}, {"id": 194217, "ingredient1": "Cyclosporine", "ingredient2": "Oseltamivir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194445/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 194218, "ingredient1": "Cyclosporine", "ingredient2": "Torasemide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194446/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Etacrynic acid, Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, Probenecid, Diclofenamide, Mafenide, Tioconazole, More", "updated_at": 1767369485}, {"id": 194219, "ingredient1": "Cyclosporine", "ingredient2": "Moxifloxacin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194447/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Rifamycin, Oxytetracycline, Lomefloxacin, Trifluridine, Benzylpenicillin, Ampicillin, Chlorhexidine, Levofloxacin, Povidone-iodine, Enoxacin, Levofloxacin, More", "updated_at": 1767369485}, {"id": 194220, "ingredient1": "Gadodiamide", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194448/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Gadobutrol, Gadofosveset trisodium, Gadopentetic acid, Gadoxetic acid, Gadoteric acid, Gadobenic acid, Gadoteridol, Ferumoxsil", "updated_at": 1767369485}, {"id": 194221, "ingredient1": "Cyclosporine", "ingredient2": "Pregabalin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194449/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More", "updated_at": 1767369485}, {"id": 194222, "ingredient1": "Cyclosporine", "ingredient2": "Temazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194450/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Eszopiclone, Dexmedetomidine, More", "updated_at": 1767369485}, {"id": 194223, "ingredient1": "Dapsone", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194451/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Vitamin A, Azelaic acid, Adapalene, Isotretinoin, Clofazimine", "updated_at": 1767369485}, {"id": 194224, "ingredient1": "Cyclosporine", "ingredient2": "Metoprolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194452/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Nebivolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol, Nebivolol, Pindolol, Penbutolol", "updated_at": 1767369485}, {"id": 194225, "ingredient1": "Cyclosporine", "ingredient2": "Ropinirole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194453/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Apomorphine, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 194226, "ingredient1": "Isradipine", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194454/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "alternatives_b": "Clevidipine, Nimodipine", "updated_at": 1767369485}, {"id": 194227, "ingredient1": "Cyclosporine", "ingredient2": "Topiramate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194455/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More", "updated_at": 1767369485}, {"id": 194228, "ingredient1": "Cyclosporine", "ingredient2": "Lidocaine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194456/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "alternatives_b": "Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Doxepin, Pheniramine, Chlorhexidine, Povidone-iodine, More", "updated_at": 1767369485}, {"id": 194229, "ingredient1": "Cyclosporine", "ingredient2": "Travoprost", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194457/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Methazolamide, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, Diclofenamide, Carteolol, Apraclonidine, Guanethidine", "updated_at": 1767369485}, {"id": 194230, "ingredient1": "Cyclosporine", "ingredient2": "Morphine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194458/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Opium, Diphenoxylate, Difenoxin, Oliceridine, Oxymorphone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Pentazocine, More", "updated_at": 1767369485}, {"id": 194231, "ingredient1": "Cyclosporine", "ingredient2": "Valproic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194459/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More", "updated_at": 1767369485}, {"id": 194232, "ingredient1": "Cyclosporine", "ingredient2": "Piperacillin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194460/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Sulbactam, Oxacillin, Dicloxacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 194233, "ingredient1": "Fluorometholone", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194461/", "reference_text": "-", "alternatives_a": "Golimumab, Antithymocyte immunoglobulin (rabbit), Ravulizumab, Diroximel fumarate, Methotrexate, Inebilizumab, Belumosudil, Ozanimod, Emapalumab, Natalizumab, Fingolimod, More", "alternatives_b": "Mometasone furoate, Fluocinolone acetonide, Mometasone furoate, Beclomethasone dipropionate, Amcinonide, Fluocinolone acetonide, Bromfenac, Fluocinolone acetonide, Procaine, Tetracaine, Isosorbide dinitrate, More", "updated_at": 1767369485}, {"id": 194234, "ingredient1": "Hydromorphone", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194462/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Oliceridine, Oxymorphone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Dihydrocodeine, Naloxone, Codeine", "updated_at": 1767369485}, {"id": 194235, "ingredient1": "Ethambutol", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194463/", "reference_text": "-", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Rifamycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 194236, "ingredient1": "Cyclosporine", "ingredient2": "Metformin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194464/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More", "updated_at": 1767369485}, {"id": 194237, "ingredient1": "Cyclosporine", "ingredient2": "Olanzapine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194465/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, Clozapine, More", "updated_at": 1767369485}, {"id": 194238, "ingredient1": "Cyclosporine", "ingredient2": "Minoxidil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194466/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, More", "alternatives_b": "Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Povidone-iodine, Nitroprusside, Diazoxide", "updated_at": 1767369485}, {"id": 194239, "ingredient1": "Cyclosporine", "ingredient2": "Mirtazapine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194467/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194240, "ingredient1": "Cyclosporine", "ingredient2": "Timolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194468/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol, Methazolamide, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, More", "updated_at": 1767369485}, {"id": 194241, "ingredient1": "Cyclosporine", "ingredient2": "Rosiglitazone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194469/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More", "updated_at": 1767369485}, {"id": 194242, "ingredient1": "Cyclosporine", "ingredient2": "Pramipexole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194470/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Apomorphine, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 194243, "ingredient1": "Cyclosporine", "ingredient2": "Phenoxymethylpenicillin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194471/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, More", "alternatives_b": "Sulbactam, Oxacillin, Dicloxacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 194244, "ingredient1": "Cyclosporine", "ingredient2": "Methocarbamol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194472/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Chlorzoxazone, Chlormezanone", "updated_at": 1767369485}, {"id": 194245, "ingredient1": "Cyclosporine", "ingredient2": "Zolpidem", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194473/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Eszopiclone, Dexmedetomidine, More", "updated_at": 1767369485}, {"id": 194246, "ingredient1": "Famciclovir", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194474/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 194247, "ingredient1": "Cyclosporine", "ingredient2": "Prochlorperazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194475/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, Clozapine, More", "updated_at": 1767369485}, {"id": 194248, "ingredient1": "Gemcitabine", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194476/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine", "updated_at": 1767369485}, {"id": 194249, "ingredient1": "Cyclosporine", "ingredient2": "Meperidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194477/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Oliceridine, Oxymorphone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Dihydrocodeine, Naloxone, Codeine", "updated_at": 1767369485}, {"id": 194250, "ingredient1": "Cyclosporine", "ingredient2": "Loratadine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194478/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "updated_at": 1767369485}, {"id": 194251, "ingredient1": "Cyclosporine", "ingredient2": "Acitretin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194479/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Etretinate, Methoxsalen, Trioxsalen", "updated_at": 1767369485}, {"id": 194252, "ingredient1": "Cyclosporine", "ingredient2": "Montelukast", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194480/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 194253, "ingredient1": "Duloxetine", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194481/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194254, "ingredient1": "Cyclosporine", "ingredient2": "Lenalidomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194482/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 194255, "ingredient1": "Cyclosporine", "ingredient2": "Raloxifene", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194483/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ospemifene, Prasterone, Bazedoxifene", "updated_at": 1767369485}, {"id": 194256, "ingredient1": "Cyclosporine", "ingredient2": "Sotalol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194484/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol, Nebivolol, Nebivolol", "updated_at": 1767369485}, {"id": 194257, "ingredient1": "Haloperidol", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194485/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, Clozapine, More", "updated_at": 1767369485}, {"id": 194258, "ingredient1": "Cyclosporine", "ingredient2": "Cisplatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194486/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 194259, "ingredient1": "Gadoversetamide", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194487/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Gadobutrol, Gadofosveset trisodium, Gadopentetic acid, Gadoxetic acid, Gadoteric acid, Gadobenic acid, Gadoteridol, Ferumoxsil", "updated_at": 1767369485}, {"id": 194260, "ingredient1": "Cyclosporine", "ingredient2": "Nortriptyline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194488/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194261, "ingredient1": "Fluorouracil", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194489/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine", "updated_at": 1767369485}, {"id": 194262, "ingredient1": "Cyclosporine", "ingredient2": "Pyridostigmine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194490/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ambenonium, Bethanechol, Neostigmine", "updated_at": 1767369485}, {"id": 194263, "ingredient1": "Cyclosporine", "ingredient2": "Lamotrigine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194491/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More", "updated_at": 1767369485}, {"id": 194264, "ingredient1": "Hydroxyzine", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194492/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194265, "ingredient1": "Cyclosporine", "ingredient2": "Propranolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194493/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Nebivolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol, Nebivolol", "updated_at": 1767369485}, {"id": 194266, "ingredient1": "Cyclosporine", "ingredient2": "Atropine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194494/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Homatropine, Methscopolamine, Ephedrine, Tropicamide, Phenylephrine, Glycopyrronium, Methscopolamine, Clidinium, Hyoscyamine, Propantheline, Hyoscyamine, Methscopolamine", "updated_at": 1767369485}, {"id": 194267, "ingredient1": "Cyclosporine", "ingredient2": "Lactulose", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194495/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Alvimopan, Sorbitol, Bisacodyl, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 194268, "ingredient1": "Cyclosporine", "ingredient2": "Nizatidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194496/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Vonoprazan, Bismuth subcitrate potassium, Levofloxacin", "updated_at": 1767369485}, {"id": 194269, "ingredient1": "Doxazosin", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194497/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Prazosin, Guanethidine", "updated_at": 1767369485}, {"id": 194270, "ingredient1": "Cyclosporine", "ingredient2": "Labetalol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194498/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Nebivolol, Pindolol, Penbutolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol", "updated_at": 1767369485}, {"id": 194271, "ingredient1": "Cyclosporine", "ingredient2": "Linezolid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194499/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Oritavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 194272, "ingredient1": "Cyclosporine", "ingredient2": "Nystatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194500/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Selenium Sulfide, Thiabendazole, Econazole, Tioconazole, Chlorphenesin, Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, More", "updated_at": 1767369485}, {"id": 194273, "ingredient1": "Cyclosporine", "ingredient2": "Latanoprost", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194501/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Methazolamide, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, Diclofenamide, Carteolol, Apraclonidine, Guanethidine", "updated_at": 1767369485}, {"id": 194274, "ingredient1": "Cyclosporine", "ingredient2": "Trazodone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194502/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194275, "ingredient1": "Cyclosporine", "ingredient2": "Sumatriptan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194503/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Frovatriptan, Eptinezumab, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab, Ascorbic acid, Methazolamide, More", "updated_at": 1767369485}, {"id": 194276, "ingredient1": "Cyclosporine", "ingredient2": "Tamoxifen", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194504/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Darolutamide, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, Abiraterone, Exemestane", "updated_at": 1767369485}, {"id": 194277, "ingredient1": "Cyclosporine", "ingredient2": "Midazolam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194505/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Eszopiclone, Dexmedetomidine, More", "updated_at": 1767369485}, {"id": 194278, "ingredient1": "Cyclosporine", "ingredient2": "Tizanidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194506/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Chlorzoxazone, Chlormezanone", "updated_at": 1767369485}, {"id": 194279, "ingredient1": "Cyclosporine", "ingredient2": "Nitrofurantoin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194507/", "reference_text": "-", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Siponimod, Anakinra, More", "alternatives_b": "Oritavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 194280, "ingredient1": "Cyclosporine", "ingredient2": "Tamsulosin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194508/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, Probenecid, Diclofenamide, Mafenide, Tioconazole, Furazolidone, More", "updated_at": 1767369485}, {"id": 194281, "ingredient1": "Cyclosporine", "ingredient2": "Lamivudine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194509/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 194282, "ingredient1": "Cyclosporine", "ingredient2": "Paroxetine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194510/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194283, "ingredient1": "Cyclosporine", "ingredient2": "Adefovir dipivoxil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194511/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 194284, "ingredient1": "Imiquimod", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194512/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Mafenide", "updated_at": 1767369485}, {"id": 194285, "ingredient1": "Cyclosporine", "ingredient2": "Nitroglycerin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194513/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Nesiritide, Isosorbide dinitrate, Vericiguat, Fluocinolone acetonide, Procaine, Tetracaine, Isosorbide dinitrate", "updated_at": 1767369485}, {"id": 194286, "ingredient1": "Cyclosporine", "ingredient2": "Risperidone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194514/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Trifluoperazine, Paliperidone, Chlorpromazine, Mesoridazine, Methotrimeprazine, Clozapine, More", "updated_at": 1767369485}, {"id": 194287, "ingredient1": "Deferoxamine", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194515/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 194288, "ingredient1": "Cyclosporine", "ingredient2": "Scopolamine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194516/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Eszopiclone, Dexmedetomidine, More", "updated_at": 1767369485}, {"id": 194289, "ingredient1": "Cyclosporine", "ingredient2": "Tretinoin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194517/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 194290, "ingredient1": "Dolasetron", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194518/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Nabilone, Dronabinol, Palonosetron", "updated_at": 1767369485}, {"id": 194291, "ingredient1": "Cyclosporine", "ingredient2": "Tetracycline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194519/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Rifamycin, Chlorhexidine, Vonoprazan, Bismuth subcitrate potassium, Levofloxacin, Chlorhexidine, Omadacycline, Oxytetracycline, Eravacycline, Demeclocycline, Rifamycin, More", "updated_at": 1767369485}, {"id": 194292, "ingredient1": "Cyclosporine", "ingredient2": "Potassium chloride", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194520/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Potassium citrate, Potassium bicarbonate, Potassium gluconate, Sodium acetate, Magnesium sulfate, Arginine, Sodium glycerophosphate, Tromethamine, Sodium phosphate, monobasic, Sodium chloride, Potassium acetate, More", "updated_at": 1767369485}, {"id": 194293, "ingredient1": "Cyclosporine", "ingredient2": "Olopatadine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194521/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Ketotifen, Cromoglicic acid, Nedocromil, Phenylephrine, Azelastine, Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, More", "updated_at": 1767369485}, {"id": 194294, "ingredient1": "Cyclosporine", "ingredient2": "Pentoxifylline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194522/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, More", "updated_at": 1767369485}, {"id": 194295, "ingredient1": "Cyclosporine", "ingredient2": "Ribavirin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194523/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 194296, "ingredient1": "Cyclosporine", "ingredient2": "Propofol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194524/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Remifentanil, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Halothane, Etomidate", "updated_at": 1767369485}, {"id": 194297, "ingredient1": "Diazepam", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194525/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194298, "ingredient1": "Cyclosporine", "ingredient2": "Oxazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194526/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194299, "ingredient1": "Cyclosporine", "ingredient2": "Nalbuphine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194527/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Oliceridine, Oxymorphone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Dihydrocodeine, Naloxone, Codeine", "updated_at": 1767369485}, {"id": 194300, "ingredient1": "Cyclosporine", "ingredient2": "Penicillamine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194528/", "reference_text": "-", "alternatives_a": "Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, Abatacept, More", "alternatives_b": "Aurothioglucose, Sodium aurothiomalate", "updated_at": 1767369485}, {"id": 194301, "ingredient1": "Cyclosporine", "ingredient2": "Risedronic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194529/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194302, "ingredient1": "Granisetron", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194530/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Nabilone, Dronabinol, Palonosetron", "updated_at": 1767369485}, {"id": 194303, "ingredient1": "Cyclosporine", "ingredient2": "Triazolam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194531/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Cladribine, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Eszopiclone, Dexmedetomidine, More", "updated_at": 1767369485}, {"id": 194304, "ingredient1": "Cyclosporine", "ingredient2": "Ondansetron", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194532/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Nabilone, Dronabinol, Palonosetron", "updated_at": 1767369485}, {"id": 194305, "ingredient1": "Cyclosporine", "ingredient2": "Bimatoprost", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194533/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Methazolamide, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, Diclofenamide, Carteolol, Apraclonidine, Guanethidine", "updated_at": 1767369485}, {"id": 194306, "ingredient1": "Cyclosporine", "ingredient2": "Zonisamide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194534/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More", "updated_at": 1767369485}, {"id": 194307, "ingredient1": "Cyclosporine", "ingredient2": "Paricalcitol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194535/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol", "updated_at": 1767369485}, {"id": 194308, "ingredient1": "Famotidine", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194536/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Vonoprazan, Bismuth subcitrate potassium, Levofloxacin", "updated_at": 1767369485}, {"id": 194309, "ingredient1": "Cyclosporine", "ingredient2": "Misoprostol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194537/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Dinoprostone, Oxytocin, Vonoprazan, Bismuth subcitrate potassium, Levofloxacin, Chondroitin sulfate, Glucosamine", "updated_at": 1767369485}, {"id": 194310, "ingredient1": "Cyclosporine", "ingredient2": "Salmeterol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194538/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Olodaterol, Cromoglicic acid, Ipratropium, Orciprenaline, Pirbuterol, More", "updated_at": 1767369485}, {"id": 194311, "ingredient1": "Fexofenadine", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194539/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "updated_at": 1767369485}, {"id": 194312, "ingredient1": "Cyclosporine", "ingredient2": "Carboplatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194540/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 194313, "ingredient1": "Cyclosporine", "ingredient2": "Zaleplon", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194541/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Eszopiclone, Dexmedetomidine, More", "updated_at": 1767369485}, {"id": 194314, "ingredient1": "Desloratadine", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194542/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "updated_at": 1767369485}, {"id": 194315, "ingredient1": "Cyclosporine", "ingredient2": "Methyldopa", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194543/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Rauwolfia serpentina root, Reserpine, Deserpidine", "updated_at": 1767369485}, {"id": 194316, "ingredient1": "Dipyridamole", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194544/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "updated_at": 1767369485}, {"id": 194317, "ingredient1": "Cyclosporine", "ingredient2": "Auranofin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194545/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Secukinumab, Canakinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, Abatacept, Upadacitinib, Siponimod, More", "alternatives_b": "Aurothioglucose, Sodium aurothiomalate", "updated_at": 1767369485}, {"id": 194318, "ingredient1": "Gabapentin", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194546/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More", "updated_at": 1767369485}, {"id": 194319, "ingredient1": "Hydroxyurea", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194547/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "updated_at": 1767369485}, {"id": 194320, "ingredient1": "Cyclosporine", "ingredient2": "Cinacalcet", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194548/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol", "updated_at": 1767369485}, {"id": 194321, "ingredient1": "Cyclosporine", "ingredient2": "Minocycline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194549/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Vitamin A, Azelaic acid, Adapalene, Isotretinoin, Omadacycline, Oxytetracycline, Eravacycline, Demeclocycline, Chlorhexidine", "updated_at": 1767369485}, {"id": 194322, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194550/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Nesiritide, Isosorbide dinitrate, Vericiguat", "updated_at": 1767369485}, {"id": 194323, "ingredient1": "Cyclosporine", "ingredient2": "Phylloquinone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194551/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human", "updated_at": 1767369485}, {"id": 194324, "ingredient1": "Cyclosporine", "ingredient2": "Mercaptopurine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194552/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine, Theophylline, Omalizumab, Tezepelumab, Aminophylline, More", "updated_at": 1767369485}, {"id": 194325, "ingredient1": "Cyclosporine", "ingredient2": "Thalidomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194553/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 194326, "ingredient1": "Gatifloxacin", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194554/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Rifamycin, Oxytetracycline, Lomefloxacin, Trifluridine, Benzylpenicillin, Ampicillin, Chlorhexidine, Levofloxacin, Povidone-iodine, Enoxacin, Levofloxacin, More", "updated_at": 1767369485}, {"id": 194327, "ingredient1": "Fluocinonide", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194555/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Fluocinolone acetonide, Procaine, Tetracaine, Isosorbide dinitrate, Fluocinolone acetonide, Mometasone furoate, Beclomethasone dipropionate, Amcinonide, Fluocinolone acetonide, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 194328, "ingredient1": "Cyclosporine", "ingredient2": "Oxybutynin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194556/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 194329, "ingredient1": "Cyclosporine", "ingredient2": "Promethazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194557/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "updated_at": 1767369485}, {"id": 194330, "ingredient1": "Fludarabine", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194558/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Capecitabine", "updated_at": 1767369485}, {"id": 194331, "ingredient1": "Cyclosporine", "ingredient2": "Tegaserod", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194559/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Alvimopan, Sorbitol, Bisacodyl, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 194332, "ingredient1": "Cyclosporine", "ingredient2": "Pilocarpine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194560/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Ambenonium, Bethanechol, Neostigmine, Methazolamide, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, Diclofenamide, Carteolol, Apraclonidine, Guanethidine", "updated_at": 1767369485}, {"id": 194333, "ingredient1": "Iloprost", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194561/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More", "updated_at": 1767369485}, {"id": 194334, "ingredient1": "Cyclosporine", "ingredient2": "Atovaquone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194562/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Quinacrine, Secnidazole, Furazolidone, Nitazoxanide, Trimetrexate, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, More", "updated_at": 1767369485}, {"id": 194335, "ingredient1": "Cyclosporine", "ingredient2": "Pioglitazone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194563/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More", "updated_at": 1767369485}, {"id": 194336, "ingredient1": "Cyclosporine", "ingredient2": "Terazosin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194564/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194337, "ingredient1": "Cyclosporine", "ingredient2": "Calcium chloride", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194565/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Calcium glucoheptonate, Calcium lactate, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium carbonate, Calcium Phosphate, Ascorbic acid, Calcium citrate, Calcium carbonate, Calcium acetate, More", "updated_at": 1767369485}, {"id": 194338, "ingredient1": "Cyclosporine", "ingredient2": "Ofloxacin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194566/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Enoxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin, Cefixime, Levofloxacin, More", "updated_at": 1767369485}, {"id": 194339, "ingredient1": "Cyclosporine", "ingredient2": "Orphenadrine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194567/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Chlorzoxazone, Chlormezanone, Biperiden, Trihexyphenidyl, Benzatropine, Procyclidine", "updated_at": 1767369485}, {"id": 194340, "ingredient1": "Ifosfamide", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194568/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Temozolomide, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan flufenamide, Uracil mustard", "updated_at": 1767369485}, {"id": 194341, "ingredient1": "Cyclosporine", "ingredient2": "Brinzolamide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194569/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Methazolamide, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, Diclofenamide, Carteolol, Apraclonidine, Guanethidine, Ascorbic acid, Methazolamide, More", "updated_at": 1767369485}, {"id": 194342, "ingredient1": "Flecainide", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194570/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More", "alternatives_b": "Tocainide, Procainamide, Mexiletine, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 194343, "ingredient1": "Cyclosporine", "ingredient2": "Zopiclone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194571/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Remimazolam, Chloral hydrate, Nitrazepam, Flurazepam, Quazepam, Paraldehyde, Propiomazine, Ramelteon, Meprobamate, Eszopiclone, Dexmedetomidine, More", "updated_at": 1767369485}, {"id": 194344, "ingredient1": "Cyclosporine", "ingredient2": "Levetiracetam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194572/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More", "updated_at": 1767369485}, {"id": 194345, "ingredient1": "Cyclosporine", "ingredient2": "Nadolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194573/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Nebivolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol", "updated_at": 1767369485}, {"id": 194346, "ingredient1": "Cyclosporine", "ingredient2": "Levobunolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194574/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Methazolamide, Neostigmine, Acetylcholine, Physostigmine, Betaxolol, Diclofenamide, Carteolol, Apraclonidine, Guanethidine", "updated_at": 1767369485}, {"id": 194347, "ingredient1": "Finasteride", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194575/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Povidone-iodine", "updated_at": 1767369485}, {"id": 194348, "ingredient1": "Cyclosporine", "ingredient2": "Ketamine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194576/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Remifentanil, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Halothane, Etomidate", "updated_at": 1767369485}, {"id": 194349, "ingredient1": "Cyclosporine", "ingredient2": "Sevoflurane", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194577/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Remifentanil, Sodium oxybate, Isoflurane, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, Halothane, Etomidate", "updated_at": 1767369485}, {"id": 194350, "ingredient1": "Cyclosporine", "ingredient2": "Varenicline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194578/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "Diamorphine, Acamprosate, Lofexidine, Disulfiram, Nalmefene", "updated_at": 1767369485}, {"id": 194351, "ingredient1": "Hydralazine", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194579/", "reference_text": "-", "alternatives_a": "Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More", "alternatives_b": "Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine", "updated_at": 1767369485}, {"id": 194352, "ingredient1": "Cyclosporine", "ingredient2": "Sodium bicarbonate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194580/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Sorbitol, Sodium citrate, Magnesium citrate, Sodium chloride, Chlorhexidine, Sodium acetate, Magnesium sulfate, Arginine, Sodium glycerophosphate, Tromethamine, Sodium phosphate, monobasic, More", "updated_at": 1767369485}, {"id": 194353, "ingredient1": "Cyclosporine", "ingredient2": "Tiotropium", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194581/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Olodaterol, Cromoglicic acid, Ipratropium, Orciprenaline, Pirbuterol, More", "updated_at": 1767369485}, {"id": 194354, "ingredient1": "Cyclosporine", "ingredient2": "Thiotepa", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194582/", "reference_text": "-", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More", "alternatives_b": "Temozolomide, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan flufenamide, Uracil mustard", "updated_at": 1767369485}, {"id": 194355, "ingredient1": "Cyclosporine", "ingredient2": "Vitamin D", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194583/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194356, "ingredient1": "Cyclosporine", "ingredient2": "Clobetasol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194584/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Fluocinolone acetonide, Mometasone furoate, Beclomethasone dipropionate, Amcinonide, Fluocinolone acetonide, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 194357, "ingredient1": "Fluticasone", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194585/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Nedocromil, Beclomethasone dipropionate, Fluocinolone acetonide, More", "updated_at": 1767369485}, {"id": 194358, "ingredient1": "Hydrocortisone butyrate", "ingredient2": "Cyclosporine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194586/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Fluocinolone acetonide, Mometasone furoate, Beclomethasone dipropionate, Amcinonide, Fluocinolone acetonide", "updated_at": 1767369485}, {"id": 194359, "ingredient1": "Cyclosporine", "ingredient2": "Loteprednol etabonate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194587/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194360, "ingredient1": "Bortezomib", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194588/", "reference_text": "-", "alternatives_a": "Norethisterone, Nafarelin, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 194361, "ingredient1": "Sucralfate", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194589/", "reference_text": "-", "alternatives_a": "Nafarelin, Elagolix, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Clarithromycin, More", "updated_at": 1767369485}, {"id": 194362, "ingredient1": "Sorafenib", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194590/", "reference_text": "-", "alternatives_a": "Norethisterone, Nafarelin, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin", "alternatives_b": "Imatinib, Dabrafenib, Dacomitinib, Pacritinib, Fedratinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Vandetanib, Cobimetinib, More", "updated_at": 1767369485}, {"id": 194363, "ingredient1": "Zoledronic acid", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194591/", "reference_text": "-", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Tiludronic acid, Vosoritide, Etidronic acid, Denosumab, Ibandronate, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194364, "ingredient1": "Allopurinol", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194592/", "reference_text": "-", "alternatives_a": "Nafarelin, Elagolix, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 194365, "ingredient1": "Octreotide", "ingredient2": "Montelukast", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194593/", "reference_text": "-", "alternatives_a": "Nafarelin, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, More", "updated_at": 1767369485}, {"id": 194366, "ingredient1": "Cisplatin", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194594/", "reference_text": "-", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 194367, "ingredient1": "Caspofungin", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194595/", "reference_text": "-", "alternatives_a": "Norethisterone, Nafarelin, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Micafungin, Itraconazole, Miconazole, Posaconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin, Voriconazole", "updated_at": 1767369485}, {"id": 194368, "ingredient1": "Bosentan", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194596/", "reference_text": "-", "alternatives_a": "Nafarelin, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 194369, "ingredient1": "Octreotide", "ingredient2": "Lactulose", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194597/", "reference_text": "-", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Ganirelix, Lanreotide, Gonadorelin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 194370, "ingredient1": "Simvastatin", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194598/", "reference_text": "-", "alternatives_a": "Nafarelin, Elagolix, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Guar gum, Cholestyramine, Mipomersen, Evinacumab, Dextrothyroxine, Probucol, Cerivastatin, Lomitapide, Niacin, Ezetimibe, Colesevelam, More", "updated_at": 1767369485}, {"id": 194371, "ingredient1": "Octreotide", "ingredient2": "Nystatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194599/", "reference_text": "-", "alternatives_a": "Nafarelin, Elagolix, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, Flucytosine, Tioconazole, More", "updated_at": 1767369485}, {"id": 194372, "ingredient1": "Tamsulosin", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194600/", "reference_text": "-", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Terazosin, Alfuzosin, Tadalafil, Finasteride, Silodosin, Dutasteride, Solifenacin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More", "updated_at": 1767369485}, {"id": 194373, "ingredient1": "Rosuvastatin", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194601/", "reference_text": "-", "alternatives_a": "Nafarelin, Elagolix, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Lovastatin, Ezetimibe, Perindopril, Pravastatin, Niacin, Bempedoic acid, Indapamide, Cholestyramine, Mipomersen, Evinacumab, Dextrothyroxine, More", "updated_at": 1767369485}, {"id": 194374, "ingredient1": "Valganciclovir", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194602/", "reference_text": "-", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194375, "ingredient1": "Fluticasone", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194603/", "reference_text": "-", "alternatives_a": "Nafarelin, Elagolix, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More", "updated_at": 1767369485}, {"id": 194376, "ingredient1": "Cyclosporine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194604/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "updated_at": 1767369485}, {"id": 194377, "ingredient1": "Cyanocobalamin", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194605/", "reference_text": "-", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "updated_at": 1767369485}, {"id": 194378, "ingredient1": "Folic acid", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194606/", "reference_text": "-", "alternatives_a": "Mecobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, More", "updated_at": 1767369485}, {"id": 194379, "ingredient1": "Cyanocobalamin", "ingredient2": "Pravastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194607/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Lomitapide, More", "updated_at": 1767369485}, {"id": 194380, "ingredient1": "Fluvoxamine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194608/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194381, "ingredient1": "Cyanocobalamin", "ingredient2": "Valsartan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194609/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan, Bempedoic acid, Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan", "updated_at": 1767369485}, {"id": 194382, "ingredient1": "Cyanocobalamin", "ingredient2": "Ramipril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194610/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate", "alternatives_b": "Moexipril, Bisoprolol, Benazepril, Bempedoic acid, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194383, "ingredient1": "Flunisolide", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194611/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mupirocin, Ciclesonide, Mometasone furoate, Mometasone, Epinephrine, Ephedrine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Betamethasone, Nedocromil, More", "updated_at": 1767369485}, {"id": 194384, "ingredient1": "Cyanocobalamin", "ingredient2": "Lorazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194612/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194385, "ingredient1": "Cyanocobalamin", "ingredient2": "Bortezomib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194613/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 194386, "ingredient1": "Cyanocobalamin", "ingredient2": "Tramadol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194614/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Meperidine, Hydromorphone, Dezocine, Opium, More", "updated_at": 1767369485}, {"id": 194387, "ingredient1": "Fluconazole", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194615/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tinidazole, Tetracycline, Norfloxacin, Secnidazole, Cefixime, Amikacin, Levofloxacin, Caspofungin, Micafungin, Amphotericin B, Miconazole, More", "updated_at": 1767369485}, {"id": 194388, "ingredient1": "Cyanocobalamin", "ingredient2": "Oseltamivir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194616/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194389, "ingredient1": "Erythromycin", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194617/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Telithromycin, Lincomycin, Troleandomycin, Dirithromycin, Minocycline, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Rifamycin, More", "updated_at": 1767369485}, {"id": 194390, "ingredient1": "Cyanocobalamin", "ingredient2": "Sildenafil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194618/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 194391, "ingredient1": "Cyanocobalamin", "ingredient2": "Torasemide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194619/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Etacrynic acid, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "updated_at": 1767369485}, {"id": 194392, "ingredient1": "Cyanocobalamin", "ingredient2": "Moxifloxacin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194620/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron sucrose", "alternatives_b": "Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, Benzylpenicillin, Levofloxacin, More", "updated_at": 1767369485}, {"id": 194393, "ingredient1": "Glimepiride", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194621/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194394, "ingredient1": "Cyanocobalamin", "ingredient2": "Lovastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194622/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Lomitapide, More", "updated_at": 1767369485}, {"id": 194395, "ingredient1": "Cyanocobalamin", "ingredient2": "Pregabalin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194623/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 194396, "ingredient1": "Cyanocobalamin", "ingredient2": "Temazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194624/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 194397, "ingredient1": "Cyanocobalamin", "ingredient2": "Mesalazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194625/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Cromoglicic acid, Olsalazine, Balsalazide, Betamethasone, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 194398, "ingredient1": "Dapsone", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194626/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Minocycline, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Clofazimine", "updated_at": 1767369485}, {"id": 194399, "ingredient1": "Doxycycline", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194627/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin", "alternatives_b": "Tetracycline, Minocycline, Oxytetracycline, Omadacycline, Eravacycline, Demeclocycline, Sarecycline, Tigecycline, Tetracycline, Minocycline, Amphotericin B, More", "updated_at": 1767369485}, {"id": 194400, "ingredient1": "Cyanocobalamin", "ingredient2": "Metoprolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194628/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Nebivolol, Bisoprolol, Ivabradine, Acebutolol, Labetalol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, Carteolol, More", "updated_at": 1767369485}, {"id": 194401, "ingredient1": "Cyanocobalamin", "ingredient2": "Ropinirole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194629/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Apomorphine, Opicapone, Cabergoline, Rasagiline, Tolcapone, Selegiline, Rotigotine, Bromocriptine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 194402, "ingredient1": "Isradipine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194630/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Nisoldipine, Nicardipine, Clevidipine, Levamlodipine, Nimodipine, Mibefradil", "updated_at": 1767369485}, {"id": 194403, "ingredient1": "Cyanocobalamin", "ingredient2": "Topiramate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194631/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 194404, "ingredient1": "Cyanocobalamin", "ingredient2": "Lidocaine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194632/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, More", "updated_at": 1767369485}, {"id": 194405, "ingredient1": "Cyanocobalamin", "ingredient2": "Pamidronic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194633/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194406, "ingredient1": "Cyanocobalamin", "ingredient2": "Acarbose", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194634/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194407, "ingredient1": "Cyanocobalamin", "ingredient2": "Venlafaxine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194635/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194408, "ingredient1": "Cyanocobalamin", "ingredient2": "Morphine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194636/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Opium, Eluxadoline, Diphenoxylate, Difenoxin, Codeine, Oliceridine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, More", "updated_at": 1767369485}, {"id": 194409, "ingredient1": "Cyanocobalamin", "ingredient2": "Valproic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194637/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 194410, "ingredient1": "Gefitinib", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194638/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 194411, "ingredient1": "Indomethacin", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194639/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fluocinolone acetonide, Fludrocortisone, Betamethasone, Fluorometholone, Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, More", "updated_at": 1767369485}, {"id": 194412, "ingredient1": "Cyanocobalamin", "ingredient2": "Metformin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194640/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194413, "ingredient1": "Cyanocobalamin", "ingredient2": "Olanzapine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194641/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194414, "ingredient1": "Diltiazem", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194642/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 194415, "ingredient1": "Cyanocobalamin", "ingredient2": "Vinorelbine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194643/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Topotecan, Teniposide, Irinotecan, Etoposide", "updated_at": 1767369485}, {"id": 194416, "ingredient1": "Cyanocobalamin", "ingredient2": "Sucralfate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194644/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tinidazole, Amoxicillin, Tetracycline, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194417, "ingredient1": "Cyanocobalamin", "ingredient2": "Mirtazapine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194645/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194418, "ingredient1": "Cyanocobalamin", "ingredient2": "Timolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194646/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acebutolol, Labetalol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, Carteolol, Apraclonidine, Methazolamide, Neostigmine, More", "updated_at": 1767369485}, {"id": 194419, "ingredient1": "Cyanocobalamin", "ingredient2": "Trihexyphenidyl", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194647/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Biperiden, Procyclidine, Orphenadrine, Benzatropine", "updated_at": 1767369485}, {"id": 194420, "ingredient1": "Cyanocobalamin", "ingredient2": "Mexiletine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194648/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Amiodarone, Dronedarone, Tocainide, Propafenone, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 194421, "ingredient1": "Digoxin", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194649/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Digitoxin", "updated_at": 1767369485}, {"id": 194422, "ingredient1": "Cyanocobalamin", "ingredient2": "Progesterone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194650/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Norethisterone, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, Norgestrel, Norethisterone, More", "updated_at": 1767369485}, {"id": 194423, "ingredient1": "Cyanocobalamin", "ingredient2": "Sorafenib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194651/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 194424, "ingredient1": "Cyanocobalamin", "ingredient2": "Zoledronic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194652/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194425, "ingredient1": "Cyanocobalamin", "ingredient2": "Rosiglitazone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194653/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194426, "ingredient1": "Cyanocobalamin", "ingredient2": "Pramipexole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194654/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Apomorphine, Opicapone, Cabergoline, Rasagiline, Tolcapone, Selegiline, Rotigotine, Bromocriptine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 194427, "ingredient1": "Cyanocobalamin", "ingredient2": "Spironolactone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194655/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Eplerenone, Amiloride, Triamterene, Finerenone", "updated_at": 1767369485}, {"id": 194428, "ingredient1": "Cyanocobalamin", "ingredient2": "Methylphenidate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194656/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline", "updated_at": 1767369485}, {"id": 194429, "ingredient1": "Cyanocobalamin", "ingredient2": "Methocarbamol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194657/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Baclofen, Chlorzoxazone, Orphenadrine, Chlormezanone", "updated_at": 1767369485}, {"id": 194430, "ingredient1": "Cyanocobalamin", "ingredient2": "Zolpidem", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194658/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 194431, "ingredient1": "Cyanocobalamin", "ingredient2": "Prochlorperazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194659/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194432, "ingredient1": "Allopurinol", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194660/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 194433, "ingredient1": "Gemcitabine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194661/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, Tioguanine, Capecitabine", "updated_at": 1767369485}, {"id": 194434, "ingredient1": "Cyanocobalamin", "ingredient2": "Loratadine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194662/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More", "updated_at": 1767369485}, {"id": 194435, "ingredient1": "Cyanocobalamin", "ingredient2": "Prazosin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194663/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Rauwolfia serpentina root, Hydralazine, Reserpine, Guanethidine, Deserpidine, Guanethidine", "updated_at": 1767369485}, {"id": 194436, "ingredient1": "Cyanocobalamin", "ingredient2": "Nabumetone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194664/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, Tolmetin, Meclofenamic acid", "updated_at": 1767369485}, {"id": 194437, "ingredient1": "Cyanocobalamin", "ingredient2": "Montelukast", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194665/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 194438, "ingredient1": "Fluoxetine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194666/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194439, "ingredient1": "Duloxetine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194667/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194440, "ingredient1": "Cyanocobalamin", "ingredient2": "Lenalidomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194668/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 194441, "ingredient1": "Cyanocobalamin", "ingredient2": "Raloxifene", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194669/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Ulipristal, Danazol, Mifepristone, Ospemifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 194442, "ingredient1": "Cyanocobalamin", "ingredient2": "Sotalol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194670/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acebutolol, Labetalol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, Carteolol, Acebutolol, Labetalol, Nebivolol, More", "updated_at": 1767369485}, {"id": 194443, "ingredient1": "Fosinopril", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194671/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate", "alternatives_b": "Moexipril, Bisoprolol, Benazepril, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194444, "ingredient1": "Entacapone", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194672/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron sucrose", "alternatives_b": "Apomorphine, Opicapone, Cabergoline, Rasagiline, Tolcapone, Selegiline, Rotigotine, Bromocriptine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 194445, "ingredient1": "Darifenacin", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194673/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 194446, "ingredient1": "Cyanocobalamin", "ingredient2": "Oxycodone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194674/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Meperidine, Hydromorphone, Dezocine, Opium, More", "updated_at": 1767369485}, {"id": 194447, "ingredient1": "Haloperidol", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194675/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194448, "ingredient1": "Cyanocobalamin", "ingredient2": "Ritonavir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194676/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194449, "ingredient1": "Cyanocobalamin", "ingredient2": "Vancomycin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194677/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, More", "updated_at": 1767369485}, {"id": 194450, "ingredient1": "Cyanocobalamin", "ingredient2": "Cisplatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194678/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 194451, "ingredient1": "Cyanocobalamin", "ingredient2": "Trandolapril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194679/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate", "alternatives_b": "Moexipril, Benazepril, Moexipril, Bisoprolol, Benazepril", "updated_at": 1767369485}, {"id": 194452, "ingredient1": "Cyanocobalamin", "ingredient2": "Metolazone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194680/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Trichlormethiazide, Chlorthalidone, Bendroflumethiazide, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, More", "updated_at": 1767369485}, {"id": 194453, "ingredient1": "Cyanocobalamin", "ingredient2": "Oxaliplatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194681/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 194454, "ingredient1": "Cyanocobalamin", "ingredient2": "Cyclophosphamide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194682/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, Ifosfamide, More", "updated_at": 1767369485}, {"id": 194455, "ingredient1": "Cyanocobalamin", "ingredient2": "Rofecoxib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194683/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, Tolmetin, Meclofenamic acid", "updated_at": 1767369485}, {"id": 194456, "ingredient1": "Cyanocobalamin", "ingredient2": "Nortriptyline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194684/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194457, "ingredient1": "Cyanocobalamin", "ingredient2": "Vincristine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194685/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Topotecan, Teniposide, Irinotecan, Etoposide", "updated_at": 1767369485}, {"id": 194458, "ingredient1": "Fluorouracil", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194686/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, Tioguanine, Capecitabine", "updated_at": 1767369485}, {"id": 194459, "ingredient1": "Cyanocobalamin", "ingredient2": "Zafirlukast", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194687/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 194460, "ingredient1": "Cyanocobalamin", "ingredient2": "Piroxicam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194688/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, Tolmetin, Meclofenamic acid, Phenylbutazone, Tolazoline, More", "updated_at": 1767369485}, {"id": 194461, "ingredient1": "Cyanocobalamin", "ingredient2": "Lamotrigine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194689/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 194462, "ingredient1": "Hydroxyzine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194690/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194463, "ingredient1": "Cyanocobalamin", "ingredient2": "Bosentan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194691/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 194464, "ingredient1": "Cyanocobalamin", "ingredient2": "Methotrexate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194692/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 194465, "ingredient1": "Cyanocobalamin", "ingredient2": "Propranolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194693/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Nebivolol, Bisoprolol, Ivabradine, Acebutolol, Labetalol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, Carteolol, More", "updated_at": 1767369485}, {"id": 194466, "ingredient1": "Cyanocobalamin", "ingredient2": "Valaciclovir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194694/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194467, "ingredient1": "Cyanocobalamin", "ingredient2": "Valdecoxib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194695/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, Tolmetin, Meclofenamic acid", "updated_at": 1767369485}, {"id": 194468, "ingredient1": "Cyanocobalamin", "ingredient2": "Lactulose", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194696/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 194469, "ingredient1": "Cyanocobalamin", "ingredient2": "Voriconazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194697/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 194470, "ingredient1": "Enalapril", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194698/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate", "alternatives_b": "Moexipril, Bisoprolol, Benazepril, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194471, "ingredient1": "Diclofenac", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194699/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fluocinolone acetonide, Fludrocortisone, Betamethasone, Fluorometholone, Salicylic acid, Ketorolac, Fluocinolone acetonide, Cortisone, Flurbiprofen, Betamethasone, Fluorometholone, More", "updated_at": 1767369485}, {"id": 194472, "ingredient1": "Doxazosin", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194700/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Guanethidine", "updated_at": 1767369485}, {"id": 194473, "ingredient1": "Cyanocobalamin", "ingredient2": "Linezolid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194701/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 194474, "ingredient1": "Cyanocobalamin", "ingredient2": "Sulindac", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194702/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, Tolmetin, Meclofenamic acid", "updated_at": 1767369485}, {"id": 194475, "ingredient1": "Cyanocobalamin", "ingredient2": "Triamcinolone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194703/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Mupirocin, Ciclesonide, More", "updated_at": 1767369485}, {"id": 194476, "ingredient1": "Cyanocobalamin", "ingredient2": "Testosterone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194704/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Methyltestosterone, Fluoxymesterone, Prasterone, Methyltestosterone", "updated_at": 1767369485}, {"id": 194477, "ingredient1": "Cyanocobalamin", "ingredient2": "Prednisone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194705/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Cromoglicic acid, Olsalazine, Balsalazide, Betamethasone, Beclomethasone dipropionate, Cortisone, Fludrocortisone, Betamethasone, Deflazacort", "updated_at": 1767369485}, {"id": 194478, "ingredient1": "Cyanocobalamin", "ingredient2": "Simvastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194706/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194479, "ingredient1": "Cyanocobalamin", "ingredient2": "Pemetrexed", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194707/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, Tioguanine, Capecitabine", "updated_at": 1767369485}, {"id": 194480, "ingredient1": "Cyanocobalamin", "ingredient2": "Nystatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194708/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Griseofulvin, Ketoconazole, Econazole, Flucytosine, Tioconazole, Chlorphenesin, More", "updated_at": 1767369485}, {"id": 194481, "ingredient1": "Cyanocobalamin", "ingredient2": "Latanoprost", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194709/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Travoprost, Carteolol, Brinzolamide, Acetazolamide, More", "updated_at": 1767369485}, {"id": 194482, "ingredient1": "Cyanocobalamin", "ingredient2": "Trazodone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194710/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194483, "ingredient1": "Cyanocobalamin", "ingredient2": "Sevelamer", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194711/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 194484, "ingredient1": "Cyanocobalamin", "ingredient2": "Sumatriptan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194712/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Ubrogepant, Ergotamine, Naratriptan, Galcanezumab, Zolmitriptan, More", "updated_at": 1767369485}, {"id": 194485, "ingredient1": "Galantamine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194713/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Rivastigmine, Aducanumab, Memantine, Ginkgo biloba, Tacrine", "updated_at": 1767369485}, {"id": 194486, "ingredient1": "Cyanocobalamin", "ingredient2": "Tamoxifen", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194714/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Darolutamide, Anastrozole, Aminoglutethimide, Fulvestrant, Toremifene, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More", "updated_at": 1767369485}, {"id": 194487, "ingredient1": "Cyanocobalamin", "ingredient2": "Losartan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194715/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan", "updated_at": 1767369485}, {"id": 194488, "ingredient1": "Cyanocobalamin", "ingredient2": "Warfarin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194716/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, More", "updated_at": 1767369485}, {"id": 194489, "ingredient1": "Furosemide", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194717/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Trichlormethiazide, Chlorthalidone, Bendroflumethiazide, Etacrynic acid, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, More", "updated_at": 1767369485}, {"id": 194490, "ingredient1": "Cyanocobalamin", "ingredient2": "Tizanidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194718/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Baclofen, Chlorzoxazone, Orphenadrine, Chlormezanone", "updated_at": 1767369485}, {"id": 194491, "ingredient1": "Cyanocobalamin", "ingredient2": "Nitrofurantoin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194719/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 194492, "ingredient1": "Cyanocobalamin", "ingredient2": "Tamsulosin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194720/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Silodosin, Dutasteride, Solifenacin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, More", "updated_at": 1767369485}, {"id": 194493, "ingredient1": "Cyanocobalamin", "ingredient2": "Lamivudine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194721/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194494, "ingredient1": "Ibandronate", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194722/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194495, "ingredient1": "Cyanocobalamin", "ingredient2": "Paroxetine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194723/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194496, "ingredient1": "Cyanocobalamin", "ingredient2": "Adefovir dipivoxil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194724/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194497, "ingredient1": "Cyanocobalamin", "ingredient2": "Lisinopril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194725/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate", "alternatives_b": "Moexipril, Bisoprolol, Benazepril, Bempedoic acid, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194498, "ingredient1": "Cyanocobalamin", "ingredient2": "Nitroglycerin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194726/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 194499, "ingredient1": "Cyanocobalamin", "ingredient2": "Nateglinide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194727/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194500, "ingredient1": "Cyanocobalamin", "ingredient2": "Risperidone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194728/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194501, "ingredient1": "Cyanocobalamin", "ingredient2": "Riluzole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194729/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Tetrabenazine, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 194502, "ingredient1": "Hydrocortisone", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194730/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fluocinolone acetonide, Fludrocortisone, Betamethasone, Fluorometholone, Tetracycline, Minocycline, Amphotericin B, Miconazole, Epinephrine, Chlorhexidine, Neomycin, More", "updated_at": 1767369485}, {"id": 194503, "ingredient1": "Cyanocobalamin", "ingredient2": "Modafinil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194731/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline", "updated_at": 1767369485}, {"id": 194504, "ingredient1": "Etodolac", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194732/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, Tolmetin, Meclofenamic acid", "updated_at": 1767369485}, {"id": 194505, "ingredient1": "Cyanocobalamin", "ingredient2": "Methimazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194733/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Potassium perchlorate, Propylthiouracil", "updated_at": 1767369485}, {"id": 194506, "ingredient1": "Cyanocobalamin", "ingredient2": "Olopatadine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194734/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Azelastine, Nedocromil, Cromoglicic acid, Phenylephrine, Mupirocin, Ciclesonide, Mometasone furoate, Mometasone, Epinephrine, Ephedrine, Ipratropium, More", "updated_at": 1767369485}, {"id": 194507, "ingredient1": "Cyanocobalamin", "ingredient2": "Mefenamic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194735/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, Tolmetin, Meclofenamic acid", "updated_at": 1767369485}, {"id": 194508, "ingredient1": "Cyanocobalamin", "ingredient2": "Perindopril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194736/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate", "alternatives_b": "Moexipril, Bisoprolol, Benazepril, Bempedoic acid, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194509, "ingredient1": "Cyanocobalamin", "ingredient2": "Primidone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194737/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 194510, "ingredient1": "Cyanocobalamin", "ingredient2": "Sulfasalazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194738/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 194511, "ingredient1": "Gentamicin", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194739/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, Benzylpenicillin, Levofloxacin, More", "updated_at": 1767369485}, {"id": 194512, "ingredient1": "Dicyclomine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194740/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mepenzolate, Alosetron, Glycopyrronium, Papaverine, Propantheline, Isometheptene", "updated_at": 1767369485}, {"id": 194513, "ingredient1": "Cyanocobalamin", "ingredient2": "Pentoxifylline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194741/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, More", "updated_at": 1767369485}, {"id": 194514, "ingredient1": "Indapamide", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194742/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Chlorthalidone, Moexipril, Bisoprolol, Benazepril, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, More", "updated_at": 1767369485}, {"id": 194515, "ingredient1": "Cyanocobalamin", "ingredient2": "Ribavirin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194743/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194516, "ingredient1": "Fentanyl", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194744/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Propofol, More", "updated_at": 1767369485}, {"id": 194517, "ingredient1": "Cyanocobalamin", "ingredient2": "Meloxicam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194745/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Ropivacaine, Chloroprocaine, Levobupivacaine, Tetracaine, Bupivacaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Fenoprofen, More", "updated_at": 1767369485}, {"id": 194518, "ingredient1": "Cyanocobalamin", "ingredient2": "Tadalafil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194746/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 194519, "ingredient1": "Diazepam", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194747/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194520, "ingredient1": "Cyanocobalamin", "ingredient2": "Loperamide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194748/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Opium, Eluxadoline, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 194521, "ingredient1": "Cyanocobalamin", "ingredient2": "Oxazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194749/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194522, "ingredient1": "Donepezil", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194750/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Rivastigmine, Aducanumab, Memantine, Ginkgo biloba, Tacrine", "updated_at": 1767369485}, {"id": 194523, "ingredient1": "Cyanocobalamin", "ingredient2": "Temozolomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194751/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, Ifosfamide, More", "updated_at": 1767369485}, {"id": 194524, "ingredient1": "Cyanocobalamin", "ingredient2": "Terbinafine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194752/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Griseofulvin, Ketoconazole, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Griseofulvin", "updated_at": 1767369485}, {"id": 194525, "ingredient1": "Cyanocobalamin", "ingredient2": "Prednisolone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194753/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, Fludrocortisone, More", "updated_at": 1767369485}, {"id": 194526, "ingredient1": "Cyanocobalamin", "ingredient2": "Vardenafil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194754/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 194527, "ingredient1": "Cyanocobalamin", "ingredient2": "Tacrolimus", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194755/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, More", "updated_at": 1767369485}, {"id": 194528, "ingredient1": "Cyanocobalamin", "ingredient2": "Sirolimus", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194756/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Alteplase, Ascorbic acid, Nandrolone, Potassium Iodide, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, More", "updated_at": 1767369485}, {"id": 194529, "ingredient1": "Cyanocobalamin", "ingredient2": "Quinapril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194757/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron", "alternatives_b": "Moexipril, Benazepril, Moexipril, Bisoprolol, Benazepril", "updated_at": 1767369485}, {"id": 194530, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194758/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 194531, "ingredient1": "Cyanocobalamin", "ingredient2": "Risedronic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194759/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194532, "ingredient1": "Granisetron", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194760/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Nabilone, Scopolamine, Dronabinol, Rolapitant, Aprepitant, Dolasetron, Palonosetron", "updated_at": 1767369485}, {"id": 194533, "ingredient1": "Cyanocobalamin", "ingredient2": "Triazolam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194761/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 194534, "ingredient1": "Cyanocobalamin", "ingredient2": "Ondansetron", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194762/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Nabilone, Scopolamine, Dronabinol, Rolapitant, Aprepitant, Dolasetron, Palonosetron", "updated_at": 1767369485}, {"id": 194535, "ingredient1": "Cyanocobalamin", "ingredient2": "Bimatoprost", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194763/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Travoprost, Carteolol, Brinzolamide, Acetazolamide, More", "updated_at": 1767369485}, {"id": 194536, "ingredient1": "Cyanocobalamin", "ingredient2": "Paricalcitol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194764/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate", "alternatives_b": "Etelcalcetide, Cinacalcet, Doxercalciferol, Salmon calcitonin, Calcifediol", "updated_at": 1767369485}, {"id": 194537, "ingredient1": "Cyanocobalamin", "ingredient2": "Metronidazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194765/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tinidazole, Amoxicillin, Tetracycline, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin, Tinidazole, Quinacrine, Secnidazole, Atovaquone, More", "updated_at": 1767369485}, {"id": 194538, "ingredient1": "Cyanocobalamin", "ingredient2": "Ketotifen", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194766/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Azelastine, Nedocromil, Cromoglicic acid, Phenylephrine, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, More", "updated_at": 1767369485}, {"id": 194539, "ingredient1": "Cyanocobalamin", "ingredient2": "Cyclobenzaprine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194767/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Baclofen, Chlorzoxazone, Orphenadrine, Chlormezanone", "updated_at": 1767369485}, {"id": 194540, "ingredient1": "Cyanocobalamin", "ingredient2": "Misoprostol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194768/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Methylergometrine, Dinoprostone, Ergometrine, Oxytocin, Tinidazole, Amoxicillin, Tetracycline, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin, More", "updated_at": 1767369485}, {"id": 194541, "ingredient1": "Cyanocobalamin", "ingredient2": "Salmeterol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194769/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Cromoglicic acid, Ipratropium, Orciprenaline, Pirbuterol, More", "updated_at": 1767369485}, {"id": 194542, "ingredient1": "Fexofenadine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194770/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More", "updated_at": 1767369485}, {"id": 194543, "ingredient1": "Isoniazid", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194771/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Ethambutol, More", "updated_at": 1767369485}, {"id": 194544, "ingredient1": "Cyanocobalamin", "ingredient2": "Rizatriptan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194772/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Ubrogepant, Ergotamine, Naratriptan, Galcanezumab, Zolmitriptan, More", "updated_at": 1767369485}, {"id": 194545, "ingredient1": "Cyanocobalamin", "ingredient2": "Carboplatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194773/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 194546, "ingredient1": "Cyanocobalamin", "ingredient2": "Methylprednisolone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194774/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Minocycline, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Cortisone, Fludrocortisone, Betamethasone, Deflazacort, Fluocinolone acetonide, More", "updated_at": 1767369485}, {"id": 194547, "ingredient1": "Cyanocobalamin", "ingredient2": "Pindolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194775/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Labetalol, Penbutolol, Acebutolol, Labetalol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, Carteolol", "updated_at": 1767369485}, {"id": 194548, "ingredient1": "Cyanocobalamin", "ingredient2": "Zaleplon", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194776/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 194549, "ingredient1": "Cyanocobalamin", "ingredient2": "Telmisartan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194777/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan, Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan", "updated_at": 1767369485}, {"id": 194550, "ingredient1": "Desloratadine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194778/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More", "updated_at": 1767369485}, {"id": 194551, "ingredient1": "Cyanocobalamin", "ingredient2": "Methyldopa", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194779/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron sucrose", "alternatives_b": "Guanfacine, Rauwolfia serpentina root, Reserpine, Deserpidine", "updated_at": 1767369485}, {"id": 194552, "ingredient1": "Ezetimibe", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194780/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Bempedoic acid, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, More", "updated_at": 1767369485}, {"id": 194553, "ingredient1": "Dipyridamole", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194781/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, More", "updated_at": 1767369485}, {"id": 194554, "ingredient1": "Formoterol", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194782/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Cromoglicic acid, Ipratropium, Orciprenaline, Pirbuterol, More", "updated_at": 1767369485}, {"id": 194555, "ingredient1": "Exemestane", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194783/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Darolutamide, Anastrozole, Aminoglutethimide, Fulvestrant, Toremifene, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More", "updated_at": 1767369485}, {"id": 194556, "ingredient1": "Gabapentin", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194784/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 194557, "ingredient1": "Hydrochlorothiazide", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194785/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Moexipril, Bisoprolol, Benazepril, Bendroflumethiazide, Polythiazide, Hydroflumethiazide, Chlorothiazide, Trichlormethiazide, Methyclothiazide, Olmesartan, Azilsartan medoxomil, More", "updated_at": 1767369485}, {"id": 194558, "ingredient1": "Cyanocobalamin", "ingredient2": "Letrozole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194786/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Darolutamide, Anastrozole, Aminoglutethimide, Fulvestrant, Toremifene, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, Degarelix, More", "updated_at": 1767369485}, {"id": 194559, "ingredient1": "Cyanocobalamin", "ingredient2": "Ketoprofen", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194787/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Chondroitin sulfate, Flurbiprofen, Tolmetin, Meclofenamic acid, Phenylbutazone, Tolazoline, More", "updated_at": 1767369485}, {"id": 194560, "ingredient1": "Glyburide", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194788/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194561, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194789/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Nesiritide, Vericiguat", "updated_at": 1767369485}, {"id": 194562, "ingredient1": "Cyanocobalamin", "ingredient2": "Phylloquinone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194790/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Eltrombopag, Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "updated_at": 1767369485}, {"id": 194563, "ingredient1": "Felodipine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194791/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Nebivolol, Bisoprolol, Ivabradine, Nisoldipine, Nicardipine, Clevidipine, Levamlodipine, Nimodipine, Mibefradil, Moexipril, Bisoprolol, Benazepril", "updated_at": 1767369485}, {"id": 194564, "ingredient1": "Irbesartan", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194792/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan", "updated_at": 1767369485}, {"id": 194565, "ingredient1": "Cyanocobalamin", "ingredient2": "Mercaptopurine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194793/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, Tioguanine, Capecitabine, More", "updated_at": 1767369485}, {"id": 194566, "ingredient1": "Cyanocobalamin", "ingredient2": "Tolterodine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194794/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 194567, "ingredient1": "Fenofibrate", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194795/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Bempedoic acid, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, More", "updated_at": 1767369485}, {"id": 194568, "ingredient1": "Cyanocobalamin", "ingredient2": "Thalidomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194796/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 194569, "ingredient1": "Gatifloxacin", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194797/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron sucrose", "alternatives_b": "Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, Benzylpenicillin, Levofloxacin, More", "updated_at": 1767369485}, {"id": 194570, "ingredient1": "Cyanocobalamin", "ingredient2": "Rifampicin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194798/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Ethambutol, More", "updated_at": 1767369485}, {"id": 194571, "ingredient1": "Ibuprofen", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194799/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Ubidecarenone, Regadenoson, Ranolazine, Ivabradine, Fenoprofen, More", "updated_at": 1767369485}, {"id": 194572, "ingredient1": "Cyanocobalamin", "ingredient2": "Oxybutynin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194800/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, More", "updated_at": 1767369485}, {"id": 194573, "ingredient1": "Glipizide", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194801/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194574, "ingredient1": "Cyanocobalamin", "ingredient2": "Promethazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194802/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More", "updated_at": 1767369485}, {"id": 194575, "ingredient1": "Cyanocobalamin", "ingredient2": "Atazanavir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194803/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194576, "ingredient1": "Etidronic acid", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194804/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194577, "ingredient1": "Cyanocobalamin", "ingredient2": "Tegaserod", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194805/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 194578, "ingredient1": "Cyanocobalamin", "ingredient2": "Orlistat", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194806/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Phentermine, Lorcaserin, Sibutramine, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 194579, "ingredient1": "Cyanocobalamin", "ingredient2": "Pilocarpine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194807/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Bethanechol, Neostigmine, Pyridostigmine, Ambenonium, Cevimeline, Apraclonidine, Methazolamide, Neostigmine, Physostigmine, Acetylcholine, Betaxolol, More", "updated_at": 1767369485}, {"id": 194580, "ingredient1": "Fluvastatin", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194808/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Lomitapide, More", "updated_at": 1767369485}, {"id": 194581, "ingredient1": "Cyanocobalamin", "ingredient2": "Leflunomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194809/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 194582, "ingredient1": "Cyanocobalamin", "ingredient2": "Rosuvastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194810/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Bempedoic acid, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, More", "updated_at": 1767369485}, {"id": 194583, "ingredient1": "Cyanocobalamin", "ingredient2": "Sertraline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194811/", "reference_text": "-", "alternatives_a": "Mecobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194584, "ingredient1": "Cyanocobalamin", "ingredient2": "Nifedipine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194812/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Nisoldipine, Nicardipine, Clevidipine, Levamlodipine, Nimodipine, Mibefradil, Nebivolol, Bisoprolol, Ivabradine", "updated_at": 1767369485}, {"id": 194585, "ingredient1": "Cyanocobalamin", "ingredient2": "Pioglitazone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194813/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194586, "ingredient1": "Doxepin", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194814/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194587, "ingredient1": "Cyanocobalamin", "ingredient2": "Nefazodone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194815/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194588, "ingredient1": "Cyanocobalamin", "ingredient2": "Terazosin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194816/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Silodosin, Dutasteride, Solifenacin", "updated_at": 1767369485}, {"id": 194589, "ingredient1": "Cyanocobalamin", "ingredient2": "Ofloxacin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194817/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron sucrose", "alternatives_b": "Enoxacin, Levofloxacin, Norfloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin, More", "updated_at": 1767369485}, {"id": 194590, "ingredient1": "Itraconazole", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194818/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 194591, "ingredient1": "Flecainide", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194819/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Amiodarone, Dronedarone, Tocainide, Propafenone, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 194592, "ingredient1": "Cyanocobalamin", "ingredient2": "Zopiclone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194820/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 194593, "ingredient1": "Cyanocobalamin", "ingredient2": "Levetiracetam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194821/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Tiagabine, Oxcarbazepine, Ethotoin, Rufinamide, Paramethadione, More", "updated_at": 1767369485}, {"id": 194594, "ingredient1": "Cyanocobalamin", "ingredient2": "Nadolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194822/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Acebutolol, Labetalol, Nebivolol, Bisoprolol, Acebutolol, Labetalol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, Carteolol", "updated_at": 1767369485}, {"id": 194595, "ingredient1": "Cyanocobalamin", "ingredient2": "Clarithromycin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194823/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tinidazole, Amoxicillin, Tetracycline, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin, Telithromycin, Lincomycin, Troleandomycin, Dirithromycin", "updated_at": 1767369485}, {"id": 194596, "ingredient1": "Estazolam", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194824/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 194597, "ingredient1": "Finasteride", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194825/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, More", "updated_at": 1767369485}, {"id": 194598, "ingredient1": "Cyanocobalamin", "ingredient2": "Quetiapine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194826/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194599, "ingredient1": "Cyanocobalamin", "ingredient2": "Paclitaxel", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194827/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Topotecan, Teniposide, Irinotecan, Etoposide", "updated_at": 1767369485}, {"id": 194600, "ingredient1": "Cyanocobalamin", "ingredient2": "Metoclopramide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194828/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Cisapride", "updated_at": 1767369485}, {"id": 194601, "ingredient1": "Dexamethasone", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194829/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mupirocin, Ciclesonide, Mometasone furoate, Mometasone, Epinephrine, Ephedrine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Betamethasone, Nedocromil, More", "updated_at": 1767369485}, {"id": 194602, "ingredient1": "Cyanocobalamin", "ingredient2": "Aripiprazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194830/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194603, "ingredient1": "Gemfibrozil", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194831/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Cerivastatin, Lomitapide, More", "updated_at": 1767369485}, {"id": 194604, "ingredient1": "Docetaxel", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194832/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Topotecan, Teniposide, Irinotecan, Etoposide", "updated_at": 1767369485}, {"id": 194605, "ingredient1": "Cyanocobalamin", "ingredient2": "Varenicline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194833/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Disulfiram, Methadone, Levacetylmethadol, Nalmefene, Nicotine, Buprenorphine", "updated_at": 1767369485}, {"id": 194606, "ingredient1": "Cyanocobalamin", "ingredient2": "Sodium bicarbonate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194834/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron sucrose", "alternatives_b": "Sorbitol, Sulfamethizole, Sodium citrate, Magnesium citrate, Mannitol, Sodium chloride, Chlorhexidine, Neomycin, Calcium chloride, Zinc sulfate, Magnesium sulfate, More", "updated_at": 1767369485}, {"id": 194607, "ingredient1": "Cyanocobalamin", "ingredient2": "Tiotropium", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194835/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Cromoglicic acid, Ipratropium, Orciprenaline, Pirbuterol, More", "updated_at": 1767369485}, {"id": 194608, "ingredient1": "Cyanocobalamin", "ingredient2": "Cefpodoxime", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194836/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, More", "updated_at": 1767369485}, {"id": 194609, "ingredient1": "Cyanocobalamin", "ingredient2": "Ursodeoxycholic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194837/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Maralixibat, Obeticholic acid, Cholic Acid, Odevixibat, Chenodeoxycholic acid", "updated_at": 1767369485}, {"id": 194610, "ingredient1": "Cyanocobalamin", "ingredient2": "Quazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194838/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Folic acid, Iron protein succinylate, Folic acid, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Paraldehyde, More", "updated_at": 1767369485}, {"id": 194611, "ingredient1": "Hydroxychloroquine", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194839/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 194612, "ingredient1": "Cyanocobalamin", "ingredient2": "Vitamin D", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194840/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194613, "ingredient1": "Fluticasone", "ingredient2": "Cyanocobalamin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194841/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, Beclomethasone dipropionate, More", "updated_at": 1767369485}, {"id": 194614, "ingredient1": "Cyclosporine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194842/", "reference_text": "-", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "alternatives_b": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "updated_at": 1767369485}, {"id": 194615, "ingredient1": "Cyanocobalamin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194843/", "reference_text": "-", "alternatives_a": "Mecobalamin, Hydroxocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate", "alternatives_b": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "updated_at": 1767369485}, {"id": 194616, "ingredient1": "Folic acid", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194844/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "updated_at": 1767369485}, {"id": 194617, "ingredient1": "Calcitriol", "ingredient2": "Pravastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194845/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Cerivastatin, Lomitapide, Bempedoic acid, More", "updated_at": 1767369485}, {"id": 194618, "ingredient1": "Fluvoxamine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194846/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 194619, "ingredient1": "Calcitriol", "ingredient2": "Valsartan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194847/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan, Bempedoic acid, Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan", "updated_at": 1767369485}, {"id": 194620, "ingredient1": "Calcitriol", "ingredient2": "Ramipril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194848/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Moexipril, Benazepril, Bempedoic acid, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194621, "ingredient1": "Calcitriol", "ingredient2": "Lorazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194849/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194622, "ingredient1": "Calcitriol", "ingredient2": "Bortezomib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194850/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 194623, "ingredient1": "Calcitriol", "ingredient2": "Tramadol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194851/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Methadone, More", "updated_at": 1767369485}, {"id": 194624, "ingredient1": "Fluconazole", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194852/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Micafungin, Miconazole, Posaconazole, Oteseconazole, More", "updated_at": 1767369485}, {"id": 194625, "ingredient1": "Erythromycin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194853/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Clindamycin, Troleandomycin, Dirithromycin, Azithromycin, Lincomycin, Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, More", "updated_at": 1767369485}, {"id": 194626, "ingredient1": "Calcitriol", "ingredient2": "Sildenafil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194854/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Vemurafenib, Darunavir, More", "updated_at": 1767369485}, {"id": 194627, "ingredient1": "Calcitriol", "ingredient2": "Ticlopidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194855/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More", "updated_at": 1767369485}, {"id": 194628, "ingredient1": "Calcitriol", "ingredient2": "Midodrine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194856/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More", "updated_at": 1767369485}, {"id": 194629, "ingredient1": "Calcitriol", "ingredient2": "Pantoprazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194857/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194630, "ingredient1": "Calcitriol", "ingredient2": "Torasemide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194858/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Etacrynic acid, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Vemurafenib, More", "updated_at": 1767369485}, {"id": 194631, "ingredient1": "Citalopram", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194859/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 194632, "ingredient1": "Calcitriol", "ingredient2": "Moxifloxacin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194860/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Netilmicin, Polymyxin B, Trifluridine, Benzylpenicillin, Levofloxacin, Neomycin, More", "updated_at": 1767369485}, {"id": 194633, "ingredient1": "Glimepiride", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194861/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194634, "ingredient1": "Gadodiamide", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194862/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Gadobutrol, Gadofosveset trisodium, Gadopentetic acid, Gadoxetic acid, Gadoteric acid, Gadobenic acid, Gadoteridol, Ferumoxsil", "updated_at": 1767369485}, {"id": 194635, "ingredient1": "Calcitriol", "ingredient2": "Lovastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194863/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Cerivastatin, Lomitapide, Bempedoic acid, More", "updated_at": 1767369485}, {"id": 194636, "ingredient1": "Calcitriol", "ingredient2": "Pregabalin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194864/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 194637, "ingredient1": "Calcitriol", "ingredient2": "Temazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194865/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Lemborexant, More", "updated_at": 1767369485}, {"id": 194638, "ingredient1": "Calcitriol", "ingredient2": "Mesalazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194866/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Cromoglicic acid, Olsalazine, Balsalazide, Betamethasone, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 194639, "ingredient1": "Dapsone", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194867/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Azelaic acid, Adapalene, Clofazimine", "updated_at": 1767369485}, {"id": 194640, "ingredient1": "Doxycycline", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194868/", "reference_text": "-", "alternatives_a": "Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tetracycline, Minocycline, Oxytetracycline, Omadacycline, Eravacycline, Demeclocycline, Sarecycline, Tigecycline, Tetracycline, Minocycline, Miconazole, More", "updated_at": 1767369485}, {"id": 194641, "ingredient1": "Clotrimazole", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194869/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Griseofulvin, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin, More", "updated_at": 1767369485}, {"id": 194642, "ingredient1": "Calcitriol", "ingredient2": "Metoprolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194870/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nebivolol, Ivabradine, Sotalol, Acebutolol, Nadolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Sotalol, More", "updated_at": 1767369485}, {"id": 194643, "ingredient1": "Calcitriol", "ingredient2": "Ropinirole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194871/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Apomorphine, Opicapone, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 194644, "ingredient1": "Isradipine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194872/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nisoldipine, Nicardipine, Clevidipine, Levamlodipine, Nimodipine, Mibefradil", "updated_at": 1767369485}, {"id": 194645, "ingredient1": "Calcitriol", "ingredient2": "Topiramate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194873/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 194646, "ingredient1": "Calcitriol", "ingredient2": "Lidocaine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194874/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Bacitracin, Flurbiprofen, Chlorhexidine, More", "updated_at": 1767369485}, {"id": 194647, "ingredient1": "Calcitriol", "ingredient2": "Pamidronic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194875/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194648, "ingredient1": "Calcitriol", "ingredient2": "Acarbose", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194876/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194649, "ingredient1": "Calcitriol", "ingredient2": "Venlafaxine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194877/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 194650, "ingredient1": "Calcitriol", "ingredient2": "Travoprost", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194878/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Acetazolamide, Carteolol, Brinzolamide, More", "updated_at": 1767369485}, {"id": 194651, "ingredient1": "Calcitriol", "ingredient2": "Morphine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194879/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Opium, Eluxadoline, Diphenoxylate, Difenoxin, Codeine, Oliceridine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, More", "updated_at": 1767369485}, {"id": 194652, "ingredient1": "Ertapenem", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194880/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 194653, "ingredient1": "Calcitriol", "ingredient2": "Valproic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194881/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 194654, "ingredient1": "Gefitinib", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194882/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 194655, "ingredient1": "Hydromorphone", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194883/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Methadone, More", "updated_at": 1767369485}, {"id": 194656, "ingredient1": "Indomethacin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194884/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fluocinolone acetonide, Fludrocortisone, Betamethasone, Fluorometholone, Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Piroxicam, Chondroitin sulfate, More", "updated_at": 1767369485}, {"id": 194657, "ingredient1": "Calcitriol", "ingredient2": "Metformin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194885/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194658, "ingredient1": "Calcitriol", "ingredient2": "Olanzapine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194886/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194659, "ingredient1": "Calcitriol", "ingredient2": "Omeprazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194887/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194660, "ingredient1": "Cetirizine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194888/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ketotifen, Olopatadine, Cromoglicic acid, Nedocromil, Phenylephrine, Azelastine, Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, More", "updated_at": 1767369485}, {"id": 194661, "ingredient1": "Diltiazem", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194889/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 194662, "ingredient1": "Calcitriol", "ingredient2": "Minoxidil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194890/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Deoxycholic acid, Pimecrolimus, Calcium gluconate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, Dupilumab, Tralokinumab, More", "updated_at": 1767369485}, {"id": 194663, "ingredient1": "Calcitriol", "ingredient2": "Mirtazapine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194891/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 194664, "ingredient1": "Calcitriol", "ingredient2": "Timolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194892/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acebutolol, Nadolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Sotalol, Pindolol, Apraclonidine, Methazolamide, More", "updated_at": 1767369485}, {"id": 194665, "ingredient1": "Calcitriol", "ingredient2": "Progesterone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194893/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Norethisterone, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, Norgestrel, More", "updated_at": 1767369485}, {"id": 194666, "ingredient1": "Calcitriol", "ingredient2": "Sorafenib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194894/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 194667, "ingredient1": "Calcitriol", "ingredient2": "Zoledronic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194895/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194668, "ingredient1": "Calcitriol", "ingredient2": "Mupirocin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194896/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ciclesonide, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More", "updated_at": 1767369485}, {"id": 194669, "ingredient1": "Calcitriol", "ingredient2": "Rosiglitazone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194897/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194670, "ingredient1": "Calcitriol", "ingredient2": "Pramipexole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194898/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Apomorphine, Opicapone, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 194671, "ingredient1": "Calcitriol", "ingredient2": "Spironolactone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194899/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Eplerenone, Amiloride, Triamterene, Finerenone", "updated_at": 1767369485}, {"id": 194672, "ingredient1": "Calcitriol", "ingredient2": "Methocarbamol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194900/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Chlormezanone", "updated_at": 1767369485}, {"id": 194673, "ingredient1": "Calcitriol", "ingredient2": "Zolpidem", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194901/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Lemborexant, More", "updated_at": 1767369485}, {"id": 194674, "ingredient1": "Famciclovir", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194902/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194675, "ingredient1": "Calcitriol", "ingredient2": "Prochlorperazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194903/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194676, "ingredient1": "Allopurinol", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194904/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 194677, "ingredient1": "Ceftazidime", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194905/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 194678, "ingredient1": "Gemcitabine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194906/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Pemetrexed, Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, More", "updated_at": 1767369485}, {"id": 194679, "ingredient1": "Calcitriol", "ingredient2": "Lansoprazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194907/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194680, "ingredient1": "Droperidol", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194908/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194681, "ingredient1": "Calcitriol", "ingredient2": "Meperidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194909/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Methadone, More", "updated_at": 1767369485}, {"id": 194682, "ingredient1": "Calcitriol", "ingredient2": "Loratadine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194910/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "updated_at": 1767369485}, {"id": 194683, "ingredient1": "Imipramine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194911/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 194684, "ingredient1": "Calcitriol", "ingredient2": "Montelukast", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194912/", "reference_text": "-", "alternatives_a": "Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, More", "updated_at": 1767369485}, {"id": 194685, "ingredient1": "Fluoxetine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194913/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 194686, "ingredient1": "Duloxetine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194914/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 194687, "ingredient1": "Calcitriol", "ingredient2": "Lenalidomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194915/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 194688, "ingredient1": "Calcitriol", "ingredient2": "Raloxifene", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194916/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ulipristal, Danazol, Mifepristone, Ospemifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 194689, "ingredient1": "Celecoxib", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194917/", "reference_text": "-", "alternatives_a": "Tazarotene, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Methadone, More", "updated_at": 1767369485}, {"id": 194690, "ingredient1": "Fosinopril", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194918/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Moexipril, Benazepril, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194691, "ingredient1": "Cefotaxime", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194919/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 194692, "ingredient1": "Calcitriol", "ingredient2": "Oxycodone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194920/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Methadone, More", "updated_at": 1767369485}, {"id": 194693, "ingredient1": "Haloperidol", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194921/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194694, "ingredient1": "Calcitriol", "ingredient2": "Ritonavir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194922/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194695, "ingredient1": "Calcitriol", "ingredient2": "Vancomycin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194923/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, More", "updated_at": 1767369485}, {"id": 194696, "ingredient1": "Calcitriol", "ingredient2": "Trandolapril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194924/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Moexipril, Benazepril, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194697, "ingredient1": "Caspofungin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194925/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Micafungin, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 194698, "ingredient1": "Foscarnet", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194926/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194699, "ingredient1": "Cyclophosphamide", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194927/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, Melphalan flufenamide, Uracil mustard", "updated_at": 1767369485}, {"id": 194700, "ingredient1": "Calcitriol", "ingredient2": "Rofecoxib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194928/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Piroxicam, Chondroitin sulfate, Nabumetone, Flurbiprofen, Esomeprazole, Tolmetin, More", "updated_at": 1767369485}, {"id": 194701, "ingredient1": "Ciprofloxacin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194929/", "reference_text": "-", "alternatives_a": "Tazarotene, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Tetracycline, Polymyxin B, Chloramphenicol, Chlorhexidine, More", "updated_at": 1767369485}, {"id": 194702, "ingredient1": "Gadoversetamide", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194930/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Gadobutrol, Gadofosveset trisodium, Gadopentetic acid, Gadoxetic acid, Gadoteric acid, Gadobenic acid, Gadoteridol, Ferumoxsil", "updated_at": 1767369485}, {"id": 194703, "ingredient1": "Calcitriol", "ingredient2": "Nortriptyline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194931/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 194704, "ingredient1": "Calcitriol", "ingredient2": "Vincristine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194932/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Irinotecan, Vinorelbine", "updated_at": 1767369485}, {"id": 194705, "ingredient1": "Fluorouracil", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194933/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Pemetrexed, Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, More", "updated_at": 1767369485}, {"id": 194706, "ingredient1": "Calcitriol", "ingredient2": "Lamotrigine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194934/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 194707, "ingredient1": "Hydroxyzine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194935/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194708, "ingredient1": "Calcitriol", "ingredient2": "Bosentan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194936/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Vemurafenib, Darunavir, More", "updated_at": 1767369485}, {"id": 194709, "ingredient1": "Calcitriol", "ingredient2": "Methotrexate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194937/", "reference_text": "-", "alternatives_a": "Tazarotene, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 194710, "ingredient1": "Cephalexin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194938/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 194711, "ingredient1": "Calcitriol", "ingredient2": "Propranolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194939/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nebivolol, Ivabradine, Sotalol, Acebutolol, Nadolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Sotalol, More", "updated_at": 1767369485}, {"id": 194712, "ingredient1": "Clonidine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194940/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Acetazolamide, Carteolol, Brinzolamide, More", "updated_at": 1767369485}, {"id": 194713, "ingredient1": "Calcitriol", "ingredient2": "Valaciclovir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194941/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194714, "ingredient1": "Calcitriol", "ingredient2": "Valdecoxib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194942/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Piroxicam, Chondroitin sulfate, Nabumetone, Flurbiprofen, Esomeprazole, Tolmetin, More", "updated_at": 1767369485}, {"id": 194715, "ingredient1": "Calcitriol", "ingredient2": "Lactulose", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194943/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Sodium sulfate, Linaclotide, More", "updated_at": 1767369485}, {"id": 194716, "ingredient1": "Calcitriol", "ingredient2": "Voriconazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194944/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Micafungin, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 194717, "ingredient1": "Enalapril", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194945/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Moexipril, Benazepril, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194718, "ingredient1": "Calcitriol", "ingredient2": "Nizatidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194946/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194719, "ingredient1": "Diclofenac", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194947/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fluocinolone acetonide, Fludrocortisone, Betamethasone, Fluorometholone, Salicylic acid, Ketorolac, Fluocinolone acetonide, Cortisone, Piroxicam, Flurbiprofen, Betamethasone, More", "updated_at": 1767369485}, {"id": 194720, "ingredient1": "Doxazosin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194948/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Prazosin, Guanethidine", "updated_at": 1767369485}, {"id": 194721, "ingredient1": "Calcitriol", "ingredient2": "Labetalol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194949/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acebutolol, Nebivolol, Nadolol, Sotalol, Pindolol, Penbutolol, Acebutolol, Nadolol, Esmolol, Betaxolol, Nebivolol, More", "updated_at": 1767369485}, {"id": 194722, "ingredient1": "Calcitriol", "ingredient2": "Linezolid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194950/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, More", "updated_at": 1767369485}, {"id": 194723, "ingredient1": "Calcitriol", "ingredient2": "Sulindac", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194951/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Piroxicam, Chondroitin sulfate, Nabumetone, Flurbiprofen, Esomeprazole, Tolmetin, More", "updated_at": 1767369485}, {"id": 194724, "ingredient1": "Calcitriol", "ingredient2": "Triamcinolone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194952/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Mometasone, More", "updated_at": 1767369485}, {"id": 194725, "ingredient1": "Calcitriol", "ingredient2": "Prednisone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194953/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Cromoglicic acid, Olsalazine, Balsalazide, Betamethasone, Beclomethasone dipropionate, Cortisone, Fludrocortisone, Betamethasone, Deflazacort", "updated_at": 1767369485}, {"id": 194726, "ingredient1": "Calcitriol", "ingredient2": "Simvastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194954/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194727, "ingredient1": "Calcitriol", "ingredient2": "Nystatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194955/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Griseofulvin, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin, More", "updated_at": 1767369485}, {"id": 194728, "ingredient1": "Calcitriol", "ingredient2": "Latanoprost", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194956/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Acetazolamide, Carteolol, Brinzolamide, More", "updated_at": 1767369485}, {"id": 194729, "ingredient1": "Calcitriol", "ingredient2": "Tamoxifen", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194957/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Darolutamide, Anastrozole, Aminoglutethimide, Fulvestrant, Toremifene, Abarelix, Flutamide, Enzalutamide, Relugolix, Degarelix, Nilutamide, More", "updated_at": 1767369485}, {"id": 194730, "ingredient1": "Calcitriol", "ingredient2": "Losartan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194958/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan", "updated_at": 1767369485}, {"id": 194731, "ingredient1": "Calcitriol", "ingredient2": "Warfarin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194959/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More", "updated_at": 1767369485}, {"id": 194732, "ingredient1": "Calcitriol", "ingredient2": "Tobramycin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194960/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Netilmicin, Polymyxin B, Trifluridine, Benzylpenicillin, Levofloxacin, Neomycin, More", "updated_at": 1767369485}, {"id": 194733, "ingredient1": "Furosemide", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194961/", "reference_text": "-", "alternatives_a": "Tazarotene, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Etacrynic acid, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Vemurafenib, More", "updated_at": 1767369485}, {"id": 194734, "ingredient1": "Calcitriol", "ingredient2": "Tizanidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194962/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Chlormezanone", "updated_at": 1767369485}, {"id": 194735, "ingredient1": "Calcitriol", "ingredient2": "Tamsulosin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194963/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Silodosin, Alfuzosin, Solifenacin, Tadalafil, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 194736, "ingredient1": "Calcitriol", "ingredient2": "Lamivudine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194964/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194737, "ingredient1": "Ibandronate", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194965/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194738, "ingredient1": "Calcitriol", "ingredient2": "Paroxetine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194966/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 194739, "ingredient1": "Calcitriol", "ingredient2": "Lisinopril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194967/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Moexipril, Benazepril, Bempedoic acid, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194740, "ingredient1": "Calcitriol", "ingredient2": "Nitroglycerin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194968/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 194741, "ingredient1": "Calcitriol", "ingredient2": "Nateglinide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194969/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194742, "ingredient1": "Calcitriol", "ingredient2": "Risperidone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194970/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194743, "ingredient1": "Hydrocortisone", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194971/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fluocinolone acetonide, Fludrocortisone, Betamethasone, Fluorometholone, Tetracycline, Minocycline, Miconazole, Epinephrine, Chlorhexidine, Neomycin, Salicylic acid, More", "updated_at": 1767369485}, {"id": 194744, "ingredient1": "Calcitriol", "ingredient2": "Modafinil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194972/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline", "updated_at": 1767369485}, {"id": 194745, "ingredient1": "Etodolac", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194973/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Piroxicam, Chondroitin sulfate, Nabumetone, Flurbiprofen, Esomeprazole, Tolmetin, More", "updated_at": 1767369485}, {"id": 194746, "ingredient1": "Calcitriol", "ingredient2": "Tretinoin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194974/", "reference_text": "-", "alternatives_a": "Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 194747, "ingredient1": "Dolasetron", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194975/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nabilone, Scopolamine, Dronabinol, Rolapitant, Aprepitant, Palonosetron", "updated_at": 1767369485}, {"id": 194748, "ingredient1": "Clopidogrel", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194976/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More", "updated_at": 1767369485}, {"id": 194749, "ingredient1": "Calcitriol", "ingredient2": "Potassium chloride", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194977/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Potassium citrate, Potassium bicarbonate, Potassium gluconate, Calcium chloride, Zinc sulfate, Sodium acetate, Arginine, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium phosphate, monobasic, More", "updated_at": 1767369485}, {"id": 194750, "ingredient1": "Etoposide", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194978/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Irinotecan, Vinorelbine", "updated_at": 1767369485}, {"id": 194751, "ingredient1": "Calcitriol", "ingredient2": "Perindopril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194979/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Moexipril, Benazepril, Bempedoic acid, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194752, "ingredient1": "Calcitriol", "ingredient2": "Sulfasalazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194980/", "reference_text": "-", "alternatives_a": "Tazarotene, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Vemurafenib, Darunavir, More", "updated_at": 1767369485}, {"id": 194753, "ingredient1": "Gentamicin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194981/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Netilmicin, Polymyxin B, Trifluridine, Benzylpenicillin, Levofloxacin, Neomycin, More", "updated_at": 1767369485}, {"id": 194754, "ingredient1": "Calcitriol", "ingredient2": "Pentoxifylline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194982/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, More", "updated_at": 1767369485}, {"id": 194755, "ingredient1": "Calcitriol", "ingredient2": "Ribavirin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194983/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194756, "ingredient1": "Fentanyl", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194984/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, More", "updated_at": 1767369485}, {"id": 194757, "ingredient1": "Calcitriol", "ingredient2": "Meloxicam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194985/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ropivacaine, Chloroprocaine, Levobupivacaine, Tetracaine, Bupivacaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Fenoprofen, More", "updated_at": 1767369485}, {"id": 194758, "ingredient1": "Calcitriol", "ingredient2": "Propofol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194986/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Halothane, Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, More", "updated_at": 1767369485}, {"id": 194759, "ingredient1": "Diazepam", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194987/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194760, "ingredient1": "Cefaclor", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194988/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 194761, "ingredient1": "Calcitriol", "ingredient2": "Loperamide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194989/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Opium, Eluxadoline, Diphenoxylate, Difenoxin", "updated_at": 1767369485}, {"id": 194762, "ingredient1": "Calcitriol", "ingredient2": "Oxazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194990/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Clobazam, Meprobamate, Halazepam, Clorazepic acid, Chlordiazepoxide", "updated_at": 1767369485}, {"id": 194763, "ingredient1": "Donepezil", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194991/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Galantamine, Aducanumab, Memantine, Ginkgo biloba, Tacrine", "updated_at": 1767369485}, {"id": 194764, "ingredient1": "Calcitriol", "ingredient2": "Temozolomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194992/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, Melphalan flufenamide, Uracil mustard", "updated_at": 1767369485}, {"id": 194765, "ingredient1": "Calcitriol", "ingredient2": "Prednisolone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194993/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fludrocortisone, Betamethasone, More", "updated_at": 1767369485}, {"id": 194766, "ingredient1": "Calcitriol", "ingredient2": "Ranitidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194994/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194767, "ingredient1": "Calcitriol", "ingredient2": "Tacrolimus", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194995/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Deoxycholic acid, Pimecrolimus, Calcium gluconate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, Dupilumab, Tralokinumab, More", "updated_at": 1767369485}, {"id": 194768, "ingredient1": "Calcitriol", "ingredient2": "Sirolimus", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194996/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Nandrolone, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, More", "updated_at": 1767369485}, {"id": 194769, "ingredient1": "Calcitriol", "ingredient2": "Quinapril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194997/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Moexipril, Benazepril, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194770, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194998/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 194771, "ingredient1": "Calcitriol", "ingredient2": "Risedronic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/194999/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194772, "ingredient1": "Granisetron", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195000/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nabilone, Scopolamine, Dronabinol, Rolapitant, Aprepitant, Palonosetron", "updated_at": 1767369485}, {"id": 194773, "ingredient1": "Calcitriol", "ingredient2": "Triazolam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195001/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Lemborexant, More", "updated_at": 1767369485}, {"id": 194774, "ingredient1": "Calcitriol", "ingredient2": "Ondansetron", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195002/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nabilone, Scopolamine, Dronabinol, Rolapitant, Aprepitant, Palonosetron", "updated_at": 1767369485}, {"id": 194775, "ingredient1": "Calcitriol", "ingredient2": "Bimatoprost", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195003/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Acetazolamide, Carteolol, Brinzolamide, More", "updated_at": 1767369485}, {"id": 194776, "ingredient1": "Calcitriol", "ingredient2": "Zonisamide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195004/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 194777, "ingredient1": "Calcitriol", "ingredient2": "Repaglinide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195005/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194778, "ingredient1": "Calcitriol", "ingredient2": "Metronidazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195006/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, Levofloxacin, Tinidazole, Quinacrine, Secnidazole, More", "updated_at": 1767369485}, {"id": 194779, "ingredient1": "Cyclobenzaprine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195007/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Chlormezanone", "updated_at": 1767369485}, {"id": 194780, "ingredient1": "Famotidine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195008/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194781, "ingredient1": "Calcitriol", "ingredient2": "Misoprostol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195009/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Methylergometrine, Dinoprostone, Ergometrine, Oxytocin, Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, More", "updated_at": 1767369485}, {"id": 194782, "ingredient1": "Calcitriol", "ingredient2": "Salmeterol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195010/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Olodaterol, Cromoglicic acid, Ipratropium, Orciprenaline, More", "updated_at": 1767369485}, {"id": 194783, "ingredient1": "Fexofenadine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195011/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "updated_at": 1767369485}, {"id": 194784, "ingredient1": "Carboplatin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195012/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 194785, "ingredient1": "Calcitriol", "ingredient2": "Methylprednisolone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195013/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Azelaic acid, Adapalene, Cortisone, Fludrocortisone, Betamethasone, More", "updated_at": 1767369485}, {"id": 194786, "ingredient1": "Calcitriol", "ingredient2": "Telmisartan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195014/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan, Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan", "updated_at": 1767369485}, {"id": 194787, "ingredient1": "Desloratadine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195015/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "updated_at": 1767369485}, {"id": 194788, "ingredient1": "Calcitriol", "ingredient2": "Methyldopa", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195016/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Guanfacine, Rauwolfia serpentina root, Reserpine, Deserpidine", "updated_at": 1767369485}, {"id": 194789, "ingredient1": "Ezetimibe", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195017/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Bempedoic acid, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Cerivastatin, Lomitapide, More", "updated_at": 1767369485}, {"id": 194790, "ingredient1": "Dipyridamole", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195018/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More", "updated_at": 1767369485}, {"id": 194791, "ingredient1": "Calcitriol", "ingredient2": "Telithromycin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195019/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Clindamycin, Troleandomycin, Dirithromycin, Azithromycin, Lincomycin", "updated_at": 1767369485}, {"id": 194792, "ingredient1": "Calcitriol", "ingredient2": "Rivastigmine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195020/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Galantamine, Aducanumab, Memantine, Ginkgo biloba, Tacrine", "updated_at": 1767369485}, {"id": 194793, "ingredient1": "Calcitriol", "ingredient2": "Auranofin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195021/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Penicillamine, Aurothioglucose, Sodium aurothiomalate", "updated_at": 1767369485}, {"id": 194794, "ingredient1": "Gabapentin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195022/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 194795, "ingredient1": "Ganciclovir", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195023/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194796, "ingredient1": "Calcitriol", "ingredient2": "Letrozole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195024/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Darolutamide, Anastrozole, Aminoglutethimide, Fulvestrant, Toremifene, Abarelix, Flutamide, Enzalutamide, Relugolix, Degarelix, Nilutamide, More", "updated_at": 1767369485}, {"id": 194797, "ingredient1": "Calcitriol", "ingredient2": "Ketoprofen", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195025/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fenoprofen, Ketorolac, Phenylbutazone, Glucosamine, Oxaprozin, Piroxicam, Chondroitin sulfate, Nabumetone, Flurbiprofen, Esomeprazole, Tolmetin, More", "updated_at": 1767369485}, {"id": 194798, "ingredient1": "Cinacalcet", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195026/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Etelcalcetide, Salmon calcitonin", "updated_at": 1767369485}, {"id": 194799, "ingredient1": "Glyburide", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195027/", "reference_text": "-", "alternatives_a": "Tazarotene, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194800, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195028/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nesiritide, Vericiguat", "updated_at": 1767369485}, {"id": 194801, "ingredient1": "Felodipine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195029/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nebivolol, Ivabradine, Sotalol, Nisoldipine, Nicardipine, Clevidipine, Levamlodipine, Nimodipine, Mibefradil, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194802, "ingredient1": "Calcitriol", "ingredient2": "Mycophenolic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195030/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 194803, "ingredient1": "Calcitriol", "ingredient2": "Ketoconazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195031/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Vemurafenib, Darunavir, More", "updated_at": 1767369485}, {"id": 194804, "ingredient1": "Irbesartan", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195032/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan", "updated_at": 1767369485}, {"id": 194805, "ingredient1": "Calcitriol", "ingredient2": "Mercaptopurine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195033/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Pemetrexed, Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, More", "updated_at": 1767369485}, {"id": 194806, "ingredient1": "Calcitriol", "ingredient2": "Tolterodine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195034/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 194807, "ingredient1": "Fenofibrate", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195035/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Bempedoic acid, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Cerivastatin, Lomitapide, More", "updated_at": 1767369485}, {"id": 194808, "ingredient1": "Calcitriol", "ingredient2": "Thalidomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195036/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 194809, "ingredient1": "Gatifloxacin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195037/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Netilmicin, Polymyxin B, Trifluridine, Benzylpenicillin, Levofloxacin, Neomycin, More", "updated_at": 1767369485}, {"id": 194810, "ingredient1": "Ibuprofen", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195038/", "reference_text": "-", "alternatives_a": "Tazarotene, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ritodrine, Bremelanotide, Flibanserin, Black cohosh, Bromocriptine, Alprostadil, Ranolazine, Ubidecarenone, Ivabradine, Adenosine, Regadenoson, More", "updated_at": 1767369485}, {"id": 194811, "ingredient1": "Calcitriol", "ingredient2": "Norfloxacin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195039/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, More", "updated_at": 1767369485}, {"id": 194812, "ingredient1": "Calcitriol", "ingredient2": "Oxybutynin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195040/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 194813, "ingredient1": "Glipizide", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195041/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194814, "ingredient1": "Clonazepam", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195042/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 194815, "ingredient1": "Calcitriol", "ingredient2": "Promethazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195043/", "reference_text": "-", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More", "updated_at": 1767369485}, {"id": 194816, "ingredient1": "Etidronic acid", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195044/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194817, "ingredient1": "Calcitriol", "ingredient2": "Tegaserod", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195045/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Sodium sulfate, Linaclotide, More", "updated_at": 1767369485}, {"id": 194818, "ingredient1": "Iloprost", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195046/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More", "updated_at": 1767369485}, {"id": 194819, "ingredient1": "Fluvastatin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195047/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Cerivastatin, Lomitapide, Bempedoic acid, Alirocumab", "updated_at": 1767369485}, {"id": 194820, "ingredient1": "Calcitriol", "ingredient2": "Leflunomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195048/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 194821, "ingredient1": "Calcitriol", "ingredient2": "Rosuvastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195049/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Bempedoic acid, Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Cerivastatin, Lomitapide, More", "updated_at": 1767369485}, {"id": 194822, "ingredient1": "Calcitriol", "ingredient2": "Sertraline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195050/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 194823, "ingredient1": "Cefuroxime", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195051/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Azithromycin, Netilmicin, Polymyxin B, Trifluridine, Benzylpenicillin, Levofloxacin, Neomycin, More", "updated_at": 1767369485}, {"id": 194824, "ingredient1": "Calcitriol", "ingredient2": "Nifedipine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195052/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nisoldipine, Nicardipine, Clevidipine, Levamlodipine, Nimodipine, Mibefradil, Nebivolol, Ivabradine, Sotalol", "updated_at": 1767369485}, {"id": 194825, "ingredient1": "Dutasteride", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195053/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Silodosin, Alfuzosin, Solifenacin, Tadalafil", "updated_at": 1767369485}, {"id": 194826, "ingredient1": "Calcitriol", "ingredient2": "Rabeprazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195054/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, Levofloxacin, Fenoprofen, Ketorolac, Phenylbutazone, More", "updated_at": 1767369485}, {"id": 194827, "ingredient1": "Calcitriol", "ingredient2": "Pioglitazone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195055/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194828, "ingredient1": "Carvedilol", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195056/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Acebutolol, Nadolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Sotalol, Pindolol, Nebivolol, Ivabradine, Sotalol", "updated_at": 1767369485}, {"id": 194829, "ingredient1": "Cefadroxil", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195057/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 194830, "ingredient1": "Doxepin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195058/", "reference_text": "-", "alternatives_a": "Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 194831, "ingredient1": "Calcitriol", "ingredient2": "Terazosin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195059/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Silodosin, Alfuzosin, Solifenacin, Tadalafil", "updated_at": 1767369485}, {"id": 194832, "ingredient1": "Calcitriol", "ingredient2": "Ofloxacin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195060/", "reference_text": "-", "alternatives_a": "Tazarotene, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Enoxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Grepafloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin, Tinidazole, More", "updated_at": 1767369485}, {"id": 194833, "ingredient1": "Itraconazole", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195061/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Micafungin, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 194834, "ingredient1": "Ifosfamide", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195062/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, Melphalan flufenamide, Uracil mustard", "updated_at": 1767369485}, {"id": 194835, "ingredient1": "Captopril", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195063/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Moexipril, Benazepril, Moexipril, Benazepril", "updated_at": 1767369485}, {"id": 194836, "ingredient1": "Calcitriol", "ingredient2": "Zopiclone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195064/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Lemborexant, More", "updated_at": 1767369485}, {"id": 194837, "ingredient1": "Calcitriol", "ingredient2": "Levetiracetam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195065/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Brivaracetam, Ezogabine, Cenobamate, Ethosuximide, Lacosamide, Tiagabine, Ethotoin, Paramethadione, Perampanel, Ganaxolone, Vigabatrin, More", "updated_at": 1767369485}, {"id": 194838, "ingredient1": "Clarithromycin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195066/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Esomeprazole, Vonoprazan, Levofloxacin, Clindamycin, Troleandomycin, Dirithromycin, More", "updated_at": 1767369485}, {"id": 194839, "ingredient1": "Ceftriaxone", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195067/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 194840, "ingredient1": "Estazolam", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195068/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Lemborexant, More", "updated_at": 1767369485}, {"id": 194841, "ingredient1": "Finasteride", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195069/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Deoxycholic acid, Pimecrolimus, Calcium gluconate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, Dupilumab, Tralokinumab, More", "updated_at": 1767369485}, {"id": 194842, "ingredient1": "Calcitriol", "ingredient2": "Quetiapine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195070/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fluphenazine, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, More", "updated_at": 1767369485}, {"id": 194843, "ingredient1": "Calcitriol", "ingredient2": "Metoclopramide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195071/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Cisapride", "updated_at": 1767369485}, {"id": 194844, "ingredient1": "Dexamethasone", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195072/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ciclesonide, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More", "updated_at": 1767369485}, {"id": 194845, "ingredient1": "Gemfibrozil", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195073/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Cerivastatin, Lomitapide, Bempedoic acid, Alirocumab", "updated_at": 1767369485}, {"id": 194846, "ingredient1": "Docetaxel", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195074/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Irinotecan, Vinorelbine", "updated_at": 1767369485}, {"id": 194847, "ingredient1": "Hydralazine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195075/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine", "updated_at": 1767369485}, {"id": 194848, "ingredient1": "Cefazolin", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195076/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 194849, "ingredient1": "Calcitriol", "ingredient2": "Sodium bicarbonate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195077/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Sorbitol, Sulfamethizole, Sodium citrate, Sodium chloride, Chlorhexidine, Neomycin, Calcium chloride, Zinc sulfate, Sodium acetate, Arginine, Sodium glycerophosphate, More", "updated_at": 1767369485}, {"id": 194850, "ingredient1": "Calcitriol", "ingredient2": "Tiotropium", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195078/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Epinephrine, Olodaterol, Cromoglicic acid, Ipratropium, Orciprenaline, More", "updated_at": 1767369485}, {"id": 194851, "ingredient1": "Cefepime", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195079/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 194852, "ingredient1": "Cefpodoxime", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195080/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefdinir, More", "updated_at": 1767369485}, {"id": 194853, "ingredient1": "Calcitriol", "ingredient2": "Acenocoumarol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195081/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More", "updated_at": 1767369485}, {"id": 194854, "ingredient1": "Calcitriol", "ingredient2": "Ursodeoxycholic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195082/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Cholic Acid, Odevixibat, Chenodeoxycholic acid, Obeticholic acid", "updated_at": 1767369485}, {"id": 194855, "ingredient1": "Calcitriol", "ingredient2": "Nitrazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195083/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, Lemborexant, More", "updated_at": 1767369485}, {"id": 194856, "ingredient1": "Calcitriol", "ingredient2": "Valganciclovir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195084/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194857, "ingredient1": "Hydroxychloroquine", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195085/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, More", "updated_at": 1767369485}, {"id": 194858, "ingredient1": "Ambrisentan", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195086/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Riociguat, Macitentan, Metyrosine, Tadalafil", "updated_at": 1767369485}, {"id": 194859, "ingredient1": "Calcitriol", "ingredient2": "Vitamin D", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195087/", "reference_text": "-", "alternatives_a": "Tazarotene, Methoxsalen, Calcipotriol, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 194860, "ingredient1": "Clobetasol", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195088/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Fluocinolone acetonide, Fluocinonide, Betamethasone, More", "updated_at": 1767369485}, {"id": 194861, "ingredient1": "Fluticasone", "ingredient2": "Calcitriol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195089/", "reference_text": "-", "alternatives_a": "Methoxsalen, Trioxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcifediol", "alternatives_b": "Ciclesonide, Umeclidinium, Mometasone furoate, Aclidinium, Glycopyrronium, Flunisolide, Ipratropium, Cromoglicic acid, Betamethasone, Revefenacin, Nedocromil, More", "updated_at": 1767369485}, {"id": 194862, "ingredient1": "Folic acid", "ingredient2": "Octreotide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195090/", "reference_text": "-", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "updated_at": 1767369485}, {"id": 194863, "ingredient1": "Folic acid", "ingredient2": "Pravastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195091/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Lomitapide, Bempedoic acid, Colesevelam, More", "updated_at": 1767369485}, {"id": 194864, "ingredient1": "Folic acid", "ingredient2": "Valsartan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195092/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan, Bempedoic acid, Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan", "updated_at": 1767369485}, {"id": 194865, "ingredient1": "Folic acid", "ingredient2": "Ramipril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195093/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, More", "alternatives_b": "Trandolapril, Bempedoic acid, Trandolapril", "updated_at": 1767369485}, {"id": 194866, "ingredient1": "Folic acid", "ingredient2": "Lorazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195094/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Meprobamate, Clorazepic acid, Clobazam, Halazepam", "updated_at": 1767369485}, {"id": 194867, "ingredient1": "Folic acid", "ingredient2": "Bortezomib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195095/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 194868, "ingredient1": "Folic acid", "ingredient2": "Tramadol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195096/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Dezocine, Opium, Dextropropoxyphene, Methadone, Pentazocine, Dihydrocodeine, More", "updated_at": 1767369485}, {"id": 194869, "ingredient1": "Hydroxocobalamin", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195097/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Mecobalamin, Folic acid, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 194870, "ingredient1": "Folic acid", "ingredient2": "Sildenafil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195098/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, Darunavir, Ketoconazole, More", "updated_at": 1767369485}, {"id": 194871, "ingredient1": "Folic acid", "ingredient2": "Dofetilide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195099/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Propafenone, Dronedarone, Tocainide, Procainamide, Disopyramide, Mexiletine, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 194872, "ingredient1": "Folic acid", "ingredient2": "Pantoprazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195100/", "reference_text": "-", "alternatives_a": "Iron sucrose, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Magnesium sulfate, Gonadorelin, Vitamin A, Caffeine, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194873, "ingredient1": "Folic acid", "ingredient2": "Torasemide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195101/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Etacrynic acid, Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, Darunavir, More", "updated_at": 1767369485}, {"id": 194874, "ingredient1": "Folic acid", "ingredient2": "Moxifloxacin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195102/", "reference_text": "-", "alternatives_a": "Iron sucrose, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Galactose, Vitamin A, Caffeine, Metyrapone, More", "alternatives_b": "Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Lomefloxacin, Trifluridine, Tobramycin, Benzylpenicillin, Amikacin, Levofloxacin, More", "updated_at": 1767369485}, {"id": 194875, "ingredient1": "Folic acid", "ingredient2": "Nelfinavir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195103/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194876, "ingredient1": "Glimepiride", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195104/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sorbitol, More", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194877, "ingredient1": "Gadodiamide", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195105/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Gadoversetamide, Gadobutrol, Gadofosveset trisodium, Gadopentetic acid, Gadoxetic acid, Gadoteric acid, Gadobenic acid, Gadoteridol, Ferumoxsil", "updated_at": 1767369485}, {"id": 194878, "ingredient1": "Folic acid", "ingredient2": "Lovastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195106/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Lomitapide, Bempedoic acid, Colesevelam, More", "updated_at": 1767369485}, {"id": 194879, "ingredient1": "Folic acid", "ingredient2": "Pregabalin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195107/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 194880, "ingredient1": "Folic acid", "ingredient2": "Temazepam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195108/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Suvorexant, Methohexital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, More", "updated_at": 1767369485}, {"id": 194881, "ingredient1": "Folic acid", "ingredient2": "Nevirapine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195109/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194882, "ingredient1": "Folic acid", "ingredient2": "Mesalazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195110/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, More", "alternatives_b": "Beclomethasone dipropionate, Betamethasone, Cromoglicic acid, Olsalazine", "updated_at": 1767369485}, {"id": 194883, "ingredient1": "Folic acid", "ingredient2": "Ziprasidone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195111/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, More", "alternatives_b": "Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, Mesoridazine, More", "updated_at": 1767369485}, {"id": 194884, "ingredient1": "Folic acid", "ingredient2": "Metoprolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195112/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methylene blue, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Nebivolol, Ivabradine, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol, Nebivolol, Pindolol, Penbutolol", "updated_at": 1767369485}, {"id": 194885, "ingredient1": "Folic acid", "ingredient2": "Ropinirole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195113/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Edrophonium, Indocyanine green, Tolbutamide, Inulin, More", "alternatives_b": "Apomorphine, Opicapone, Rasagiline, Tolcapone, Selegiline, Rotigotine, Bromocriptine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 194886, "ingredient1": "Isradipine", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195114/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Nicardipine, Clevidipine, Levamlodipine, Nimodipine, Mibefradil", "updated_at": 1767369485}, {"id": 194887, "ingredient1": "Folic acid", "ingredient2": "Topiramate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195115/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 194888, "ingredient1": "Folic acid", "ingredient2": "Lidocaine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195116/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Neomycin, Povidone-iodine, Bacitracin, More", "updated_at": 1767369485}, {"id": 194889, "ingredient1": "Folic acid", "ingredient2": "Pamidronic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195117/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194890, "ingredient1": "Folic acid", "ingredient2": "Acarbose", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195118/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sorbitol, More", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194891, "ingredient1": "Folic acid", "ingredient2": "Venlafaxine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195119/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Fluvoxamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194892, "ingredient1": "Folic acid", "ingredient2": "Travoprost", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195120/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Carteolol, Brinzolamide, Guanethidine, Levobunolol", "updated_at": 1767369485}, {"id": 194893, "ingredient1": "Folic acid", "ingredient2": "Atomoxetine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195121/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, More", "alternatives_b": "Amphetamine, Pemoline, Metamfetamine, Lisdexamfetamine, Solriamfetol, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline", "updated_at": 1767369485}, {"id": 194894, "ingredient1": "Folic acid", "ingredient2": "Morphine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195122/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Opium, Eluxadoline, Diphenoxylate, Difenoxin, Codeine, Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Dezocine, Opium, More", "updated_at": 1767369485}, {"id": 194895, "ingredient1": "Folic acid", "ingredient2": "Ertapenem", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195123/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefalotin, Cefpodoxime, More", "updated_at": 1767369485}, {"id": 194896, "ingredient1": "Folic acid", "ingredient2": "Zolmitriptan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195124/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Ubrogepant, Ergotamine, Naratriptan, Galcanezumab, Atogepant, Erenumab, More", "updated_at": 1767369485}, {"id": 194897, "ingredient1": "Gefitinib", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195125/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 194898, "ingredient1": "Hydromorphone", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195126/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, More", "alternatives_b": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Dezocine, Opium, Dextropropoxyphene, Methadone, Pentazocine, Dihydrocodeine, More", "updated_at": 1767369485}, {"id": 194899, "ingredient1": "Indomethacin", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195127/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Fluocinolone acetonide, Fludrocortisone, Betamethasone, Fluorometholone, Fenoprofen, Phenylbutazone, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolmetin, Meclofenamic acid, More", "updated_at": 1767369485}, {"id": 194900, "ingredient1": "Folic acid", "ingredient2": "Metformin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195128/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sorbitol, More", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194901, "ingredient1": "Folic acid", "ingredient2": "Olanzapine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195129/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, Mesoridazine, More", "updated_at": 1767369485}, {"id": 194902, "ingredient1": "Folic acid", "ingredient2": "Omeprazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195130/", "reference_text": "-", "alternatives_a": "Iron sucrose, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Magnesium sulfate, Caffeine, Metyrapone, Edrophonium, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194903, "ingredient1": "Folic acid", "ingredient2": "Minoxidil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195131/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Cromoglicic acid, Abrocitinib, Dupilumab, Tralokinumab, More", "updated_at": 1767369485}, {"id": 194904, "ingredient1": "Folic acid", "ingredient2": "Vinorelbine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195132/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 194905, "ingredient1": "Folic acid", "ingredient2": "Sucralfate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195133/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194906, "ingredient1": "Folic acid", "ingredient2": "Mirtazapine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195134/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Fluvoxamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194907, "ingredient1": "Folic acid", "ingredient2": "Timolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195135/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methylene blue, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol, Apraclonidine, Methazolamide, Neostigmine, Physostigmine, Acetylcholine, More", "updated_at": 1767369485}, {"id": 194908, "ingredient1": "Folic acid", "ingredient2": "Palonosetron", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195136/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, More", "alternatives_b": "Scopolamine, Nabilone, Rolapitant, Dronabinol", "updated_at": 1767369485}, {"id": 194909, "ingredient1": "Folic acid", "ingredient2": "Progesterone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195137/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, More", "alternatives_b": "Norethisterone, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, Norgestrel, Norethisterone, More", "updated_at": 1767369485}, {"id": 194910, "ingredient1": "Folic acid", "ingredient2": "Sorafenib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195138/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 194911, "ingredient1": "Folic acid", "ingredient2": "Zoledronic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195139/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194912, "ingredient1": "Folic acid", "ingredient2": "Nisoldipine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195140/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, More", "alternatives_b": "Nicardipine, Clevidipine, Levamlodipine, Nimodipine, Mibefradil", "updated_at": 1767369485}, {"id": 194913, "ingredient1": "Folic acid", "ingredient2": "Mupirocin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195141/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Ciclesonide, Mometasone furoate, Mometasone, Ephedrine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Betamethasone, Nedocromil, Phenylephrine, Beclomethasone dipropionate, More", "updated_at": 1767369485}, {"id": 194914, "ingredient1": "Folic acid", "ingredient2": "Rosiglitazone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195142/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sorbitol, More", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194915, "ingredient1": "Folic acid", "ingredient2": "Pramipexole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195143/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Apomorphine, Opicapone, Rasagiline, Tolcapone, Selegiline, Rotigotine, Bromocriptine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 194916, "ingredient1": "Folic acid", "ingredient2": "Spironolactone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195144/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Eplerenone, Amiloride, Finerenone", "updated_at": 1767369485}, {"id": 194917, "ingredient1": "Folic acid", "ingredient2": "Methylphenidate", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195145/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Amphetamine, Pemoline, Metamfetamine, Lisdexamfetamine, Solriamfetol, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline", "updated_at": 1767369485}, {"id": 194918, "ingredient1": "Folic acid", "ingredient2": "Methocarbamol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195146/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Chlormezanone", "updated_at": 1767369485}, {"id": 194919, "ingredient1": "Folic acid", "ingredient2": "Zolpidem", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195147/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Suvorexant, Methohexital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, More", "updated_at": 1767369485}, {"id": 194920, "ingredient1": "Folic acid", "ingredient2": "Prochlorperazine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195148/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, Mesoridazine, More", "updated_at": 1767369485}, {"id": 194921, "ingredient1": "Folic acid", "ingredient2": "Allopurinol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195149/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase", "updated_at": 1767369485}, {"id": 194922, "ingredient1": "Gemcitabine", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195150/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Tioguanine", "updated_at": 1767369485}, {"id": 194923, "ingredient1": "Folic acid", "ingredient2": "Lansoprazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195151/", "reference_text": "-", "alternatives_a": "Iron sucrose, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Magnesium sulfate, Gonadorelin, Caffeine, Metyrapone, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194924, "ingredient1": "Folic acid", "ingredient2": "Meperidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195152/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, More", "alternatives_b": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Dezocine, Opium, Dextropropoxyphene, Methadone, Pentazocine, Dihydrocodeine, More", "updated_at": 1767369485}, {"id": 194925, "ingredient1": "Folic acid", "ingredient2": "Loratadine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195153/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More", "updated_at": 1767369485}, {"id": 194926, "ingredient1": "Imipramine", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195154/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, More", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Fluvoxamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194927, "ingredient1": "Folic acid", "ingredient2": "Nabumetone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195155/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Fenoprofen, Phenylbutazone, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid", "updated_at": 1767369485}, {"id": 194928, "ingredient1": "Folic acid", "ingredient2": "Ketorolac", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195156/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, More", "alternatives_b": "Fenoprofen, Phenylbutazone, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid, Homatropine, Atropine, Scopolamine, More", "updated_at": 1767369485}, {"id": 194929, "ingredient1": "Folic acid", "ingredient2": "Montelukast", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195157/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 194930, "ingredient1": "Folic acid", "ingredient2": "Duloxetine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195158/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Fluvoxamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194931, "ingredient1": "Folic acid", "ingredient2": "Lenalidomide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195159/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 194932, "ingredient1": "Folic acid", "ingredient2": "Raloxifene", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195160/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Ulipristal, Mifepristone, Ospemifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 194933, "ingredient1": "Folic acid", "ingredient2": "Sotalol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195161/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methylene blue, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol, Nebivolol, Nebivolol, Ivabradine", "updated_at": 1767369485}, {"id": 194934, "ingredient1": "Fosinopril", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195162/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, More", "alternatives_b": "Trandolapril, Trandolapril", "updated_at": 1767369485}, {"id": 194935, "ingredient1": "Folic acid", "ingredient2": "Entacapone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195163/", "reference_text": "-", "alternatives_a": "Iron sucrose, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, More", "alternatives_b": "Apomorphine, Opicapone, Rasagiline, Tolcapone, Selegiline, Rotigotine, Bromocriptine, Pergolide, Safinamide, Levodopa", "updated_at": 1767369485}, {"id": 194936, "ingredient1": "Folic acid", "ingredient2": "Zidovudine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195164/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194937, "ingredient1": "Folic acid", "ingredient2": "Darifenacin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195165/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Indocyanine green, Tolbutamide, Inulin, More", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Avanafil, Papaverine, More", "updated_at": 1767369485}, {"id": 194938, "ingredient1": "Folic acid", "ingredient2": "Oxycodone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195166/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Codeine, Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Dezocine, Opium, Dextropropoxyphene, Methadone, Pentazocine, Dihydrocodeine, More", "updated_at": 1767369485}, {"id": 194939, "ingredient1": "Haloperidol", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195167/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, Mesoridazine, More", "updated_at": 1767369485}, {"id": 194940, "ingredient1": "Folic acid", "ingredient2": "Ritonavir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195168/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194941, "ingredient1": "Folic acid", "ingredient2": "Vancomycin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195169/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, More", "updated_at": 1767369485}, {"id": 194942, "ingredient1": "Folic acid", "ingredient2": "Cisplatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195170/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 194943, "ingredient1": "Folic acid", "ingredient2": "Metolazone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195171/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Trichlormethiazide, Bendroflumethiazide, Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, More", "updated_at": 1767369485}, {"id": 194944, "ingredient1": "Folic acid", "ingredient2": "Oxaliplatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195172/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 194945, "ingredient1": "Folic acid", "ingredient2": "Erlotinib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195173/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 194946, "ingredient1": "Folic acid", "ingredient2": "Rofecoxib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195174/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Fenoprofen, Phenylbutazone, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid", "updated_at": 1767369485}, {"id": 194947, "ingredient1": "Folic acid", "ingredient2": "Cefdinir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195175/", "reference_text": "-", "alternatives_a": "Iron sucrose, Cyanocobalamin, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, More", "alternatives_b": "Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Cefditoren, Meropenem, Cefalotin, Cefpodoxime, More", "updated_at": 1767369485}, {"id": 194948, "ingredient1": "Folic acid", "ingredient2": "Nortriptyline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195176/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Fluvoxamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194949, "ingredient1": "Folic acid", "ingredient2": "Vincristine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195177/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 194950, "ingredient1": "Folic acid", "ingredient2": "Zafirlukast", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195178/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Roflumilast, Bromotheophylline", "updated_at": 1767369485}, {"id": 194951, "ingredient1": "Folic acid", "ingredient2": "Piroxicam", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195179/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Fenoprofen, Phenylbutazone, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid, Phenylbutazone, Tolazoline, Tolmetin, More", "updated_at": 1767369485}, {"id": 194952, "ingredient1": "Hydroxyzine", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195180/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Meprobamate, Clorazepic acid, Clobazam, Halazepam", "updated_at": 1767369485}, {"id": 194953, "ingredient1": "Folic acid", "ingredient2": "Bosentan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195181/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, Darunavir, Ketoconazole, More", "updated_at": 1767369485}, {"id": 194954, "ingredient1": "Folic acid", "ingredient2": "Propranolol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195182/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methylene blue, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Nebivolol, Ivabradine, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol, Nebivolol", "updated_at": 1767369485}, {"id": 194955, "ingredient1": "Folic acid", "ingredient2": "Valaciclovir", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195183/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194956, "ingredient1": "Folic acid", "ingredient2": "Valdecoxib", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195184/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Fenoprofen, Phenylbutazone, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid", "updated_at": 1767369485}, {"id": 194957, "ingredient1": "Folic acid", "ingredient2": "Lactulose", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195185/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Prucalopride, More", "updated_at": 1767369485}, {"id": 194958, "ingredient1": "Folic acid", "ingredient2": "Voriconazole", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195186/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Micafungin, Caspofungin, Miconazole, Posaconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 194959, "ingredient1": "Folic acid", "ingredient2": "Nizatidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195187/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 194960, "ingredient1": "Folic acid", "ingredient2": "Labetalol", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195188/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methylene blue, Hexaminolevulinate, Secretin human, Sermorelin, More", "alternatives_b": "Nebivolol, Pindolol, Penbutolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Carteolol, Pindolol", "updated_at": 1767369485}, {"id": 194961, "ingredient1": "Folic acid", "ingredient2": "Linezolid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195189/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 194962, "ingredient1": "Folic acid", "ingredient2": "Sulindac", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195190/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Fenoprofen, Phenylbutazone, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolmetin, Meclofenamic acid, Mefenamic acid", "updated_at": 1767369485}, {"id": 194963, "ingredient1": "Imatinib", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195191/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 194964, "ingredient1": "Folic acid", "ingredient2": "Triamcinolone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195192/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Betamethasone, Fluorometholone, Beclomethasone dipropionate, Ciclesonide, Mometasone furoate, Mometasone, Ephedrine, More", "updated_at": 1767369485}, {"id": 194965, "ingredient1": "Folic acid", "ingredient2": "Testosterone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195193/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Methyltestosterone, Fluoxymesterone, Prasterone, Methyltestosterone", "updated_at": 1767369485}, {"id": 194966, "ingredient1": "Folic acid", "ingredient2": "Prednisone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195194/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Beclomethasone dipropionate, Betamethasone, Cromoglicic acid, Olsalazine, Cortisone, Fludrocortisone, Betamethasone, Deflazacort", "updated_at": 1767369485}, {"id": 194967, "ingredient1": "Folic acid", "ingredient2": "Simvastatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195195/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194968, "ingredient1": "Folic acid", "ingredient2": "Pemetrexed", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195196/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Tioguanine", "updated_at": 1767369485}, {"id": 194969, "ingredient1": "Folic acid", "ingredient2": "Nystatin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195197/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Salicylic acid, Thiabendazole, Miconazole, Griseofulvin, Ketoconazole, Flucytosine, Tioconazole, Chlorphenesin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More", "updated_at": 1767369485}, {"id": 194970, "ingredient1": "Folic acid", "ingredient2": "Stavudine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195198/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194971, "ingredient1": "Folic acid", "ingredient2": "Latanoprost", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195199/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Apraclonidine, Methazolamide, Neostigmine, Physostigmine, Acetylcholine, Betaxolol, Diclofenamide, Carteolol, Brinzolamide, Guanethidine, Levobunolol", "updated_at": 1767369485}, {"id": 194972, "ingredient1": "Folic acid", "ingredient2": "Trazodone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195200/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Fluvoxamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194973, "ingredient1": "Folic acid", "ingredient2": "Sevelamer", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195201/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 194974, "ingredient1": "Folic acid", "ingredient2": "Sumatriptan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195202/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Ubrogepant, Ergotamine, Naratriptan, Galcanezumab, Atogepant, Erenumab, More", "updated_at": 1767369485}, {"id": 194975, "ingredient1": "Folic acid", "ingredient2": "Aprepitant", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195203/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, More", "alternatives_b": "Scopolamine, Nabilone, Rolapitant, Dronabinol", "updated_at": 1767369485}, {"id": 194976, "ingredient1": "Galantamine", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195204/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Ginkgo biloba, Tacrine, Aducanumab", "updated_at": 1767369485}, {"id": 194977, "ingredient1": "Folic acid", "ingredient2": "Tamoxifen", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195205/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Darolutamide, Aminoglutethimide, Fulvestrant, Toremifene, Abarelix, Flutamide, Enzalutamide, Relugolix, Degarelix, Nilutamide, Apalutamide, More", "updated_at": 1767369485}, {"id": 194978, "ingredient1": "Folic acid", "ingredient2": "Losartan", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195206/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan", "updated_at": 1767369485}, {"id": 194979, "ingredient1": "Folic acid", "ingredient2": "Warfarin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195207/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, More", "updated_at": 1767369485}, {"id": 194980, "ingredient1": "Folic acid", "ingredient2": "Moexipril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195208/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Trandolapril, Trandolapril", "updated_at": 1767369485}, {"id": 194981, "ingredient1": "Furosemide", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195209/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Trichlormethiazide, Bendroflumethiazide, Etacrynic acid, Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 194982, "ingredient1": "Folic acid", "ingredient2": "Tizanidine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195210/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Chlormezanone", "updated_at": 1767369485}, {"id": 194983, "ingredient1": "Folic acid", "ingredient2": "Nitrofurantoin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195211/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Tolbutamide, Inulin, More", "alternatives_b": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 194984, "ingredient1": "Folic acid", "ingredient2": "Tamsulosin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195212/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Silodosin, Solifenacin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, More", "updated_at": 1767369485}, {"id": 194985, "ingredient1": "Folic acid", "ingredient2": "Lamivudine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195213/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 194986, "ingredient1": "Ibandronate", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195214/", "reference_text": "-", "alternatives_a": "Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, More", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 194987, "ingredient1": "Folic acid", "ingredient2": "Paroxetine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195215/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Maprotiline, St. John's Wort, Milnacipran, Vortioxetine, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Esketamine, Fluvoxamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 194988, "ingredient1": "Folic acid", "ingredient2": "Lisinopril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195216/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, More", "alternatives_b": "Trandolapril, Bempedoic acid, Trandolapril", "updated_at": 1767369485}, {"id": 194989, "ingredient1": "Folic acid", "ingredient2": "Nitroglycerin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195217/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate", "updated_at": 1767369485}, {"id": 194990, "ingredient1": "Folic acid", "ingredient2": "Nateglinide", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195218/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sorbitol, More", "alternatives_b": "Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Albiglutide, More", "updated_at": 1767369485}, {"id": 194991, "ingredient1": "Folic acid", "ingredient2": "Risperidone", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195219/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, Lurasidone, Mesoridazine, More", "updated_at": 1767369485}, {"id": 194992, "ingredient1": "Hydrocortisone", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195220/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Fluocinolone acetonide, Fludrocortisone, Betamethasone, Fluorometholone, Minocycline, Neomycin, Miconazole, Salicylic acid, Fluocinolone acetonide, Cortisone, Betamethasone, More", "updated_at": 1767369485}, {"id": 194993, "ingredient1": "Folic acid", "ingredient2": "Modafinil", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195221/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Amphetamine, Pemoline, Metamfetamine, Lisdexamfetamine, Solriamfetol, Dexmethylphenidate, Dextroamphetamine, Armodafinil, Citicoline", "updated_at": 1767369485}, {"id": 194994, "ingredient1": "Isoflurane", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195222/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Halothane, Thiopental, Alfentanil, Remifentanil, Sodium oxybate, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Enflurane, Esketamine, More", "updated_at": 1767369485}, {"id": 194995, "ingredient1": "Folic acid", "ingredient2": "Tretinoin", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195223/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 194996, "ingredient1": "Folic acid", "ingredient2": "Tetracycline", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195224/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Galactose, Gonadorelin, Caffeine, Metyrapone, More", "alternatives_b": "Polymyxin B, Rifamycin, Neomycin, Miconazole, Tinidazole, Dexlansoprazole, Bismuth subcitrate potassium, Rifabutin, Esomeprazole, Vonoprazan, Levofloxacin, More", "updated_at": 1767369485}, {"id": 194997, "ingredient1": "Folic acid", "ingredient2": "Potassium chloride", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195225/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Potassium citrate, Potassium bicarbonate, Potassium gluconate, Sodium acetate, Zinc sulfate, Magnesium sulfate, Arginine, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium phosphate, monobasic, More", "updated_at": 1767369485}, {"id": 194998, "ingredient1": "Irinotecan", "ingredient2": "Folic acid", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195226/", "reference_text": "-", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, More", "alternatives_b": "Trabectedin, Cabazitaxel, Vinblastine, Topotecan, Teniposide", "updated_at": 1767369485}, {"id": 194999, "ingredient1": "Folic acid", "ingredient2": "Olopatadine", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195227/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Ketotifen, Nedocromil, Cromoglicic acid, Phenylephrine, Ciclesonide, Mometasone furoate, Mometasone, Ephedrine, Ipratropium, Cromoglicic acid, Hyaluronic acid, More", "updated_at": 1767369485}, {"id": 195000, "ingredient1": "Folic acid", "ingredient2": "Perindopril", "severity": "Unknown", "effect": "None", "source": "DDInter", "management_text": "-", "mechanism_text": "", "recommendation": "-", "risk_level": "Unknown", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/195228/", "reference_text": "-", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, More", "alternatives_b": "Trandolapril, Bempedoic acid, Trandolapril", "updated_at": 1767369485}]